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Respiratory syncytial virus (RSV) is a single-stranded, negative sense RNA virus that is the leading 
viral cause of serious respiratory tract infections in infants and young children worldwide. The 
virus is highly infectious and a majority of children are infected during their first RSV season. 
Decades of research has provided critical information detailing mechanisms of viral pathogenesis 
and host immune subversion however, a regretfully incomplete understanding of the infant RSV 
immune response still exists. Generally, infants are heavily reliant on innate immunity to respond 
to pathogens and they divert normal, pro-inflammatory responses to allergy-inducing innate 
immune responses, making them particularly vulnerable to intracellular pathogens like RSV. 
While this diversion can protect infants from over-exuberant immunopathology, allergic responses 
can potentiate mucus production and airway obstruction acutely as well as increase the 
predisposition towards atopy and asthma later in life. Clinical observations have noted an inverse 
relationship between increased pro-inflammatory RSV immune responses and reduced RSV 
disease severity in children, but the acute and long-term effects of pro-inflammatory 
immunomodulation during primary, infant RSV infection are not well understood. In this 
dissertation, we hypothesized that pro-inflammatory immunomodulation during primary infant 
RSV infection alters acute and memory RSV immune responses.  
 We demonstrate that both innate and adaptive infant RSV immunity is less robust when 
compared to adult responses. Alveolar macrophages (AMs), critical innate immune cells, were less 
activated and had fewer differentially expressed genes (DEGs) in response to RSV infection than 
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adults. Administration of the pro-inflammatory cytokine, interferon gamma (IFNγ), during 
primary RSV infection reduced viral titers, increased AM activation, and increased RSV-specific 
CD8+ T cell responses. Not only did IFNγ treatment have an effect on primary RSV immune 
responses, it also increased RSV-specific memory CD8+ T cell responses, reduced airway 
hyperresponsiveness, and contributed to signals of innate trained immunity upon secondary 
infection. We also demonstrated that passive immunization with RSV-neutralizing maternal 
antibodies resulted in heightened innate immune activation and increased mucus production. Our 
data suggests that immunomodulation of the primary infant RSV immune response can have 
beneficial acute and long-term effects but must be properly balanced to avoid immunopathology. 
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1.0  INTRODUCTION 
Since the discovery of RSV in the late 1950’s, it was quickly recognized as the most important 
viral cause of severe respiratory tract infections in infants and children worldwide. Decades of 
research have given us a more complete understanding of RSV pathogenesis but most of the data 
generated from preclinical RSV studies have relied on adult animal models. Our lab has worked 
extensively to characterize RSV pathogenesis using an infant model of RSV infection (1) to better 
identify age-specific therapeutic opportunities. Data in this dissertation continues the work in 
characterizing infant RSV immune responses as well as investigates two therapeutic 
immunomodulatory agents; IFNγ and anti-RSV maternal antibodies. Evidence from the studies 
detailed in the following chapters will demonstrate that infant RSV immune responses are 
dramatically different from those of adults and that immunomodulation of primary infant RSV 
results in acute and long-term changes in RSV immunity. 
1.1.1 Viral structure and function 
RSV is a member of the Paramyxoviridae family of viruses, which includes viruses responsible 
for measles, mumps, and a number of viruses causing respiratory tract infections (2). There are 
animal versions of RSV, suggesting that as the virus evolved it jumped between species, but there 
is no animal reservoir for human RSV (3). The virus is a non-segmented, negative-sense, single-
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stranded, enveloped RNA virus that has 10 genes that encode 11 proteins. Approximately half of 
RSV’s proteins are involved in the nucleocapsid structure and/or RNA synthesis, including the N, 
L, P, M2-1, and M2-2 proteins (4). The encapsidation of genomic RNA, as well as, the positive-
sense replicative intermediate, is performed by the nucleocapsid N protein. The large L protein 
and P phosphoprotein are the major polymerase subunit and co-factor in RNA synthesis, 
respectively (3-5). M2 proteins are involved in transcription and maintaining the balance between 
transcription and RNA replication (3), with the M2-1 protein being essential for viral viability (6).  
Two non-structural proteins, NS1 and NS2, are small nonessential proteins that modulate 
the host immune response to RSV infection. These accessory proteins act as virulence factors for 
the virus and have been shown to alter the host immune response in a number of ways. NS1 and 
NS2 are known to antagonize the type I and III interferon responses, and inhibit type I interferon 
receptor signaling (7-13). The proteins have also demonstrated the ability to inhibit apoptosis, 
allowing the virus to continue to replicate within airway epithelial cells (14). Additional effects of 
these accessory proteins include, decreased maturation of dendritic cells (DCs), skewed T cell 
responses, and decreased nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
activation (13, 15-17).  
The four remaining viral proteins associate with the lipid bilayer and form the viral 
envelope. Viron morphogenesis is influenced by the M matrix protein, which lines the inner 
envelope surface. The small hydrophobic SH proteins are transmembrane surface glycoproteins, 
while the heavily glycosylated G and F proteins are the two major protective antigens eliciting 
neutralization (4). Although RSV has a single serotype, it has two subgroups, A and B, which are 
distinguished primarily by variations in the G protein. The G protein is critical for infection and 
plays a major role in viral attachment (18). Interestingly, this protein is also expressed in a secreted 
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form that acts as an antigen decoy and inhibits the antibody-mediated effects of innate leukocytes 
bearing Fc receptors (19, 20). The G protein has also been found to reduce respiratory rates through 
the induction of substance P (21), which may be a factor in apneic episodes that can occur in infants 
with severe RSV bronchiolitis. Finally, the fusion F protein is the surface glycoprotein that directs 
viral penetration through membrane fusion and mediates the formation of syncytia by directing the 
fusion of an infected cell with neighboring cells (3).  
The F protein is unique in that it is a major target of vaccine development because its 
sequence is highly conserved between RSV subgroups and it is required for viral entry (22). Recent 
atomic structure analyses of the F protein have demonstrated that it exists in two distinct 
conformations, pre-fusion and post-fusion (23-25). Mediation of viral-cell membrane fusion 
requires an irreversible transition from the metastable pre-F to a stable post-F conformation. While 
pre- and post-F have unique shapes, they share approximately 50% of their surface area and two 
antigenic sites (II and IV) that are moderately sensitive to neutralization. On the surface unique to 
pre-F, at least three highly neutralization sensitive antigenic sites have been reported (Ø, III, and 
V), with site Ø having the highest neutralization potential (22). The neutralizing activity of 
antibodies in the sera of naturally RSV infected individuals (> 7 years of age) are primarily derived 
from pre-F specific antibodies (26). Therefore, effective neutralization of RSV requires that RSV 
F-specific antibodies must recognize and interrupt pre-F prior to the conformational change to its 
post-F structure (27). 
1.1.2 Epidemiology, clinical symptoms, pathogenesis 
In 1956, RSV was isolated from a laboratory chimpanzee with symptoms of a cold and 
subsequently determined to be of human origin (4). Since the time of its discovery, RSV was 
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quickly recognized as the leading viral cause of serious respiratory tract disease in the pediatric 
population. Recently, global RSV burden has been estimated to cause 33 million annual, acute 
lower respiratory tract infections, resulting in 3.2 million hospital admissions, and approximately 
60,000 in-hospital deaths in children (< 5 years). Infants (< 6 months of age) accounted for nearly 
half of all hospitalizations and in-hospital deaths (28). Overall estimates of annual RSV mortality 
could be as high as 120,000.  
The risk of severe RSV disease increases according to factors that are known to 
compromise an individual’s ability to control a respiratory infection, including the following: 
young age (<6 months of age), premature birth (< 35 week gestation), bronchopulmonary 
dysplasia, congenital heart disease, immunodeficiency or immunosuppression, narrow airways, 
low birth weight, and old age (3, 29). While these factors play an important role in the development 
of severe disease, the overwhelming majority (80%) of children hospitalized for severe RSV were 
previously healthy (30).  
In the United States, RSV infections typically begin in November and end in May with 
both A and B strains circulating concurrently (31). Although the two strains maintain a high degree 
of antigenic relatedness, epidemics usually involve multiple circulating strains and the strains may 
alternate in dominance every 1 or 2 years (3). This alternation is thought to play a role in the 
potential for RSV to re-infect its hosts, but strain differences do not seem to play a role in disease 
variability. RSV is a highly contagious human pathogen, rivaling the measles virus (3). It is readily 
introduced and spreads with ease in settings with close contact such as, daycares, hospitals, nursing 
homes, and within families. For example, natural introduction of RSV into a daycare setting 
resulted in infection of more than 90% of infants and children (32) and approximately 50% of 
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families became infected when RSV was introduced during an outbreak, usually by an older child 
(33).  
Primary RSV infection is thought to almost always be symptomatic. Inoculation typically 
occurs via large particle aerosol or through direct contact via the eyes or nose. Over the next 4 to 
5 days, the virus replicates in the nasopharynx, which can be followed by spreading to the lower 
respiratory tract (31). Symptoms of upper airway disease include rhinorrhea, cough, otitis media, 
and low grade fever. The most common form of lower airway disease is bronchiolitis, 
characterized by airway resistance, air trapping, and wheezing, but can also include pneumonia 
and croup (3, 31, 34).  
RSV produces a very superficial infection and is restricted to the ciliated cells of the small 
bronchioles and type 1 pneumocytes in the alveoli. Compared to the rapid and extensive 
cytopathology induced by influenza infection, RSV infection has demonstrated a minimally 
cytopathic effect within the first 48 hours (35, 36). However, as the infection progresses and 
through the action of NS2, infected columnar, ciliated epithelial cells become rounded and are 
extruded from intact epithelium (37). Extruded epithelial cells mix with increased mucus and 
infiltrating immune cells in the lumen of an edematous airway to create an occlusion. Airway 
obstructions produce many of the clinical characteristics of bronchiolitis mentioned previously. 
Histologically, evidence of recovery begins in a matter of days but reconstitution of sloughed, 
ciliated epithelial cells takes at least two weeks. Complete restoration of epithelial integrity takes 
four to eight weeks, correlating with clinical symptoms of prolonged coughing, wheezing, and 
altered pulmonary function (31, 38). Approximately half of infants and children hospitalized with 
severe RSV have subsequent episodes of wheezing, asthma, and decreased lung function well into 
early adolescence (39, 40). Pre-clinical (41) and clinical data (42) have supported the association 
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between severe RSV infection, elevated concentrations of Th2 and Th17 cytokines, and the 
development of recurrent wheeze or asthma. Prevention of RSV through the administration of 
palivizumab in otherwise healthy preterm infants during RSV season significantly reduced the 
number of wheezing days in the first year of life, but had no effect on the incidence of asthma later 
in childhood (43, 44). This likely indicates that the association between RSV infection and 
increased risk of asthma continues well past infancy when children are at highest risk of severe 
RSV disease. 
1.1.3 Characteristics of infant immunity 
RSV has been primarily recognized as a problematic virus for children, as it infects individuals at 
an earlier age with greater consequences than other respiratory viruses. Rhinovirus is another 
respiratory virus common in the first year of life and has been associated with wheezing, but much 
less commonly infects infants less than six months of age (45). In contrast, the peak age of RSV 
hospitalization occurs at 2 months of age (3). The very young age of severe RSV increases the 
impact of the infectious process, as younger infants are less resilient to the effects of respiratory 
illnesses due to the narrow diameter of their airway, making them more susceptible to obstruction.  
In addition to the anatomical vulnerabilities of the infant airway, infants mount biased 
immune responses to pathogens like RSV that set in motion poor immunological memory that 
likely contributes to recurrent RSV infections throughout life. In utero, the fetus is an allograft of 
their mother, so pro-inflammatory/T helper type 1 (Th1) cytokine responses must be 
avoided/limited to reduce the risk of rejection, resulting in abortion and/or pre-term delivery (46). 
This risk of fetal rejection is likely the reason why fetal immune systems are heavily biased towards 
T helper type 2 (Th2) cytokine responses (47). Lack of Th1 cytokine production in response to 
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stimulus was originally thought to be due to an impairment of neonatal immunity, but production 
of certain cytokines (IL-6, IL-10, IL-23, etc.) by innate immune cells in response to stimuli 
sometimes exceeded that of adults (48, 49). However, this bias away from Th1 polarizing 
cytokines leaves neonates vulnerable to intracellular pathogens and compromises their responses 
to vaccination. 
In utero, infants have very limited antigen exposure required to induce adaptive immunity, 
thereby making infants heavily reliant on the innate immune system for protection from infections. 
One mechanism of pathogen recognition involves toll-like receptors (TLRs), whereby components 
of microbes are recognized by innate immune cells, stimulating anti-microbial defenses. Many 
neonatal TLR responses from antigen presenting cells (APCs), like macrophages and dendritic 
cells, are altered when compared to adult responses. These age-dependent changes may be due to 
differences in TLR expression or because of altered cytokine responses (50, 51). Generally, infant 
APCs have reduced Th1 cytokine responses following TLR stimulation and instead favor 
production of Th2 and Th17 cytokines (Table 1.1). Although RSV stimulates TLR4, TLR2, and 
the intracellular sensors, retinoic acid-induced gene I (RIG-I) and TLR3 (52-56), infants have 
reduced levels of IL-12, IL-18, and IFNγ in response to infection (57). Other studies have 
demonstrated qualitative and quantitative defects in neonatal DC responses that subsequently lead 
to compromised CD8+ T cell function (58). Epigenetic studies have begun to shed light on a 
mechanism behind the propensity of infant APCs to respond to stimuli with a Th2 bias. 
Hypomethylation of cytokine loci contributes to the expression of cytokine genes, while 
hypermethylation can silence other cytokine genes. The Th2 locus in CD4+ T cells is 
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hypomethylated in both human and murine infants compared to adults (59, 60), which correlates 
with increased Th2 cytokine responses in infants. 
 
Innate immunity provides the critical link between non-specific pathogen recognition and 
activation of adaptive immunity, which offers targeted pathogen-specific immunity. The ability to 
strike the right balance in overcoming Th2 biases and activating Th1 innate responses plays an 
important role in the differentiation of naïve T cells, which are critical in the clearance of RSV 
(61). While there is some evidence to suggest that robust cytotoxic CD8+ T cells responses can 
lead to immunopathology (62), other studies have demonstrated the importance of CD8+ T cells in 
ameliorating Th2-related pathology and affiliated eosinophil recruitment (63-65). Age at primary 
infection is critical in the establishment of memory T cell responses as evidenced by infant, 
primary RSV infections resulting in Th2 memory T cell development accompanied by eosinophilia 
(66). In fact, infection at a young age can divert the normal anti-inflammatory role of T regulatory 
Table 1.1 Cytokine responses of the newborn 
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cells (Tregs) into promoting Th2 responses that lead to asthma (41). Additionally, T cells that 
recently emigrated from the thymus, termed recent thymic emigrants (RTEs), are present in a high 
frequency in the periphery of human infants (67) and infant mice (68). RTEs are impaired in the 
acquisition of Th1 functionality making infants vulnerable to intracellular pathogens (67). 
Antibodies are an additional correlate of protection against RSV infection but protection 
from infection is usually short-lived. Maternal anti-RSV antibodies can offer neonates some 
protection but maternal antibody levels are highly variable and largely dependent on the time since 
last RSV exposure. Maternal antibodies can also further complicate the generation of active 
immunity in infants because of their role in epitope blocking and other immunosuppressive effects 
(69). Generally, infant antibody responses have compromised efficacy because of a shorter half-
life, higher IgG1/IgG2a ratio, a delayed onset, and are of lower affinity than adult antibodies (70). 
Elicitation of antibody production is also reduced in infants because of delayed germinal center 
maturation (71). 
1.1.4 State of therapy/prevention 
Currently, severe RSV infections are treated with supportive care as there is no effective treatment. 
Ribavirin is the only drug licensed to treat patients with severe RSV infection but due to unproven 
effectiveness and teratogenicity, it is not a part of routine clinical use. Infants at high-risk of severe 
disease can receive passive immunoprophylaxis during the RSV season through monthly injections 
of the RSV-neutralizing monoclonal antibody, palivizumab (Synagis). Prophylaxis with 
palivizumab reduces RSV-related hospitalization by 55%  (72) but is costly and is only approved 
for use in high-risk infants. The limited utility of palivizumab emphasizes the importance of more 
universal approaches, including vaccination. 
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 In the 1960s, a formalin inactivated RSV vaccine (FI-RSV) that was combined with the 
adjuvant alum was tested in children. In the following RSV season, 80% of FI-RSV immunized 
children were hospitalized with severe, vaccine enhanced RSV disease, resulting in the deaths of 
two toddlers (73). The failure of the FI-RSV vaccine hampered RSV vaccine development for 40 
years, but as researchers investigated the mechanisms behind FI-RSV immunopathology and with 
the discovery of highly neutralization sensitive epitopes on RSV pre-F, progress towards a RSV 
vaccine has been made. There are currently a number of RSV vaccine approaches that span pre-
clinical testing to Phase III clinical trials (74). Direct infant RSV immunization has been 
challenging because of biased/immature neonatal immune responses (75), the risk of vaccine-
enhanced disease (73, 76), and the short time frame between birth and first RSV exposure. An 
alternative to direct infant vaccination is maternal immunization, which can produce high levels 
of neutralizing antibodies in mothers that are subsequently transferred to their offspring. A 
maternal vaccination approach is being tested by Novavax in Phase III clinical trials and being 
pursued by a number of other entities, including preclinical testing performed by our lab and 
discussed in Chapter 6. 
In addition to new vaccine approaches and monoclonal antibodies undergoing preclinical 
or clinical testing, there are a number of antivirals being developed. The four types of RSV 
antivirals under development include: immunoglobulins, nucleoside analogues, small interfering 
RNAs (siRNA)-interference (anti-sense), and fusion inhibitors (77). All of the treatments are 
administered orally or through inhalation but all are therapies given once an infection has already 
been established. Their effectiveness is dependent on administration early in infection, which 
limits their utility based on the fact that most people present to healthcare providers at a time when 
viral replication has peaked (78).   
 11 
In summary, the infant immune response must perform a delicate balancing act. On one 
hand, infants must learn to recognize and become tolerant of commensal microorganisms that play 
critical roles in maintaining homeostasis. On the other hand, they must learn to identify pathogenic 
organisms and develop an immune response that can eliminate the organism while preventing 
immunopathology that may compromise further development of organ systems, such as the lungs. 
As researchers, we must develop a deep understanding of, not only baseline age-dependent 
differences in immunity, but also age-specific host-pathogen interactions. Recognition of RSV as 
a leading cause of morbidity in the very young has come easily in a clinical sense, but research into 
RSV pathogenesis as well as, host-pathogen interaction studies have been less willing to adopt 
“infant-centric” models. By recognizing and understanding age-dependent RSV immune 
responses, we may be able to better identify therapeutic opportunities without disrupting the 
delicate balancing act between eliminating pathogens and preventing immunopathology. 
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2.0  MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 Cell culture and reagents 
The immortalized human epithelial HEp-2 cell line was purchased from American Type Culture 
Collection (ATCC, Catalog number:  ATCC CCL-23) and cultured in MEM Earles (Life 
Technologies, Catalog number:  11095098) supplemented with 10% fetal bovine serum (FBS; 
Atlanta Biologicals, Catalog number:  S12450), 5,000 U penicillin/streptomycin (P/S, Fisher 
Scientific, Catalog number:  30-002-CI), and amphotericin B 125mcg (Fungizone, Life 
Technologies, Catalog number:  15290018). HEp-2 cells were washed with 1X phosphate buffered 
saline (PBS, Fisher Scientific, Catalog number:  BW17517Q) and harvested with 0.25% trypsin 
EDTA (Life Technologies, Catalog number:  25200056).  
 The immortalized human lung epithelial A549 cell line was purchased from ATCC 
(Catalog number:  ATCC CCL-185) and cultured in DMEM (Fisher Scientific, Catalog number:  
BW12604Q) supplemented with 10% FBS, 5,000 U P/S, and 2mM L-glutamine (Fisher Scientific, 
Catalog number:  MT25005CI). A549 cells were grown in flasks, washed with 1X PBS, and 
harvested with trypsin.  
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2.1.2 Viral strains 
Line 19 RSV (RSV L19) subtype A virus was used exclusively in our studies and was provided 
by Dr. Martin Moore (originally at Emory University, Atlanta, GA; now at Meissa Vaccines, San 
Francisco, CA).  
2.1.3 Cytokines and other pulmonary treatments 
Recombinant murine interferon gamma (IFN; Peprotech, Catalog number:  315-05) was 
reconstituted in PBS containing carrier protein (0.1% bovine serum albumin (BSA)). Recombinant 
human IFNγ (Life Technologies, Catalog number:  PHC4031) was reconstituted in PBS containing 
carrier protein (0.1% BSA). The pan-adenosine receptor antagonist 1,3-Dipropyl-8-(P-
Sulfophenyl)Xanthine (DPSPX) was reconstituted in PBS (Sigma Aldrich, Catalog number:  
A022). Clodronate liposomes (CLip) were acquired from Liposoma B.V. (The Netherlands, 
Catalog number:  C-005).  Lyophilized carboxyfluorescein succinimidyl ester (CFSE) was 
prepared by dissolving the contents of the vial in dimethyl sulfoxide (DMSO, VWR, Catalog 
number:  EM-2951) to a concentration of 5mM. The solution was further diluted to a concentration 
of 1μM using Hank’s Balanced Salt Solution (HBSS, Fisher Scientific, Catalog number:  
SH30268LS).  
2.1.4 Animals 
Mice were maintained under pathogen-free conditions at the University of Pittsburgh Division of 
Laboratory Animal Resources (Pittsburgh, PA) and handled according to University of Pittsburgh 
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Institutional Animal Care and Use Committee approved protocols. For most experiments 
pathogen-free 6-10 week old Balb/c mice (The Jackson Laboratory, Bar Harbor, ME) were 
purchased and used experimentally or bred to obtain timed pregnancies. Timed pregnancies were 
obtained by co-housing female mice for 5-7 days to synchronize estrus and then were bred (1:1) 
for a minimum of 3 days. Some studies used IFNγ receptor-1 knock out mice (IFNγR1KO, The 
Jackson Laboratory) which were either on a Balb/c or C57BL6 background. Wild-type (WT) 
C57BL6 mice (The Jackson Laboratory) were used as controls in experiments that used 
IFNγR1KO mice on a C57BL6 background. Animals were anesthetized with isoflurane (Henry 
Schein, Catalog number:  50033) for intranasal (i.n.) infections and treatments.  
2.1.5 RNA isolation 
RNA was isolated from fluorescence-activated cell sorting (FACS) using the MagMAX-96 Total 
RNA Isolation Kit (Fisher Scientific, Catalog number:  AM1830).   
2.1.6 Flow cytometry materials and antibodies 
Bronchoalveolar lavage (BAL) cells were collected via washes with HBSS + EDTA (30μM, 
Invitrogen, Catalog number:  15575-020). Mediastinal lymph nodes (MSLN) were collected in 
HBSS. Lung cells (URL, LD) used for flow cytometry were isolated following collection in RPMI 
1640 media (Life Technologies, Catalog number:  11875093) supplemented with 3% FBS and 
enzyme treated with collagenase A (1mg/mL, Sigma Aldrich, C9891). Red blood cells were 
eliminated from all tissue types using ACK (ammonium chloride potassium) solution (Fisher 
Scientific, Catalog number:  A1049201).  
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 BAL and lung cells analyzed for intracellular cytokine production by innate immune cells 
were resuspended in 0% RPMI (RPMI 1640 media, HEPES (25mM, Fisher Scientific, Catalog 
number:  155630), L-glutamine (Mediatech, Catalog number:  MT25005CI), 5,000U P/S, 50μM 
β-mercaptoethanol (Sigma Aldrich, Catalog number:  M6250)) supplemented with 10% FBS and 
brefeldin A (Biolegend, Catalog number:  420601).  BAL and lung cells analyzed for intracellular 
cytokine production by T cells were resuspended in 0% RPMI supplemented with 10% FBS and 
purified anti-mouse CD28 (Biolegend, Catalog number:  102101) and placed in a plate coated with 
purified anti-mouse CD3ε (Biolegend, Catalog number:  100301). Following CD3/CD28 
stimulation, T cells were re-stimulated in 0% RPMI supplemented with 10% FBS, phorbol 12-
myristrate 13-acetate (PMA, Sigma Aldrich, Catalog number:  P8139-1MG), and ionomycin 
(Sigma Aldrich, Catalog number:  I0634).  
 Cells were typically fixed prior to analysis (one exception: alveolar macrophages isolated 
for RNA sequencing) and one of the following agents were used: 1% paraformaldehyde (Alfa 
Aesar, Catalog number:  43368), BD Cytofix (BD Biosciences, Catalog number:  554655), 
Biolegend True Nuclear Fixative (Biolegend, Catalog number:  424401), or FoxP3/Transcription 
Staining Buffer Fixative (eBioscience, Catalog number:  00-5523-00). Note: If intracellular cell 
staining occurred then the permeabilization buffer from the respective kit (listed previously) was 
used. 
 The antibodies and isotype controls used for flow cytometry are listed in Table 2.1. Cells 
were resuspended prior to flow cytometry in staining buffer (PBA: 1X PBS, 0.1% BSA, 0.02% 
sodium azide). Samples were run on a BD LSRFortessa or BD LSR II managed by the University 
of Pittsburgh United Flow Core or Children’s Hospital of Pittsburgh Rangos Research Center Flow 
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Cytometry Core Laboratory. Data was analyzed using FlowJo V10 software (FLOWJO, LLC, 
OR). 
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2.1.7 Monocyte isolation 
Blood samples were diluted (1:1) with PBS supplemented with 2% FBS. Mononuclear cells 
(MNCs) were enriched through the use of the density gradient medium, Lymphoprep 
(STEMCELL, Catalog number:  07801) and SepMate-50 tubes (STEMCELL, Catalog number:  
85450).  Enriched MNCs were resuspended in RPMI 1640 media supplemented with 10% FBS, 
1% P/S, and 1% L-glutamine (10% MDM media). The EasySep Human Monocyte Isolation Kit 
(STEMCELL, Catalog number:  19359) was used to isolate monocytes using an EasySep Magnet 
(STEMCELL, Catalog number: 18000).  The antibodies used to determine monocyte purity are 
listed in Table 2.2. Enriched monocytes were differentiated into macrophages with 10% MDM 
media supplemented with recombinant, human GM-CSF (Peprotech, Catalog number:  300-03-
100UG). 
 




2.1.8 RSV neutralizing and RSV-specific antibodies 
Serum was collected in Gel-Z Serum Separator Tubes (Sarstedt, Catalog number:  41.1500.005).  
Purified RSV L19 was adhered to high-binding microtiter plate (Fisher Scientific, Catalog number:  
14245153) in binding buffer (Na2CO3, NaHCO3, diH2O). The plate was blocked with blocking 
buffer (3% BSA; 3% bovine serum albumin in PBS). Primary and secondary antibodies used for 
the RSV neutralization assay and the RSV-specific IgG subtype analysis are listed in Table 2.3. 
TMB substrate (ThermoFisher Scientific, Catalog number:  PI34021) was added and color was 
allowed to develop before being stopped with 1M sulfuric acid (Sigma Aldrich, Catalog number:  
35276-1L). The optical density was read at 450 nm using the ELx800™ Plate Reader (BioTek, 
VT). 
 
Table 2.3 Antibodies for neutralizing and RSV-specific antibody assays 
 
2.1.9 Cytokine measurements 
Cytokine measurements from blood, lung tissue, or BAL were performed using the Bio-Plex ProTM 
Mouse Cytokine 23-plex Assay (BioRad, Catalog number:  m60009rdpd) or the Th1/Th2 8-plex 
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Assay (BioRad, Catalog number:  M6000003J7), per manufacturer’s protocol or as outlined in the 
following methods. Plates were read using a Luminex® 200 Total System machine (Luminex 
Corp, Austin, TX) located and maintained by the lab of Dr. John Alcorn at Rangos Research 
Facility at Children’s Hospital of Pittsburgh.  
2.2 METHODS 
2.2.1 RSV propagation and purification 
RSV L19 was passed through four rounds of plaque purification for generation of master stocks; 
working stocks were propagated in HEp-2 cells. Briefly, working stocks were created by growing 
flasks of HEp-2 cells to 80% confluency, removing all but 3mls of media and infecting with 1ml 
of RSV L19 master stock for 1 hour on a rocker at 37⁰ C. After incubation, the cells were 
supplemented with additional media and monitored for cytopathic effect (CPE; 80-90%), which 
occurred in approximately 36-48 hours. Once the desired CPE was reached, the cells were scraped 
and the entire contents of the flask harvested and then sonicated. Following centrifugation to 
remove cellular debris, aliquots of virus were quickly frozen in a dry ice/2-propanol (Fisher 
Scientific, Catalog number:  A426P4) bath.  
 Purified RSV L19 was used in RSV-specific ELISA assays detailed below. It was prepared 
by growing HEp-2 cells to 80% confluency, which were then washed twice with PBS. Then 6mls 
of OptiMEM (Life Technologies, Catalog number:  31985070) supplemented with 2% FBS was 
added to the flask. Master stock RSV L19 was then added to the flask and incubated on a rocker 
for 2 hours. Following incubation, additional 2% FBS-OptiMEM was added to the flask and the 
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flask was monitored for CPE. Similar to the working stock, cells were scraped and sonicated when 
there was 80-90% CPE. However, the viral solution was centrifuged in Amicon Ultra-15 
centrifugal filter tubes (Millipore, Catalog number:  UFC910024) until 1ml of viral retentate 
remained and was aliquoted. Purified RSV L19 was flash frozen in liquid nitrogen.  
2.2.2 RSV infections and intranasal treatments 
Balb/c (WT and IFNγR1KO) or C57BL/6 mice (WT and IFNγR1KO) were purchased from The 
Jackson Laboratory (Bar Harbor, ME) at 6-8 weeks of age and bred in-house, as previously 
described (1) or used experimentally. Mice were infected i.n. with 5 x 105 plaque forming units 
(pfu) of RSV L19 per gram of body weight at post-natal day (PND) 2-7 (infants, ~1.5 x 106pfu in 
10mcl) or 6-10 weeks of age (adults, ~107pfu in 100mcl) under isoflurane anesthesia. 
Recombinant-murine IFNγ (16ng/gm or 60ng/gm) was administered i.n. to PND 2-7 (or 6-10 week 
old C57BL/6 IFNγR1KO mice, where indicated) on 1, 3, and 5 days post-infection (DPI).  
To deplete AMs, clodronate liposomes (CLip) (5mcl/gm of 5mg/ml suspension) were 
administered i.n. to PND 2 mice under 2% isoflurane anesthesia beginning day -1  post-infection, 
then daily until the mice were culled via 100% isoflurane for sample collection. On days 1, 3, and 
5 when IFNγ was co-administered, the doses of CLip and IFNγ were separated by ≥ 6 hours.  
To block adenosine receptor signaling, the pan-adenosine receptor antagonist, DPSPX 
(1μM in PBS), was administered i.n. to PND 3 mice beginning -1 DPI and continued daily until 
the mice were culled (Note: DPSPX was not administered on the day of RSV infection). 
For secondary RSV infection studies, animals were allowed to recover for 6 weeks in-
between primary and secondary challenges. Animals were then challenged with RSV L19 (5 x 
105pfu/gm) and samples collected at indicated time points.  
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2.2.3 RSV viral titers 
RSV lung titers were quantified from left lung at the indicated time points using H&E plaque 
assay, as described previously (79). Lungs were snap-frozen in a dry ice bath and stored at -80 ⁰C. 
Lungs were thawed and homogenized with glass beads using a mortar and pestle. Homogenized 
lung was centrifuged and serial dilutions made in HEp-2 media. Dilutions were placed on HEp-2 
cells plated in 12-wells and grown to 80% confluency. After incubation at 37 ⁰C on a rocker for 1 
hour, infected cells were covered with methyl cellulose and left to incubate for 5 days before fixing 
with 10% formalin and H&E staining. H&E plaque assays were also used for titering of RSV L19 
working stocks as well as other viral solutions in in-vitro studies.  
2.2.4 FACS sorting and RNA isolation for RNA sequencing 
Naïve and RSV-infected infants (PND 4-5) and adult Balb/c (8-10 weeks) mice were culled and 
BAL collected at 4 and 3 DPI, respectively. Cells were processed for flow cytometry and surface 
stained (Siglec F, CD11c, CD11b, CD200R, F4/80, MHCII, Ly6G). The cells were not fixed so 
that we could ensure the highest quality RNA after sorting. Samples were then sorted on a LSRII 
Aria and AMs (Sig F+, F4/80+ CD200R+ CD11cHI, CD11b+/-, MHCII-/lo, and Ly6G-) were collected 
into PBS supplemented with 50% FBS. Isolated AMs were centrifuged and resuspended in lysis 
buffer and stored at -80 ⁰C until RNA isolation.  
RNA from sorted AMs was isolated using the MagMAX-96 Total RNA Isolation Kit 
according the manufacturer’s instructions. RNA was eluted into 25mcl and sent the lab of Dr. 
William Janssen at National Jewish Health for RNA sequencing. RNA quality was tested and 
normalized prior to library development and sequencing.   
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2.2.5 Histology 
At the indicated time point, right lungs were gravity filled (25cm from meniscus to catheter) with 
10% formalin after flushing the respiratory system with PBS. Lungs were preserved for at least 48 
hours in 10% formalin at 4 ⁰C. The lungs were paraffin-embedded, stained, and processed at the 
histology core at the McGowan Institute for Regenerative Medicine (University of Pittsburgh, PA). 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and periodic acid-Schiff 
(PAS) stains were used to identify cells undergoing apoptosis and mucus accumulation, 
respectively. Hematoxylin and Eosin (H&E) stain was used to identify inflammation. Slides were 
examined and quantified by individuals blinded to treatment group. For quantification of TUNEL 
staining, images were captured at 40X magnification and the average number of apoptotic cells 
per lung section were quantified and graphed. PAS-staining of mucus was scored according to 
previously published methods (1). In short, all airways were scored for the percentage of the airway 
staining PAS+ (bright pink) in each tissue section according to the following scale: 0 = no PAS+ 
cells; 1 = 1-25% PAS+ cells; 2 = 26-50% PAS+ cells; 3 = 51-75% PAS+ cells; 4 = 76-100% PAS+ 
cells.  
2.2.6 Measuring extracellular adenosine concentrations 
Naïve infants (PND 4-5) and adults (8-10 weeks) were culled and first wash (FW; 200mcl) 
collected. Cells were removed via centrifugation and the supernatant collected and transferred to 
a clean Eppendorf tube. FW supernatant was boiled for 90 seconds to deactivate enzymes that may 
metabolize adenosine. Samples were then sent to the lab of Dr. Edwin Jackson for adenosine 
quantification via liquid chromatography-mass spectrometry/mass spectrometry.  
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2.2.7 Pharmacokinetics and cytokine measurements 
For the pharmacokinetic study, a single dose of murine IFNγ was administered i.n. to RSV-naive 
infant (PND 4-7) and adult (8-10 weeks) mice. Following the single dose of IFNγ, infant and adult 
mice were culled and samples collected at 0, 0.5, 1, 2, 4, 6, 8, 12, 18, 24, and 48 hours post-dose. 
Right lungs were collected, weighed and immediately snap-frozen in liquid nitrogen. Samples 
were stored at -80 ⁰C until they were processed for protein quantification and cytokine analysis as 
previously described (80). Briefly, frozen lungs were homogenized in cold Tissue Protein 
Extraction Reagent (T-PER, Thermo Scientific) and protease inhibitor (HALT Protease Inhibitor 
Cocktail, Thermo Scientific) (1ml T-PER + 10mcl HALT protease inhibitor cocktail used for every 
100mcg of frozen lung tissue), then centrifuged at 9,000g for 10 minutes at 4 ⁰C. The supernatant 
was collected and total protein was quantified by bicinchoninic acid assay (BCA assay, Thermo 
Scientific Pierce) per manufacturer’s instructions. The remaining supernatant was stored at -80 ⁰C 
for cytokine analysis. IFNγ concentrations in lung homogenate and blood were analyzed by a 
murine 23-plex multiplex cytokine kit (Bio-Rad, Hercules, CA).  Homogenized lung samples were 
diluted to a total protein concentration of 500mcg/ml using a 1:1 mixture of T-PER and sample 
diluent (provided by manufacturer). Blood was collected following cardiac puncture (adults) or 
severing of the abdominal aorta (infants) and allowed to clot for 45 minutes prior to processing. 
Following clotting, blood samples were centrifuged at 1,000 x g for 15 minutes at 4 ⁰C. 
Supernatants were transferred and centrifuged again at 10,000 x g for 10 minutes at 4 ⁰C.  Samples 
were analyzed using a Luminex® 200™ Total System machine (Luminex Corp, Austin, Tx).  
 Lung IFNγ concentration-time data after a single i.n. IFNγ dose was analyzed by non-
compartmental analysis (NCA). The terminal elimination rate constant, kel, was estimated by log-
linear regression of at least three time points visually assessed to be in the terminal phase of each 
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lung concentration-time plot. The terminal phase (elimination) half-life, t1/2, was calculated as 
ln2/kel. The area under the lung concentration versus time curve, AUC0→∞, was also calculated. 
Using the linear trapezoidal rule (81), AUClast→∞ was extrapolated to infinity by calculating 
Clast/kel. The AUC0→∞ was calculated as the sum of AUClast→∞ and AUC0→t. Other pharmacokinetic 
parameters calculated include IFNγ total body clearance, estimated as dose/AUC. The estimated 
neonatal dose capable of achieving adult AUC values was calculated by dividing the adult 
AUC0→∞ by neonatal total body clearance. 
2.2.8 IFNγ treatment of A549 cells 
12-well plates were seeded with A549 cells (1.5x105cells/ml) and incubated for 24 hours until the 
wells were 70-80% confluent. Cells were pre-treated with IFN (100ng) by removing conditioned 
media and replaced with A549 media supplemented with IFN and incubated for 1 hour. IFN 
A549 media was then aspirated and replaced with IFN A549 media spiked with RSV L19 
(multiplicity of infection = 2) and incubated for 3 hours with rocking. At the end of infection, well 
volumes were brought to a total of 1 ml with IFN A549 media and the plates were incubated until 
the desired time point.  
 Extracellular (budded) virus was quantified by collecting the supernatant from each well 
and centrifuging samples. Clarified supernatant was serially diluted and plated onto pre-prepared 
HEp-2 cells in 12-well plates (70-80% confluent) for viral plaque quantification via standard H&E 
assay described previously. 
 In order to quantify intracellular virus, A549 cells were detached from the plate via trypsin. 
The trypsin was deactivated with media and the cells were transferred to snap-cap tubes and 
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centrifuged. The cell pellet was resuspended in HEp-2 media and placed at -80 ⁰C for 1 hour. 
Tubes were removed from the freezer and allowed to equilibrate to room temperature before 
repeating the freeze thaw cycle. Then, tubes were centrifuged and serial dilutions made from 
supernatant. Serial dilutions were placed on pre-prepared 12-well plates seeded with HEp-2 cells 
(70-80% confluent) and standard H&E plaque assays performed to determine viral titer, as 
described previously. 
2.2.9 Cell preparation, cytokine analysis, and flow cytometry 
FW and BAL were collected by instilling HBSS+EDTA into the alveolar space (FW-100mcl, 
BAL-1.2ml). The right lung (RL or URL) was harvested and enzyme-digested into a single cell 
suspension, as previously described (82). FW samples were centrifuged, and the soluble fraction 
was separated and stored at -80 ⁰C for cytokine analysis. For some experiments MSLNs were 
collected and processed into single cell suspensions for flow cytometry. 
 Cytokine concentrations were determined using the Bio-Plex ProTM Mouse Cytokine 23-
plex or Th1/Th2 8-plex Assay (BioRad, CA), per manufacturer’s protocol. Measured cytokine 
concentrations from secondary RSV infection studies (2 and 4 days post-secondary challenge) 
were used by collaborators (Drs. Yoram Vodovotz and Ruben Zamora) to develop dynamic 
network analyses. 
 The cellular components of BAL and RL were processed for surface and intracellular flow 
cytometric analysis. For surface and intracellular marker detection, cells were surface stained for 
25 minutes and fixed (20-30 minutes) with one of the fixatives previously mentioned. For 
intracellular marker detection, cells were permeabilized according to manufacturer 
recommendations with one of the kits mentioned previously and stained for intracellular markers 
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for 45 minutes. Intracellular staining occurred on the same day that samples were run on the flow 
cytometer. Where indicated, BAL samples were incubated with RSV A Strain F-protein 85-93 MHC 
I pentamer, which was stained for prior to surface staining. 
Intracellular cytokine staining occurred in innate and T cells from the BAL and lung in 
some studies. For innate intracellular cytokine staining, cells were resuspended and incubated in 
0% RPMI supplemented with 10% FBS and brefeldin A (1:1000) for 3 hours. T cell intracellular 
cytokine staining occurred following overnight CD3ε/CD28 stimulation. First, a 96-well flat-
bottom plate was coated with 50mcl of a CD3ε/PBS solution (50mcg/ml) and incubated at 4 ⁰C 
overnight or at 37 ⁰C for 2 hours. Then, BAL or lung cells resuspended in 0% RPMI supplemented 
with 10% FBS and CD28 (2mcg/ml) were placed in the CD3ε coated plate and incubated at 37 ⁰C 
overnight. The next morning, the cells were restimulated with PMA (10ng/ml), brefeldin A 
(1:1000), and ionomycin (1mcg/ml) for 3 hours.  Following stimulation, cells were washed and 
then surface stained, fixed, permeabilized, and intracellularly stained as described previously. 
2.2.10 Human monocyte isolation and differentiation 
Whole blood was diluted 1:1 with PBS supplemented with 2% FBS and added to a SepMate50 
tube with 15ml of Lymphoprep. Tubes were centrifuged and the top layer containing enriched 
MNCs was poured into a new 50ml conical tube. The MNCs were washed and spun twice before 
being resuspended in 10% MDM media. 
For the plating method of isolating monocytes, MNCs were enumerated and aliquoted into 
wells. The cells were incubated at 37 ⁰C for at least 90 minutes before non-adherent cells were 
washed away. The remaining adherent cells could then undergo differentiation into macrophages. 
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For column enrichment of CD14+ CD16- monocytes, enriched MNCs were enumerated and 
aliquoted for magnetic separation according to manufacturer’s instructions in RoboSep buffer. 
Briefly, MNCs in RoboSep buffer were mixed with Platelet Removal Cocktail, Isolation Cocktail, 
and magnetic particles. The sample was then placed within the EasySep magnet where unwanted 
cell types were bound by antibodies conjugated to the magnetic particles and removed from the 
sample by the magnet. Then, enriched monocytes (CD14+ CD16-) could be poured off into a new 
tube, counted and aliquoted for differentiation into macrophages. 
Differentiation of monocytes was induced by resuspending monocytes into 10% MDM 
media supplemented with human GM-CSF (25ng/ml) for 7 days. Every 2-3 days, 50% of 
conditioned media was replaced by fresh GM-CSF supplemented 10% MDM media. After 
differentiation, cells were detached from the plate by incubating them with TrypLE (Fisher 
Scientific, Catalog number:  12604013) for 20-30 minutes following washing. The TrypLE was 
deactivated with 10% MDM media and the cells processed for flow cytometry as described 
previously. 
Monocyte purity was evaluated visually by differential cell staining after affixing isolated 
cells onto microscope slides. First, 100mcl of cell suspensions were spun onto slides then fixed 
with methanol and stained with the HEMA3 Stain Set (Fisher Scientific, Catalog number:  122-
911), according to manufacturer’s instructions. Cell purity was then assessed microscopically.  
2.2.11 Airway hyperresponsiveness 
Pulmonary function testing was measured on a flexiVent machine (SCIREZ, Montreal, Quebec, 
Canada) in the lab of Dr. John Alcorn under the assistance of Dr. Michelle Manni, as previously 
described (83). Briefly, Balb/c mice underwent secondary RSV challenge and were transferred to 
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Rangos Research Facility 6 days after secondary challenge. Animals were anesthetized and 
pulmonary function measurements taken following methacholine administration (0, 3.125, 12.5, 
and 25mg/mL). 
2.2.12 CFSE staining and adoptive transfer 
Animals that underwent primary RSV infection and IFNγ treatments as infants were rested for 6 
weeks, then culled and BAL collected. AMs collected from individual animals were combined 
within a group and resuspended (7.5 x 10 cells/ml) in warmed RPMI 1640 media supplemented 
with 5% FBS and plated in a 12-well culture plate. Cells were incubated at 37 ⁰C for 2 hours to 
allow adherence. Once adhered, the media was aspirated and the AMs were washed thoroughly 
with HBSS. After washing, AMs were incubated with the CFSE solution (1μM/ml) at 37 ⁰C for 
20 minutes with gentle rocking. After CFSE staining, AMs were washed twice with 5% RPMI and 
incubated for 10 minutes in 5% RMPI to allow the CFSE to undergo acetate hydrolysis. Then, 
AMs were washed with HBSS and removed from the plate via gentle enzyme dissociation with 
TrypLE. AMs were collected, centrifuged, counted, and resuspended in HBSS+EDTA 
(5x105cells/100mcl). Finally, the CFSE-stained AMs were kept on ice, protected from light, and 
adoptively transferred i.n. into adult, naïve recipient mice (5x105cells/100mcl). One day after 
adoptive transfer, recipient mice were challenged with RSV L19 (5x105pfu/gm) and culled at 4 
DPI for sample analysis. In this study, BAL was collected for flow cytometry and left lungs 
collected for viral titers.  
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2.2.13 Maternal Immunization 
At time of co-housing, 7 week old female BALB/c were immunized (prime) via intramuscular 
(i.m.) injection with 50mcl of vehicle (PBS), DS-Cav1 alone (10mcg/mouse; a gift from Jason 
McClellan, Dartmouth College, NH; currently at University of Texas, Austin), or in combination 
with Advax-SM (DS-Cav1 + Advax-SM; Advax-SM™, 1mg/mouse; a gift from Vaxine Pty Ltd, 
Bedford Park, Australia). A week later, mice were bred in-house and in the second week of 
gestation (21 days post-prime), female mice were boosted i.m. with their respective vaccine. Dams 
were challenged at 15 weeks of age (53 days post-prime/32 days post-boost), infants challenged 
at PND 5-6, and weanlings were weaned at 3 weeks of age and challenged 2 weeks later.  
2.2.14 Plaque reduction neutralization test (PRNT) 
Pre-challenge blood was collected from dams at 50 days post-prime (3 days prior to RSV 
challenge) via submandibular bleeding. Pre-challenge serum was collected from weanling groups 
(PND 37) immediately prior to RSV challenge. Post-challenge blood was collected at 4 days-post 
RSV challenge via severing of abdominal aorta (infants) or cardiac puncture (weanling and dams) 
at time of sacrifice. Serum was separated using Gel-Z Serum Separator, heat-inactivated at 56 ⁰C 
for 30 minutes, and stored at -80 ⁰C until neutralizing titers were determined. The following 
protocol was adapted from a previously described RSV PRNT assay (84). Heat-inactivated antisera 
was initially diluted in 10% FBS-DMEM at 1:40 (pre-challenge serum) or 1:20 (post-challenge 
serum) dilutions, then 2-fold serially diluted in a 96-well plate. RSV L19 (1500 PFU/well) was 
added and the antisera/virus mixture was incubated at 37oC for 1 hour. Virus-antisera mixture 
(100mcl) was added to 1.5x104 HEp2 cells in each well of a 96-well plate and incubated at 37 ⁰C 
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for 3 days at 5% CO2. Plates were washed with PBS and fixed with acetone at 4 ⁰C for 20 minutes. 
Goat anti-RSV polyclonal antibody was added at a 1:4000 dilution and incubated at room 
temperature (RT) for 1 hour. HRP-conjugated donkey anti-goat IgG was then added at a 1:4000 
dilution and incubated at RT for 1 hour. TMB substrate was added and color was allowed to 
develop for 5 to 7 minutes, at which time 1M sulfuric acid was added to stop the reaction. Optical 
density was measured at 450nm. Reciprocal serum dilutions at which 50% of RSV L19 was 
neutralized in relation to control wells was graphed. 
2.2.15 RSV-specific IgG subtype assay 
RSV-specific IgG subtypes were measured as previously described (85). Briefly, Immulon high-
binding 96-well microtiter plates were coated with 100mcl of purified RSV L19 virus (3 x 105pfu) 
in binding buffer at 4 ⁰C overnight. After washing steps and blocking for 2 hours at 37 ⁰C with 
blocking buffer (3% BSA in PBS), antisera was diluted (dams, 1:100; weanlings, 1:20) in blocking 
buffer and incubated in triplicate overnight at 4 ⁰C. The plates were then incubated with HRP-
conjugated IgG1 or IgG2a goat anti-mouse secondary antibodies at 37 ⁰C for 90 minutes. TMB 
substrate was added and color was allowed to develop for 30 minutes at 37 ⁰C. The optical density 
was read at 450 nm. Optical densities (OD) were graphed after subtracting background OD from 
triplicate wells incubated with blocking buffer. 
2.2.16 Statistical analysis 
GraphPad Prism version 5.0 was used for all statistical analyses. Means were compared using a 
Student’s t-test, or for multiple comparisons, a one-way analysis of variance (ANOVA) was used 
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with Tukey’s or Bonferroni post hoc test to evaluate statistical significance between groups. For 
experiments where multiple groups were compared over multiple time points, a two-way ANOVA 
was used and a Bonferroni post hoc test used to evaluate statistical significance between groups. 
Repeated measures ANOVA was used to determine changes in weight over time between groups 
with a Bonferroni post hoc test.  All data are shown as mean ± SD of biological replicates within 
individual experiments. Where indicated, 2-3 infant BAL samples within a group were combined 
to form a single sample. ρ < 0.05 was considered statistically significant.  
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3.0  INFANT VERSUS ADULT RESPONSES TO RSV 
Sections of this chapter are adapted from the published manuscript: 
Katherine M. Eichinger, Jessica L. Kosanovich, and Kerry M. Empey 
Localization of the T-cell response to RSV infection is altered in infant mice. Pediatric 
Pulmonology, 2018. 53 (2): 145-153. (© Wiley Periodicals, Inc.) 
This is the peer reviewed version of the following article: Eichinger KM, Kosanovich JL, 
Empey KM. Localization of the T-cell response to RSV infection is altered in infant mice. 
Pediatric pulmonology 2018;53(2):145-153, which has been published in final form at 
[DOI:10.1002/ppul.23911]. This article may be used for non-commercial purposes in 
accordance with Wiley Terms and Conditions for Self-Archiving. 
3.1 INTRODUCTION 
 
Respiratory tract infections represent the single largest disease burden worldwide (86) and are 
especially prominent in infants and young children. In 2015, lower respiratory tract infections 
(LRTI) were responsible for 15.3% of mortality in children < 5 years old (87). Globally, RSV is 
the most common cause of acute LRTI in children resulting in a significant number of hospital 
admissions (28, 88). Despite RSV’s immense contribution to the global burden of lung disease, 
there are no effective treatments or licensed vaccines. The anti-RSV antibody, palivizumab, 
reduces the number of RSV-associated hospitalizations in high-risk infants when given 
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prophylactically (89), yet 80% of RSV-related hospitalizations consist of previously healthy 
infants and children who do not receive prophylaxis (30, 90). A more universal measure aimed at 
preventing primary RSV-related morbidity and mortality is a healthcare priority. Therefore, a more 
complete understanding of the infant immune response to RSV is necessary to guide the 
development of future vaccines and therapeutic interventions. 
Innate immunity provides the critical link between pathogen detection and induction of an 
effective adaptive immune response capable of clearing the invading organism. Eliciting an 
adaptive immune response against RSV requires pathogen detection by airway epithelial cells 
(AECs) and AMs and activation of these cells. Typically, invading pathogens activate AECs and 
AMs through pattern-recognition receptors, such as TLRs. Once activated, AMs will increase 
expression of co-stimulatory markers and both cell types will produce inflammatory cytokines that 
will recruit and activate additional immune cells. In adults, activated mononuclear cells produce 
TNFα, IL-1β, and IL-12 and increase co-stimulatory marker expression, which work in concert to 
promote inflammation and engage adaptive immunity to combat pathogens (91, 92). However, 
infant mononuclear cells activated through TLR agonists are generally characterized by a high IL-
6 to TNFα cytokine response, which is reflective of their bias away from Th1-type cytokine 
responses (TNFα, IL-12p70, and IFNγ) (48, 92, 93). In part, this reduced capacity to mount an 
effective Th1 response makes infants vulnerable to infection by intracellular pathogens (50), such 
as RSV, and compromises their ability to facilitate effective adaptive immunity. 
The importance of T lymphocytes in clearing RSV has been well established in murine (61, 
94-96) and human studies (97). However, debate still exists regarding the effectiveness of T-cell 
recruitment to the air space of RSV-infected infants (98, 99). Autopsy samples from infants 
infected with RSV revealed that T-cell infiltration into the lung was meager but importantly, the 
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small number of T-cells located within the alveolar space were highly activated, suggesting close 
proximity to RSV-infected airway epithelium increases activation (98). Similarly, BAL samples 
from RSV-infected infants showed massive neutrophil recruitment but relatively small increases 
in the frequency of T-cells (100, 101). The CD8+ T-cells recovered from the BAL of these infants 
had a highly activated, effector phenotype, were proliferating, and produced Granzyme B (101). 
However, in an infant murine model of influenza, recovery of T-cells from the alveolar space was 
deficient when compared to adults (102). Collectively these studies indicate that T-cells exert their 
anti-viral effects proximal to RSV-infected AECs within the bronchoalveolar space but the 
accumulation of infant T-cells may be inefficient. Murine studies investigating the role of T 
lymphocytes in RSV disease have relied heavily on adult models and may therefore be missing 
important differences in infant T-cell accumulation and activation in the airway. Furthermore, 
there is a scarcity of data regarding the age-dependent differences that may exist in T-cell 
accumulation throughout the pulmonary architecture of RSV-infected adult and infant mice.  
It is well appreciated that infants have higher concentrations of 
immunosuppressive/immunoregulatory factors (ex. IL-10, TGFβ, IL-27, and retinoic acid) in the 
lung environment (103-105). One such molecule that has not been investigated in the context of 
infant RSV infection is the purine nucleoside, adenosine. This molecule’s profound effects on the 
modulation of nitric oxide production, suppression of TNFα and IL-12 production, and facilitation 
of IL-10 production by macrophages has been extensively reviewed (106). High adenosine 
concentrations in neonatal plasma have been found to divert a normal Th1 cytokine response 
following TLR stimulation to a Th2-biased response (92), but the role that it may play within the 
infant airway during RSV infection has never been investigated.   
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In order to determine age-dependent differences in innate RSV immunity, a kinetic 
examination of innate immune cells was conducted in RSV-infected infant and adult mice using 
flow cytometry. Given the importance of AMs in maintaining homeostatic lung conditions as well 
as their role in initiating inflammatory immune responses, transcriptional sequencing of AMs from 
naïve and RSV-infected infant and adult mice was performed, in order to identify specific age-
based differences. We also identified key differences in T cell accumulation within the pulmonary 
architecture of infant and adult mice following RSV infection. Lastly, we examined the role of 
extracellular adenosine on infant RSV immunity, which provides new insight into a previously 
unrecognized immunoregulatory molecule within the lung, disproportionately affecting infants. 
We hypothesized that increased concentrations of extracellular adenosine in the airways of infant 
mice will result in reduced innate activation following RSV challenge and subsequently, T cell 
recruitment to the infant airway will be reduced compared to adults.  
3.2 RESULTS 
3.2.1 Adult versus infant innate responses 
3.2.1.1 Phenotypic characterization of innate immune cells from BAL using flow cytometry 
in a murine model of RSV L19 
In previous flow cytometry experiments, our lab relied on antibodies directed against CD11b (αM) 
and CD11c (αX) integrins to identify innate immune cells in the BAL responding to RSV infection 
(1). However, our ability to fully characterize the innate immune response was limited by the fact 
that CD11b and CD11c are expressed by numerous cell types from both the adaptive and innate 
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immune systems. Identification of cell populations accurately using CD11b is further complicated 
by the fact that AMs and other activated immune cells increase their expression of CD11b in 
response to stimuli (107-109). To discriminate innate cell populations in the BAL using flow 
cytometry, an expanded panel of antibodies was created using data from published reports (110) 
and tested in our Balb/c model of RSV L19. Specifically for AMs, we analyzed the expression of 
markers listed in Table 3.1 and previously identified as distinguishing AM markers in a review by 
Hussell and Bell (110). Overall, AMs in our model were in agreement with those summarized by 
Hussell and Bell with the exceptions of F4/80 and CD11b. F4/80 has been widely used as a murine 
macrophage marker and was expressed by AMs harvested from the BAL. As previously 
mentioned, CD11b was not expressed by AMs in naïve mice but was quickly upregulated in 




Table 3.1. AM marker expression 
 38 
In addition to the markers highlighted in Table 3.1, Ly6G and major histocompatibility 
complex II (MHCII) were added to the panel to aid in the identification of neutrophils and dendritic 
cells, respectively. For an illustrative example, cell discrimination was conducted using flow 
cytometry and the eight marker panel (Siglec F, F4/80, CD206, CD200R, CD11c, CD11b, MHCII, 
and Ly6G) in a BAL sample collected from an adult animal with complex cellular infiltrate, as a 
result of a secondary RSV infection (Figure 3.1A). This innate immunophenotyping flow 
cytometry panel allows for discrimination of six, well defined, innate immune cell types. 
Additionally, the complexity of innate cellular immunophenotyping is highlighted when a naïve 
BAL sample is compared to a BAL sample harvested from an adult mouse responding to a 
secondary RSV infection in the context of CD11b and CD11c expression (Figure 3.1B). From the 
BAL of a naïve mouse, the overwhelming majority of cells are CD11cHI CD11b- and with the use 
of the innate immunophenotyping panel, these cells were identified in the overlay panel as AMs 
(Sig F+ F4/80+ MRHI CD200R+ CD11cHI) (Figure 3.1B). The introduction of secondary RSV 
results in a massive infiltration of innate immune cells that cannot be identified with CD11c and 
CD11b alone, as illustrated in the secondary RSV panel of single cells (Figure 3.1B). However, 
when the secondary RSV sample is viewed in the overlay panel, AMs, eosinophils (Sig F+ F4/80+ 
CD206lo/- CD200R- CD11c- CD11bint), neutrophils (Sig F- Ly6G+ CD11bHI CD11c-), Sig F- AMs 
(Sig F- F4/80+ CD206HI, CD200R+ CD11cHI), monocytes (Sig F- F4/80+ CD206lo/- CD11c+ 
CD11b+), and dendritic cells (Sig F- CD11c+ MHCIIHI) can be viewed as discrete populations 
(Figure 3.1B). This demonstrates the necessity of using a well-defined flow cytometry panel to 
accurately immunophenotype cells infiltrating the airway in response to RSV infection. Without 
accurate identification, the immune response of one cell type may be misappropriated to another 
and add confusion in the RSV literature. 
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3.2.1.2 Recruitment and activation of innate immune cells in response to RSV is decreased 
in infants compared to adults 
To determine the recruitment kinetics of innate immune cell types following RSV infection, we 
analyzed the monocyte and DC frequency in the BAL of infant and adult Balb/c mice at multiple 
Figure 3.1. Innate BAL immunophenotyping using flow cytometry 
Adult (6-8 week old) Balb/c mice were re-infected with RSV L19 after being initially challenged as 
infant mice (PND 4-6). At 4 days post-secondary challenge, BAL was collected and processed for flow 
cytometry. A representative example of the gating strategy used to identify innate immune cells is shown 
(A). Single cells analyzed via flow cytometry from a naïve and a 2⁰ challenge sample were visualized 
according to their CD11b and CD11c expression (B). Then, using the gating strategy in (A), 
immunophenotyped innate immune cells were overlaid onto single cells (B).  
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time points following RSV infection. The frequency of monocytes (monos; Sig F- CD11c+ 
CD11b+) rapidly rose in adult BAL, remained steady from 3 to 10 DPI, and began to decline 
slightly by 15 DPI (Figure 3.2A). Monocyte recruitment in RSV-infected infants was dramatically 
lower than that of adults, representing a negligible percentage of BAL cells (Figure 3.2B). Similar 
to adult monocytes, DCs (Sig F- CD11c+ MHCII HI) began increasing significantly in adult BAL 
as early as 3 DPI and peaked at 10 DPI (Figure 3.2C). In contrast, RSV-infected infants 
demonstrated significant increases in DC frequency at 7 and 10 DPI but in infants, DCs represented 






AMs make up the overwhelming majority of leukocytes in the airway (111). They must 
continually survey the lung environment and selectively identify pathogens vs. innocuous 
unfiltered debris, pollutants, etc. To determine age-based differences in AM responses following 
Adult (6-8 weeks) and infant (PND 4-5) Balb/c mice were infected with RSV L19. BAL was collected 
at 3, 7, 10, and 15 DPI and processed for flow cytometry. Frequencies of monocytes (monos) and DCs 
were calculated. The percentage of adult monos (A) and DCs (C) comprising the BAL were compared 
between naïve and RSV+ adult mice using ANOVA with a Bonferroni post-test. Naïve adult BALs (n 
≥ 1) were processed simultaneously with RSV+ samples at each time point to account for day to day 
variations in analysis.  However, the data from all naïve adults were pooled and represented graphically 
as 0 DPI.  The percentage of infant monos (B) and DCs (D) comprising the BAL were compared between 
naïve and RSV infants using 2-way ANOVA with Bonferroni post-test. Naïve, infant samples were 
analyzed at each time point to account for developmental changes. Data points represent individual mice 
(naïve adults) or the mean of n ≥ 3-4 samples (2-3 infant BALs pooled per sample) per group ± SD; * 
ρ-value < 0.05. Data are representative of 2 independent experiments. 
Figure 3.2. Reduced monocyte and DC recruitment in RSV-infected infants. 
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RSV infection, the BALs of adult and infant RSV-infected mice were compared to naïve, age-
matched controls using flow cytometry. Approximately 84% of naïve, adult BAL cells were AMs 
with the proportion of AMs decreasing significantly throughout the RSV infection time course as 
other cell types infiltrate the airway (Figure 3.3A). AMs represent a smaller percentage of cells 
found in infant BAL samples compared to adult mice, although the proportion of AMs steadily 
increases as the infants age (Figure 3.3B). However, the frequencies of AMs in infant BAL did 
not diverge between naïve and RSV infants, highlighting the lack of inflammatory cell recruitment 
to the infant airway following RSV challenge (Figure 3.3B). In adults, significant increases in 
markers of AM activation, including CD11b+ (Figure 3.3C), CD80+ (Figure 3.3E), MHCII+ 
(Figure 3.3G), and the phagocytic scavenger receptor-A (SR-A+, Figure 3.3I), occurred at 
different time points in response to RSV. Significant increases in markers of AM activation 
occurred in infants in response to RSV, however the peak or duration of increased activation was 
reduced when compared to adults. The duration and peak CD11b+ expression (Figure 3.3D) was 
lower in infants compared to adults, while the peak of activation was reduced for CD80+ (Figure 








As the previous data regarding AM activation demonstrated, CD11b expression 
immediately proceeded or coincided with a number of additional markers of activation. To further 
investigate age-based differences and the relationship between CD11b expression and associated 
AM activation, AMs expressing CD11b+ were compared directly to CD11b- AMs with respect to 
their expression of activation markers in RSV-infected adults and infants. At 3 DPI, the adult AM 
population was evenly split between CD11b+ and CD11b- expression and although the CD11b+ 
expression decreases by 7 DPI, approximately 18% of AMs still express CD11b+ (Figure 3.4A) 
at that time point. In contrast, RSV-infected infants maintained a significantly higher proportion 
of CD11b- AMs throughout the time course analyzed and any increases in CD11b+ expression at 
3 DPI are lost by 7 DPI (Figure 3.4B). Interestingly, the CD80+ expression on adult AMs coincides 
entirely with CD11b+ expression (Figure 3.4C). While MHCII+ (Figure 3.4E) and SR-A+ (Figure 
3.4G) expression was significantly higher on CD11b+ AMs, CD11b- AMs also increased 
Figure 3.3 (continued) Adult (6-8 weeks) and infant (PND 4-5) Balb/c mice were infected with RSV 
L19. BAL was collected at 3, 7, 10, and 15 DPI and processed for flow cytometry. The frequency of 
adult AMs (A) and their expression of CD11b+ (C), CD80+ (E), MHCII+ (G), and SR-A+ (I) were 
compared between naïve and RSV+ adult mice using ANOVA with a Bonferroni post-test; time points 
under bar indicate significantly different means compared to 0 DPI. Naïve adult BALs (n ≥ 1) were 
processed simultaneously with RSV+ samples at each time point to account for day to day variations in 
analysis.  However, the data from all naïve adults were pooled and represented graphically as 0 DPI.  
The frequency of infant AMs (B) and their expression of CD11b+ (D), CD80+ (F), MHCII+ (H), and SR-
A+ (J) were compared between naïve and RSV+ infants using 2-way ANOVA with Bonferroni post-
test. Naïve, infant samples (2-3 infant BALs pooled per sample) were analyzed at each time point to 
account for developmental changes. Data points represent individual mice (naïve adults) or the mean of 
n ≥ 3-4 samples (infants) per group ± SD; * ρ-value < 0.05. Data are representative of 2 independent 
experiments. 
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expression of these markers in RSV-infected adults. In RSV-infected infants, the increases in 
expression of CD80+ (Figure 3.4D), MHCII+ (Figure 3.4F), and SR-A+ (Figure 3.4H) coincided 
with CD11b+ expression, with no increases in the activation markers noted for CD11b- AMs. It is 
important to note however that CD11b+ expression on infant AMs decreased from nearly 35% at 
3 DPI to 2% at 7 DPI, so the contribution of activation markers on the larger immune response 
from such a small population at time points later than 3 DPI is questionable. Taken together, these 
data suggest that activation of the innate immune system as well as the recruitment of additional 
inflammatory immune cells is reduced during the infant RSV immune responses compared to 
adults, which may have ramifications on the downstream activation of the adaptive immune 




Figure 3.4. CD11b expression on AMs correlates with enhanced activation. 
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3.2.1.3 Age-dependent differential gene expression in AMs using RNA sequencing 
As the sentinels of the airway, AMs, along with airway epithelial cells, are the first cells to detect 
pathogens and initiate an immune response. Using phenotypic data, the previous figures 
demonstrated infant AMs had reduced activation following RSV challenge compared to adults. To 
determine how age-dependent transcriptional differences may influence AMs' responses following 
RSV challenge, AMs were isolated using FACS and their transcriptional data analyzed using RNA 
sequencing. The principle component analysis revealed that AM populations were highly clustered 
according to age and RSV status (Figure 3.5). There was significant separation between AMs from 
naïve and RSV infected adult mice suggesting large differences in genetic expression following 
RSV infection in adults. Adult and infant AMs were clearly segregated indicating substantial age-
based genetic expression differences. Importantly, there was relatively little separation between 
AMs isolated from naïve and RSV infected infants, suggesting reduced differential gene 
expression in infant AMs following RSV infection compared to adults.  
Figure 3.4 (continued) Adult (6-8 weeks) and infant (PND 4-5) Balb/c mice were infected with RSV 
L19. BAL was collected at 3, 7, 10, and 15 DPI and processed for flow cytometry. AMs were gated 
according to their expression of CD11b+ (A and B) the frequency of activation markers, CD80+ (C and 
D), MHCII+ (E and F), and SR-A+ (G and H) were compared to CD11b- AMs in RSV-infected adults 
and infants, respectively. Comparisons between CD11b+ and CD11b- were made using 2-way ANOVA 
with Bonferroni post-test; bar across time points indicates a significant difference between CD11b- and 
CD11b+ at each time point under the bar. Data points represent individual samples (2-3 infant BALs 
pooled per sample) and the lines represent the mean of n ≥ 3-4 samples per group ± SD; * ρ-value < 




Transcripts per million (TPM) were modeled as a function of age, infection status, and 
using an age/infection status interaction term. Three comparisons were performed to find 
Figure 3.5. Principle component analysis of AMs 
Adult (8-10 week old) and infant (4-6 PND) Balb/c mice were infected with RSV L19.  AMs from 
pooled samples (3-4 adults and 6-7 infants/sample) were collected on post-infection days corresponding 
to peak CD11b expression on AMs (3 and 4 dpi for adults and infants, respectively) and stained for 
FACS. Isolated RNA was sent to National Jewish Health for RNA sequencing. RNA seq data was 
analyzed using CLC Genomics. 
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differentially expressed genes (DEGs) between groups: adult naïve vs. adult RSV, infant naïve vs. 
infant RSV, and naïve vs. RSV while controlling for age (interaction term). A visualization of the 
number of significant genes for each of the three comparisons and their relationship to each other 
can be seen in Figure 3.6 (FDR-adjusted p-value ≤ 0.05 and fold change ≥ 1.5). There were over 
four times as many DEGs between adult naïve and RSV samples as the infants (1376 compared to 
326). Only 16.6% of the significant DEGs in AMs from naïve compared to RSV infected adults 






Figure 3.6. Venn diagram of DEGs in AMs in response to RSV. 
Adult (8-10 week old) and infant (4-6 PND) Balb/c mice were infected with RSV L19. AMs from pooled 
samples (3-4 adults and 6-7 infants/sample) were collected on post-infection days corresponding to peak 
CD11b expression on AMs (3 and 4 dpi for adults and infants, respectively) and stained for FACS. 
Isolated RNA was sent to National Jewish Health for RNA sequencing. RNA seq data was analyzed 
using CLC Genomics and the Venn diagram represents overlapping expression resulting from three 
comparisons of isolated macrophages: RSV infected and naïve infants, RSV infected and naïve adults, 
and naïve versus RSV while controlling for age (interaction). 
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Using CLC Genomics software, a volcano plot of DEGs resulting from the comparison of 
naïve to RSV while controlling for age (interaction term) was created to identify genes that are 
highly significant and have ≥ log2 fold changes in their expression following RSV infection. 
Highlighted in red on the volcano plot are three examples of genes that underwent significant 
differential expression in adult AMs following RSV exposure but remained largely unchanged in 
infants (Figure 3.7). Reports in the literature have demonstrated the importance of Spon1 in 
macrophage TLR4 activation, cytokine production, and migration (112, 113). Plac8 has been 
recognized to play a role in innate bacterial killing (114) and in CD4+ Th1 T cell-driven clearance 
of Chlamydia from the genital tract (115). Finally, Runx3 has been shown to regulate macrophage 
differentiation (116) and negatively regulate the expression of the scavenger receptor, CD36 (117). 
The control of CD36 expression is particularly interesting because it is significantly higher in naïve 
infants compared to adults (data not shown). Collectively, the RNA seq. data from isolated AMs 
demonstrates that there are age-based transcriptional differences that contribute to the reduced 
innate immune response observed in infant compared to adult RSV-infected mice. These 
differences may also have important consequences for T cell recruitment and activation, which 






3.2.2 Adult versus infant T cell responses 
3.2.2.1 Pulmonary T-cell recruitment peaks 10 days after RSV infection in adult and infant 
mice 
To determine peak pulmonary T-cell recruitment following RSV infection, we analyzed total CD4+ 
and CD8+ T cells recovered from the lungs of infant and adult Balb/c mice at multiple time points 
following RSV infection. Total CD4+ and CD8+ T-cells peaked at 10 DPI in RSV+ adults (Figure 
3.8A & B) and infants (Figure 3.8C & D), indicating that infants and adults have similar 
Figure 3.7. Naive vs. RSV-infected DEGs in AMs. 
Adult (8-10 week old) and infant (4-6 PND) Balb/c mice were infected with RSV L19.  AMs from 
pooled samples (3-4 adults and 6-7 infants/sample) were collected on post-infection days corresponding 
to peak CD11b expression on AMs (3 and 4 dpi for adults and infants, respectively) and stained for 
FACS. Isolated RNA was sent to National Jewish Health for RNA sequencing. RNA seq data was 
analyzed using CLC Genomics and the volcano plot shows DEGs for macrophages comparing naïve 
versus RSV while controlling for age (interaction). Red highlighted genes are genes of interest that may 
be explored in future studies. 
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pulmonary T cell recruitment kinetics following RSV infection. Subsequent experiments 
characterized age-dependent, phenotypic T cell responses at this 10 DPI time point, which 




Figure 3.8. Pulmonary T-cell recruitment peaks 10 days after RSV infection in adult and infant mice. 
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3.2.2.2 T-cell accumulation in the airway is reduced in RSV-infected infant mice 
To better understand the role of age in T cell localization during RSV infection, flow cytometry 
was used to determine the frequency of CD4+ and CD8+ T-cells in the lung tissue and BAL of 
infant and adult mice. At 10 DPI, the frequencies of CD4+ and CD8+ T-cells were significantly 
higher in adult compared to infant BAL (Figure 3.9A, B, E and F).  However, both adults and 
infants had significantly higher proportions of CD4+ T-cells in the upper right lung (URL) 
compared to BAL (Figure 3.9A-E). Importantly, higher frequencies of adult CD8+ T-cells were 
present in the BAL when compared to the URL (Figure 3.9A, C, and F), whereas CD8+ T cells 
were greater in the URL compared to BAL in RSV-infected infant mice (Figure 3.9B, D, and F).  
Although the proportions of CD8+ T cells in adult BAL were significantly higher than that of 
infants (Figure 3.9F), the ratio of CD8+ to CD4+ T-cells was greater in the infant BAL compared 
to URL. These data indicate that CD4+ and CD8+ T cells accumulate in the adult airway, but 
Figure 3.8 (continued) Adult (6-8 weeks) and infant (PND 4-5) Balb/c mice were infected with RSV 
L19. Right lungs were collected at 3, 7, 10, and 15 DPI and processed for flow cytometry. Lymphocytes 
were gated from FSC vs. SSC, then CD4+ and CD8+ T-cells were determined from TCRβ+ cells in the 
lymphocyte gate. Total T cells were compared between naïve and RSV+ adult mice (A & B) using 
ANOVA with a Bonferroni post-test. Infant T cell totals (C & D) were compared using 2-way ANOVA 
with a Bonferroni post-test. Naïve adult lungs (n ≥ 1) were processed simultaneously with RSV+ 
samples at each time point to account for day to day variations in analysis.  However, the data from all 
naïve adults were pooled and represented graphically as 0 DPI.  Naïve, infant samples were analyzed at 
each time point to account for developmental changes over the course of the study. Data points represent 
individual mice (naïve adults) and lines, the mean of n ≥ 3-4 samples per group ± SD; ** ρ-value < 0.01. 
Data in A-B & C-D are representative of 2 independent experiments. Originally published in: Eichinger 
KM, Kosanovich JL, Empey KM. Localization of the T-cell response to RSV infection is altered in 
infant mice. Pediatric pulmonology 2018;53(2):145-153. 
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aggregation of CD8+ T cells is more prominent than CD4+ T cells in the BAL. Moreover, 
frequencies of infant T cells in BAL were significantly diminished compared to adults, which may 
contribute to delayed RSV clearance among infants. 
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Figure 3.9. Infant T cell accumulation in the BAL is reduced compared to adults. 
Adult (6-8 weeks) and infant (PND 4-5) Balb/c mice were infected with RSV L19. BAL and URL were 
collected at 10 DPI and processed for flow cytometry. The lymphocytes were gated according to typical 
FSC vs. SSC characteristics. CD4+ and CD8+ T cells were determined from TCRβ+ cells in the 
lymphocyte gate. The dot plots represent adult and infant BAL (A & B) and URL (C & D), respectively. 
The frequencies of CD4+ (E) and CD8+ (F) T cells were compared between URL and BAL by 2-way 
ANOVA with a Bonferroni post-test. The frequencies of CD4+ (E) and CD8+ (F) T-cells in the BAL 
(black circles) were compared between age groups using 2-tailed unpaired t test.  Points represent 
individual mice (adults) or individual samples from ≥ 2 pooled infants, lines represent the mean of n ≥ 
4 samples per group ± SD; ** ρ-value < 0.01. Data in E & F are representative of 2 independent 
experiments. Originally published in: Eichinger KM, Kosanovich JL, Empey KM. Localization of the 
T-cell response to RSV infection is altered in infant mice. Pediatric pulmonology 2018;53(2):145-153. 
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3.2.2.3 T cells within the BAL display an activated phenotype compared to the URL 
To determine the effect of age and location on T cell activation, CD44HI expression was compared 
on CD4+ and CD8+ T cells in the BAL and URL (Figure 3.10).  Adults and infants had 
significantly higher CD44HI expression with an increased median fluorescence intensity (MFI) on 
CD4+ T cells in the BAL when compared to the URL (Figure 3.10A and B). Age-based 
comparisons of CD44HI expression on CD4+ T cells in the BAL demonstrated that adults had 
significantly higher proportions of CD4+ CD44HI T cells and higher CD44 MFI than infants 
(Figure 3.10A and B). Similarly, frequency of CD8+ CD44HI T cells and the MFI of CD44 on 
CD8+ T cells was higher in adult compared to infant BAL (Figure 3.10C and D). As with the 
CD4+ T cells, the BAL consistently contained a higher percentage of CD8+ CD44HI T cells in both 
adults and infants when compared to the URL (Figure 3.10C). Age-dependent comparisons 
revealed a higher MFI of CD44 on CD8+ T cells in adult BAL compared to URL. Infants showed 
a similar trend, but was not statistically significant. These results suggest that following RSV 
infection, T cells isolated from the alveolar space (BAL) are more highly activated compared to 
those isolated from lung tissue (URL). 
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Figure 3.10. T cells isolated from the BAL express an activated phenotype compared to the URL. 
Adult (6-8 weeks) and infant (PND 4-5) Balb/c mice were infected with RSV L19. BAL and URL were 
collected at 10 DPI and processed for flow cytometry. The lymphocytes were gated according to typical 
FSC vs. SSC characteristics. % CD44HI and MFI were determined from TCRβ+ CD4+ or CD8+ T cells 
in the lymphocyte gate. The CD4+ T cell frequencies and MFI of CD44HI CD4+ (A and B, respectively) 
and CD8+ T cell frequencies and MFI of CD44HI CD8+ T cells (C and D, respectively) were compared 
between the BAL and URL using 2-way ANOVA with a Bonferroni post-test. CD4+ T cell frequencies 
and MFI of CD44HI CD4+ (A and B, respectively) and CD8+ T cell frequencies and MFI of CD44HI 
CD8+ T cells (C and D, respectively) from the BAL (black circles) were compared between age groups 
using 2-tailed unpaired t test. Points represent individual mice (adults) or individual samples from ≥ 2 
pooled infants, lines represent the mean of n ≥ 4 samples per group ± SD; ** ρ-value < 0.01. Data in A-
D are representative of 2 independent experiments. All CD44HI cells were also CD62L-. Originally 
published in: Eichinger KM, Kosanovich JL, Empey KM. Localization of the T-cell response to RSV 
infection is altered in infant mice. Pediatric pulmonology 2018;53(2):145-153. 
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3.2.2.4 Localization of Tbet+ CD4+ T cells within the alveolar space is diminished in infant 
mice   
To elucidate the phenotype of activated CD4+ T cells responding to RSV infection at the peak of 
T cell recruitment (10 DPI), intracellular transcription factor staining of CD4+ CD44HI T cells in 
the BAL and URL of RSV-infected adults and infants was performed. The ratio of CD4+ CD44HI 
Tbet+:GATA3+ T cells (using total cell counts), was near zero in adult URL samples but rose 
significantly in the BAL (Figure 3.11A). The frequency of CD4+ GATA3+ T cells remained stable 
in both URL and BAL (Figure 3.11B), indicating that increases in adult CD4+ Tbet+ T cells drove 
the increased Tbet+:GATA3+ ratio in the BAL (Figure 3.11A & B). Strikingly, infants had 
elevated Tbet+:GATA3+ ratios in their URL and BAL that were comparable to adult ratios in the 
BAL (Figure 3.11A). Analysis of individual Tbet+ and GATA+ cells demonstrated that the 
majority of Tbet+ cells were migrating to the BAL whereas in the infants, more than half of Tbet+ 
T cells remained in the URL (Figure 3.11B), suggesting an incomplete localization of Tbet+ T 
cells to the URL of infants. GATA3+ T-cell frequency was higher than that of Tbet+ T cells 
regardless of age or sample type (Figure 3.11B). These data suggest that infants do not localize 
CD4+ CD44HI Tbet+ T cells to the BAL as efficiently as adults following RSV infection.  
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3.2.2.5 Delayed RSV clearance in infant BALB/c mice 
We previously demonstrated that RSV-infected infant mice have reduced activation and 
recruitment of innate immune cells and decreased localization of T cells to the site of infection 
Figure 3.11. Localization of Tbet+ CD4+ T cells in the alveolar space is more efficient in RSV-infected 
adult compared to infant mice. 
Adult (6-8 weeks) and infant (PND 4-5) Balb/c mice were infected with RSV L19. BAL and URL were 
collected at 10 DPI and processed for flow cytometry. Lymphocytes were gated according to typical 
FSC vs. SSC characteristics. A ratio of TCRβ+ CD4+ CD44HI Tbet+ cells to TCRβ+ CD4+ CD44HI 
GATA3+ cells was calculated from total cell counts of the URL and BAL (A). A 2-way ANOVA was 
used to compare the Tbet+:GATA3+ CD4+ T cell ratios between sample type and age groups with a 
Bonferroni post-test (A). The frequency of CD4+ CD44HI GATA3+ and Tbet+ T cells were compared in 
URL and BAL for adults and infants, respectively (B). The frequencies of CD4+ CD44HI GATA3+ and 
Tbet+ T cells were compared in URL and BAL using 2-way ANOVA with a Bonferroni post-test (B). 
Points represent individual mice (adults) or individual samples from ≥ 2 pooled infants, lines represent 
the mean of n ≥ 4 samples per group ± SD; ** ρ < 0.01. Data in A & B are representative of 2 independent 
experiments. All CD44HI cells were also CD62L-. Originally published in: Eichinger KM, Kosanovich 
JL, Empey KM. Localization of the T-cell response to RSV infection is altered in infant mice. Pediatric 
pulmonology 2018;53(2):145-153. 
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compared to RSV-infected adults. To examine how these age-based differences in immune 
responses alter the kinetics of viral clearance, viral titers were quantified from left lung lobes at 
multiple time points following RSV infection in infants and adults (Figure 3.12). Viral titers 
peaked at 4 DPI in adults and became undetectable after 7 DPI. Infants had lower peak lung titers 
but virus was detectable as late as 10 DPI indicating more persistent viral growth compared to 
adults. 
 
Figure 3.12. Delayed RSV clearance in infant mice. 
Adult (8-9 weeks old) and infant (PND 2-4) BALB/c mice were infected with RSV L19. Serial viral 
titers were determined from the left lung lobe by standard H&E plaque assay. Data provided by KM 
Empey and JG Orend and published in its original form in:  Empey KM Orend JG, Stokes Peebles R, 
Egana L, Norris KA, Oury TD, Kolls JK. 2012. Stimulation of immature lung macrophages with 
intranasal interferon gamma in a novel neonatal mouse model of respiratory syncytial virus infection. 
PLoS One. 
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3.2.2.6 The immunoregulatory role of extracellular adenosine 
Our RNA seq data from isolated AMs demonstrated a lack of DGE in infants following RSV 
infection compared to adults. This lack of transcriptional upregulation in infants included markers 
of activation and inflammation, such as CD40, CD80, CD86, and TNF-α (data not shown), that 
aid in cellular recruitment and activation of T cells, which are required for RSV clearance (61). 
We hypothesized that an immunoregulatory molecule may be present in the extracellular space of 
the airway, thereby inhibiting AMs response to RSV. One such molecule that has not been 
investigated in the context of infant RSV infection is the purine nucleoside, adenosine. To 
investigate adenosine’s role in dampening the infant immune response to RSV, extracellular 
concentrations of adenosine were quantified from BAL and the in-vivo immune response to RSV 
was evaluated in infant mice who received local delivery of a pan-adenosine receptor antagonist 
to the lung. 
Our lab confirmed that extracellular adenosine concentrations were significantly higher in 
naïve infant compared to adult BAL (Figure 3.13) and may contribute to the age-dependent 






In order to determine how elevated extracellular adenosine levels may affect the infant 
RSV immune response, DPSPX, a pan-adenosine receptor antagonist was administered i.n to PND 
3 infants. A DPSPX concentration of 1 μM was administered and represents a 10 fold higher 
concentration than that used in in-vitro studies and confirmed to block adenosine signaling (118). 
DPSPX is negatively charged therefore, we felt confident that it would produce a local effect in 
the lungs and systemic exposure would remain negligible. Dosing of DPSPX began one day prior 
to infection to ensure that adenosine receptor blockade was in place at the time of infection and 
continued daily to completely inhibit adenosine signaling throughout RSV infection. Lastly, i.n. 
IFNγ was administered on 1, 3, and 5 DPI and served as a positive control. Previous work in our 
lab demonstrated i.n. IFNγ’s capacity to stimulate the infant RSV immune response (1, 119).  
Figure 3.13. Extracellular adenosine elevated in infant airway. 
Naïve adult (8-10 weeks old) and infant (PND 7-8) Balb/c mice were mock-infected. After 3 days, BAL 
was collected and extracellular adenosine was measured using LC-MS/MS. Adenosine concentrations 
were compared between adults and infants using a Student’s t-test; *ρ < 0.05. Points represent individual 
mice, lines represent the mean of n ≥ 5 samples per group ± SD. 
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Neither IFNγ nor DPSPX treatments inhibited the infant’s ability to gain weight when 
compared to vehicle alone (Figure 3.14A). However, only IFNγ treatment significantly reduced 
virus in the lungs at 5 DPI (Figure 3.14B) but virus was undetectable by 10 DPI in all groups, 




We hypothesized that AMs, as a primary sentinel of the airway, would be the cell 
predominately affected by elevated extracellular adenosine concentrations. Adenosine is known to 
be immunosuppressive in macrophages, which respond to adenosine via 4 transmembrane 
Figure 3.14. DPSPX does not inhibit weight gain or improve viral clearance. 
Infant (PND 4) Balb/c mice were infected with RSV L19 and treated with IFNγ on 1, 3, and 5 dpi or 
DPSPX daily starting at -1 dpi. Mice (litters  3) were weighed daily beginning at -1 dpi and average 
weights were compared between groups using 2-way repeated measures ANOVA (A). RSV lung titers 
were quantified from left lungs collected at 5 dpi using H&E plaque assay (B) and comparisons were 
made using ANOVA with Tukey’s post-test; *ρ < 0.05. Points represent individual samples, lines 
represent the mean of n ≥ 8 samples per group ± SD. 
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adenosine receptors (120). As such, we expected that in the presence of DPSPX, AMs would be 
stimulated by RSV and exhibit signs of activation. 
AMs constituted significantly more SSCHI cells of the BAL in DPSPX-treated infants 
compared to vehicle at 5 DPI and IFNγ at both time points, which may indicate a lesser degree of 
cellular recruitment to the BAL in this group (Figure 3.15A). Surprisingly, DPSPX treatment had 
no effect on CD11b+ upregulation at 5 DPI and may have acted to further reduce CD11b+ 
expression when compared to vehicle at 10 DPI. IFNγ treatment significantly increased CD11b+ 
expression compared to vehicle and DPSPX at 5 and 10 DPI (Figure 3.15B). Blocking adenosine 
signaling had no effect on CD73+ expression, the ecto-5’-nucleotidase enzyme that converts 
adenosine monophosphate (AMP) to adenosine, which would be expected to decrease initially 
with activation then increase to dampen the immune response (121), as was observed with IFNγ 
(although not statistically significant) (Figure 3.15C).  
 
 




Interestingly, the frequency of DCs in SSCHI cells of the BAL decreased significantly in 
DPSPX-treated infants compared to IFNγ- and vehicle-treated infants at 5 DPI (Figure 3.16A), 
which may suggest a prior trafficking event to the lymph node for T cell activation. This loss of 
DCs from the BAL correlated with increased total CD4+ T cells, activated (CD44HI CD25+) CD4+ 
T cells, and activated Th1-poised (CD44HI Tbet+) CD4+ T cells in the MSLN of DPSPX-treated 
infants at 5 DPI compared to vehicle and IFNγ-treated animals (Figure 3.16 B, D, F).  Similar 
trends were observed for CD8+ T cells but only Th1-poised (CD44HI Tbet+) CD8+ T cells were 
significantly higher in DPSPX-treated infants (Figure 3.16 C, E, and G). This data suggests that 
DCs may be affected either directly or indirectly by a blockade of adenosine signaling within the 
airway and subsequently prime for a Th1-poised T cell response.  
Figure 3.15 (continued) Infant (PND 4) Balb/c mice were infected with RSV L19 and treated with IFNγ 
on 1, 3, and 5 dpi or DPSPX daily starting at -1 dpi. BAL was collected at 5 and 10 dpi and analyzed 
for the frequency of AMs and their expression of CD11b+ (B) and CD73+ (C). Comparisons were made 
between groups using 2-way ANOVA with a Bonferroni multiple comparisons test; *ρ < 0.05. Points 
represent individual samples from ≥ 2 pooled infants, lines represent the mean of n ≥ 3 samples per 
group ± SD. 
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LRTIs represent the largest disease burden worldwide and disproportionately affect infants and 
children, which is why the scarcity of infant-specific research investigating mechanisms of 
pathogenicity and immunity in this cohort is concerning. We utilized our neonatal murine model 
of RSV to demonstrate phenotypic and transcriptional age-based differences in activation of the 
innate immune response, specifically AMs. Reduced innate activation was associated with distinct 
differences in the accumulation and phenotypic profiles of T cells within the pulmonary 
architecture. Moreover, we demonstrated increased concentrations of extracellular adenosine, a 
previously unidentified immunoregulatory molecule, in infant BAL and by blocking its effects 
gained insight into its influence on infant RSV immunity. 
 A number of prior studies have documented the importance of phagocytic mononuclear 
cells in the early control of respiratory viruses, including RSV (122-125). Neonates are 
immunologically Th2 biased and highly susceptible to microbial infections, largely due to the 
immunosuppressive nature of their immune responses, which are thought to prevent destructive 
Figure 3.16 (continued) Infant (PND 4) Balb/c mice were infected with RSV L19 and treated with IFNγ 
on 1, 3, and 5 dpi or DPSPX daily starting at -1 dpi. BAL was collected at 5 and 10 dpi and analyzed 
for the frequency of DCs (A; Sig F- CD11c+ MHCIIHI). In the MSLN, total CD4+ (B) and CD8+ (C) T 
cells were quantified from the MSLN and analyzed for expression of the activation markers, CD44HI/+ 
CD25+ (D and E, respectively). The expression of the transcription factor Tbet was analyzed on CD44HI 
CD4+ (F) and CD44+ CD8+ (G) T cells. Comparisons were made between groups using 2-way ANOVA 
with a Bonferroni multiple comparisons test; *ρ < 0.05. Points represent individual samples from ≥ 2 
pooled infants, lines represent the mean of n ≥ 2-5 samples per group ± SD. 
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reactions to commensal gut microorganisms (126). In the lung, neonatal mononuclear stimulation 
through TLR triggering is known to elicit Th2/Th17 cytokine responses, which are thought to 
protect lung development but may also compromise innate responses that can suppress viral 
replication (47, 48, 50, 51, 92, 93, 127-132). As the most abundant phagocytic mononuclear cell 
in the alveolar sacs, AMs play a central role in coordinating immunity through cytokine 
production, recruitment of lymphocytes, antimicrobial activity, phagocytosis/efferocytosis, and 
tissue repair (133-137). Our study showed that infant AMs have reduced expression of activation 
markers, like CD11b+, CD80+ MHCII+, and SR-A+, compared to RSV-infected adults. 
Additionally, we correlated CD11b+ expression on AMs with increased expression of the other 
markers of activation compared to CD11b- AMs, re-enforcing CD11b’s place as a marker of acute 
inflammation. Reduced CD11b+ expression on infant AMs with reductions in the other activation 
markers, suggests infant AMs suppress a pro-inflammatory AM phenotype. In correlation with our 
results, increased expression of CD11b+ has been shown to occur on resident AMs during periods 
of acute inflammation in response to LPS or viral challenge (107).  CD11b is a leukocyte integrin 
that binds to intercellular adhesion molecule, iC3b (cleaved product of complement 3b), and 
fibrinogen (138). Transient expression on AMs is likely involved in cell adhesion and phagocytosis 
but it is still not completely clear if inflammation associated with CD11b expression is mediated 
directly through the receptor or indirectly through AMs displaying the receptor (108). 
Age-based alterations in phenotypic signals of enhanced AM activation led us to 
investigate differences in transcriptional regulation between naïve and RSV-infected adult and 
infant AMs, to better understand the underlying mechanisms limiting infant AM activation. RNA 
sequencing of AMs demonstrated a profound deficit in differential gene expression in infants 
compared to adults in response to RSV infection. Although the analysis of our RNA seq data is 
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not yet complete and we hope to gain a better understanding of the potential consequences of 
reduced differential gene expression in infants through pathway analysis, results from clinical 
studies have also identified genetic differences that influence RSV disease severity. 
Polymorphisms in cytokine genes have been found to modify illness severity and frequency of 
complications in infants with severe RSV (139), including IFNγ polymorphisms associated with 
increased severity of illness, duration of stay in the intensive care unit, and frequency of otitis 
media. IFNγ was originally described as macrophage-activating factor and orchestrates 
antimicrobial/antitumor mechanisms, and antigen processing and presentation pathways in 
macrophages (140). We have previously demonstrated an absence of IFNγ in the BAL of RSV-
infected infant mice (1) and a lack of IFNγ may be contributing to reduced activation and minimal 
differential gene expression in infant AMs and will be further explored in upcoming chapters.  
The phenotypic and transcriptional data demonstrating reduced AM activation in RSV-
infected infants are likely indicative of functional deficits as well, and at least partially responsible 
for the reduced recruitment of DCs and monocytes. Clinical studies have demonstrated functional 
deficits in IL-6 (141) and TNFα (132) production or diminished HLA-DR expression (142) 
from/on monocytes isolated from pre-term infants. Moreover, neonatal plasmacytoid DCs exposed 
to viruses are significantly impaired in their release of type 1 interferons compared to adults (143), 
which, when combined with functional defects in monocyte activation, compromises an infant’s 
ability to suppress viral replication. In addition to compromised innate anti-viral activity, reduced 
recruitment of DCs and monocytes can significantly impair the engagement of an adaptive immune 
response as DCs and monocytes have substantial roles in antigen presentation (144-146). 
Infants have a dramatically reduced T-cell response compared to adults.  Although infants 
had lower T-cell frequencies in lung tissue compared to adults, the differences were most striking 
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in the BAL, where average CD4+ and CD8+ T cell frequencies were reduced by 95% and 86% 
(Figure 3.9), respectively. Previous reports have demonstrated reduced and delayed infant T-cell 
responses when compared to adults in models of influenza, methicillin-resistant Staphylococcus 
aureus pneumonia, and Pneumocystis carinii pneumonia (102, 147, 148). A similar observation 
was made when infant and adult lung tissues were compared following primary RSV infection 
whereby the frequencies of infant CD44HI CD62L LO CD4+ and CD8+ T cells were significantly 
lower than that of adults (149). Consistent with work published by Tregoning et al., the current 
study demonstrated reduced CD8+ T-cell frequencies in infant lung tissue. More importantly, data 
presented here showed the most dramatic age-dependent differences in the T-cell response 
following RSV infection occurred in the BAL, similar to findings published by Lines et al., in a 
neonatal murine model of influenza (102). In the infant influenza model, delayed viral clearance 
was associated with poor T cell accumulation in the BAL despite a vigorous T cell response in the 
interstitium (102). Moreover, the reduced T cell frequency in infant compared to adult airways is 
consistent with our previous findings demonstrating prolonged viral detection in RSV-infected 
infants compared to adults (1). In addition to quantitative T cell defects, these data suggest 
environmental or cellular differences are also important in regulating the activation phenotypes of 
T cells in the infant alveolar space. 
A second critical finding generated from these studies was the higher proportion of 
activated T cells in the BAL compared to lung tissue (Figure 3.10). Specifically, a greater 
proportion of T cells isolated from the alveolar space of both adults and infants were 
effector/memory T cells (CD4+/CD8+ CD44HI CD62L-) compared to T cells from lung 
homogenate.  These findings are consistent with previous studies demonstrating that RSV infects 
the superficial cells of the upper and lower airways. In-vitro studies of RSV infection in primary 
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human cartilaginous airway epithelium, as well as histologic studies in RSV-infected patients, 
have consistently demonstrated the virus’ tropism for ciliated epithelium while sparing goblet cells 
and underlying basal epithelial cells (36, 98, 150, 151). Moreover, Lukens et al. found larger 
proportions of activated and RSV-specific CD8+ T cells in the airways of adult mice compared to 
lung tissue (152). Contrary to reports highlighting the functional inactivation of RSV-specific 
CD8+ T cells in the lung parenchyma (152, 153), they also showed that RSV-specific CD8+ T cells 
isolated from the BAL remained functionally active through 21 DPI (152). This was in sharp 
contrast to RSV-specific CD8+ T cells isolated from lung homogenate whose production of IFN-γ 
dramatically decreased by ~43% between 8 and 21 DPI (152). Collectively, these results suggest 
that localization of T cells within the airway is important when considering their activation and 
functional status in response to RSV infection. 
The importance of CD8+ T cells in the clearance of RSV is widely appreciated (61, 94, 95, 
154) but what may be less recognized is the location of these cells within the pulmonary 
architecture in RSV-infected infants versus adults. In our study, adult CD8+ T cells were found in 
high frequencies in the air space where these cells made up a larger proportion of the lymphocytes 
(mean 48%) than in lung homogenate (mean 34%). Infants displayed a starkly different 
distribution, with higher frequencies of CD8+ T cells in lung homogenate (mean 22.9%) compared 
to BAL (mean 6.6%). The accumulation of CD8+ T cells in the adult airway suggests that high 
frequencies of CD8+ T cells within the alveolar space is an important factor in effective RSV 
clearance, yet a similar CD8+ T cell response is remarkably absent in infants. 
Another important age-dependent distinction was the location of CD4+ Tbet+ T cells within 
the lung architecture. CD4+ CD44HI Tbet+ T cell responses accumulated in the airways of adult 
animals but were split between the lungs and airways of infants (Figure 3.11). The frequency of 
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effector memory CD4+ T cells was higher in the BAL of RSV-infected infants than the lung tissue, 
yet infants still had significantly lower percentages than adults. Phenotypic analysis of CD4+ 
effector memory cells revealed that adults had a higher Tbet+ expression compared to infants. 
Although GATA3+ CD4+ T cells were found with high frequency throughout sample types and 
across age-groups, Tbet+ CD4+ T cells were virtually undetectable in adult lung homogenate and 
instead were found predominately in the BAL. In infants, CD4+ Tbet+ T cells were distributed 
throughout the lung tissue and airway with equal frequency, suggesting that while adults mount a 
pointed CD4+ Tbet+ T cell response at the site of RSV infection, the infant CD4+ Tbet+ T cell 
response was less focused, possibly leading to more immune-mediated pathology.  
One criticism of the infant murine model of RSV has been the fact that RSV does not 
replicate as readily in infant mice as it does in adults. Clinically, RSV symptoms track with viral 
titers (78) and although mice do not develop clinical symptoms of RSV, reduced viral replication 
in infant mice could compromise the recruitment of T cells to the airspace. Nevertheless, 
quantitative and qualitative defects in infant T cell responses have been demonstrated in other viral 
illnesses like influenza (102). Additionally, we demonstrated that CD8+ T cells in RSV-infected 
adults preferentially accumulate within the lumen of the airway, which did not occur in infants 
despite the continued presence of RSV in the infant airway at 10 DPI (Figure 3.12). Therefore, 
lower RSV titers in infants is unlikely to be the primary cause of the differences in T cell responses 
demonstrated in RSV-infected infants and adults. 
Adenosine is an endogenous purine nucleoside with immunoregulatory properties that 
appears in extracellular spaces during metabolically stressful conditions, such as inflammation, 
ischemia, and cellular damage (106, 155-157). In the extracellular space, adenosine binds to 
adenosine receptors (A1, A2A, A2B, and A3) expressed on macrophages and monocytes and 
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modulates the inflammatory responses induced through TLR stimulation (106, 120). In this way, 
extracellular adenosine provides macrophages with a gauge of the intensity of stressful stimuli and 
allows them to modify their responses to limit immunopathology (106, 120).  
Published reports have shown that infant plasma contains elevated concentrations of 
extracellular adenosine that divert normal Th1 TLR agonist responses to Th2/Th17-type cytokine 
responses (92, 93, 158). In the plasma, increased extracellular adenosine concentrations are 
mediated by the higher adenosine generating capacity of soluble enzymes, soluble 5’-nucleotidase 
and alkaline phosphatase, in neonatal blood (159). However, in this report we demonstrated that 
extracellular adenosine concentrations are elevated in the airways of infant mice compared to 
adults under homeostatic conditions. We hypothesized that elevated extracellular adenosine 
concentrations in the airways of infant mice may compromise the AM response to RSV infection 
but pan-adenosine receptor blockade with DPSPX would enhance AM activation.  Contrary to our 
original hypothesis, DPSPX treatment did not lead to robust inflammation, as animals continued 
to gain weight normally. Nor did treatment hasten viral clearance as DPSPX and vehicle treated 
animals had similar viral titers. Only IFN treatment reduced viral titers, as we have previously 
demonstrated (1). Surprisingly, adenosine receptor blockade during RSV infection did not appear 
to enhance AM activation. The frequency of AMs in the BAL increased in animals treated with 
DPSPX, which may be reflective of a reduced inflammatory cell recruitment compared to the other 
groups. Additionally, adenosine receptor blockade did not result in signals of AM activation, as 
measured by increased expression of CD11b+ and CD73+. Even in the absence of adenosine 
signaling, this lack of activation may be due in part to inefficient TLR4 triggering (92) in infant 
AMs by RSV F protein (3). As expected, IFN treatment increased AM CD11b expression across 
both time points. Prolonged expression of the activation marker CD11b+ on AMs in response to 
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IFNγ treatment is indicative of the adenosine de-sensitizing effect IFNγ has on macrophages, 
whereby IFNγ STAT1 signaling prevents adenosine receptor induction and extends the 
macrophage’s inflammatory effects (120).  Enhanced AM CD73+ expression in IFNγ treated 
animals at 10 DPI likely represents an attempt by AMs to increase extracellular adenosine through 
CD73 activity, thereby dampening inflammation via adenosine receptor signaling and preventing 
immunopathology. 
Interestingly, DPSPX treatment appeared to play a role in DC activation and the subsequent 
priming of CD4+ and CD8+ T cells in the lymph node. Animals treated with DPSPX had more 
activated (CD44HI CD25+) CD4+ and CD8+ T cells in their lymph nodes and more activated T cells 
poised to produce IFN through the expression of the transcription factor Tbet. It is possible that 
adenosine receptor blockade directly or indirectly affected dendritic cells, leading to their 
enhanced activation and migration to the lymph node. However, a limitation of this study may be 
the time points analyzed. AM activation in the presence of DPSPX may have peaked very early in 
infection and was steadily declining at 5 dpi. Our study is also limited by small sample sizes and 
a small array of markers to analyze AM activation. Nevertheless, these results give insight into 
adenosine as a previously unrecognized immunoregulatory molecule, present in higher 
concentrations in the airways of infants, that modulates the innate infant RSV immune response. 
Using our neonatal mouse model of RSV, we have demonstrated through phenotypic and 
differential gene expression data that infant AMs have reduced activation in response to RSV 
infection compared to adults. Decreased stimulation of the innate immune response may be 
partially influenced by the presence of elevated levels of extracellular adenosine in infant airway. 
An inefficient innate immune response has serious consequences on the induction of effective 
adaptive immunity, including infant T cell priming and recruitment to alveolar spaces. These 
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studies provide important information regarding the multi-level regulation of infant immunity and 
lend support to the hypothesis that simply blocking the effects of extracellular regulatory 
molecules in the milieu of the airway may not be enough to stimulate infant innate immunity. A 
combinatorial approach whereby the effects of immunoregulatory molecule(s) are blocked and 
direct stimulation is applied may be required to elicit effective infant RSV immunity. 
 77 
4.0  IFN-GAMMA IMMUNOMODULATION 
This chapter is adapted from the following published manuscripts: 
Katherine M. Eichinger, Erin Resetar, Jacob Orend, Kacey Anderson, Kerry M. Empey 
Age predicts cytokine kinetics and innate immune cell activation following intranasal delivery of 
IFNgamma and GM-CSF in a mouse model of RSV infection. Cytokine, 2017. 97: 25-37. (© 
Elsevier Ltd.), 
Katherine M. Eichinger, Loreto Egaña, Jacob G. Orend, Erin Resetar, Kacey B. Anderson, Ravi 
Patel, Kerry M. Empey 
Alveolar macrophages support interferon gamma-mediated viral clearance in RSV-infected 
neonatal mice. Respiratory Research, 2015. 16: 122. (© Eichinger, et al.), 
and 
Katherine M. Eichinger, Jessica L. Kosanovich, and Kerry M. Empey 
Localization of the T-cell response to RSV infection is altered in infant mice. Pediatric 
Pulmonology, 2018. 53 (2): 145-153. (© Wiley Periodicals, Inc.). 
4.1 INTRODUCTION 
Conventional immunization strategies that depend on antigen specificity and conditioning of the 
adaptive immune response continue to be a primary focus of ongoing research, yet there remains 
no licensed vaccine for RSV or many other viral pathogens associated with childhood bronchiolitis 
(160). Infants, unlike older children and adults, have a limited capacity to sustain an efficient 
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memory response to vaccination due to limited prior antigen exposure and a suppressive lung 
environment that favors production of Th2-polarizing cytokines (59, 161, 162). Therefore, non-
clonal stimulation of innate immunity is a viable strategy to prevent or treat viral-mediated infant 
bronchiolitis. 
Stimulation of the innate host immune response with immune potentiators is gaining 
attention for their prospective application in populations with limited immune responses to 
antigenic stimuli or against pathogens for which vaccines do not exist. The macrophage-activating 
cytokine, IFNγ, is a commercially available immune potentiator used to prevent infections in 
patients with chronic granulomatous disease (163, 164). Despite the reported anti-viral activity, 
systemic toxicity with immune potentiating cytokines discourages their use in vulnerable patient 
populations, including young children. In adults, however, inhaled delivery of IFNγ largely 
bypasses systemic exposure and was shown to be well tolerated in clinical studies among healthy 
adults and adults with lung disease (165-167). A recent study further showed that local cytokine 
delivery to the lungs of influenza-infected mice improved disease outcomes to a greater degree 
when cytokine was retained in the airway using quantum dots (168). Yet, pulmonary absorption 
of immune potentiating cytokines from the infant lung remains unknown and limits the utility of 
this therapeutic strategy in young children. 
AMs constitute 90-95% of the leukocytes in the alveoli at baseline, help to maintain 
homeostasis, and serve as the first line of defense against inhaled pathogens (168). They clear 
invading organisms through phagocytosis and microbicidal enzymes while regulating 
inflammatory responses through secretion of pro- and anti-inflammatory cytokines (107, 109, 
133). Pulmonary DCs further contribute to the anti-viral cytokine milieu in the lung during viral 
infections and are essential for antigen presentation and initiation of adaptive immunity (144, 169, 
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170). However, efficient anti-viral cytokine production and engagement of the adaptive immune 
response depends largely on AM and DC maturation, suggesting that the Th2-dominant infant lung 
environment limits maturation and activation of innate immune cells and their anti-viral activity 
(171-173). Harker and colleagues showed enhanced innate immune cell activation and viral 
clearance following infection with recombinant RSV expressing IFNγ (174). Thus, local exposure 
to pro-inflammatory cytokines in the lung is critical for proper innate cell maturation and disease 
resolution. We demonstrated (Chapter 3) substantial age-based genomic differences in AMs 
isolated from naïve as well as, RSV-infected mice, which provides detailed information regarding 
defects in infant AM maturation in response to RSV. Additionally, our lab showed that i.n. IFNγ 
administration during infant RSV infection increases markers of antigen presentation and co-
stimulation on AMs (1) but the specific role these stimulated cells have on the resolution of RSV 
is unknown.  
Activation of the innate immune system is a critical link in the development of an effective 
adaptive immune response (144, 170). It is well appreciated that T cells are essential for RSV 
clearance (61, 95, 97) but Th2-biased T cell responses lead to pathology and airway hyperreactivity 
(175). Numerous studies have demonstrated infants’ Th2 biased responses to RSV, however those 
with higher Th1 responses are associated with improved disease outcomes (176-178), expedited 
viral RSV clearance, and reduced Th2-driven pathogenesis (95, 179). Neonatal mice have 
demonstrated the ability to mount effective Th1 responses given the appropriate co-stimulation, 
such as IL-12 and/or IFNγ (180, 181). However, the ability of IFNγ to alter the T-cell phenotype 
of RSV-infected infants has not been investigated.  
To gain a better understanding of how local administration of IFNγ affects infant RSV 
infection, we determined age-based IFNγ kinetic parameters, calculating and testing an IFNγ dose 
 80 
capable of reaching adult-like exposure. We also examined the role of IFNγ-stimulated AMs in-
vivo and showed that IFNγ’s viral reducing potential is shared by AECs and AMs.  Additionally, 
our study offers new insight into how local administration of IFNγ alters infant T cell phenotypes 
and CD8+ T cell RSV specificity. We hypothesize that IFNγ will act locally in the lung, activating 
innate immune cells, which will increase recruitment of T cells to the airspace. 
4.2 RESULTS 
4.2.1 IFNγ elimination rates are reduced in infants compared to adults following 
intranasal delivery 
Cytokines are broken down by proteolysis into individual amino acids or are otherwise distributed 
out of the central compartment from which they are produced and secreted. To determine if these 
elimination processes are age-dependent in the local lung environment, a single, weight-based dose 
of IFNγ was delivered i.n. to adult and infant Balb/c mice. A total of 16ng/g of body weight was 
delivered providing 1.52ng and 1.07ng of IFNγ per mg of lung in infants and adults, respectively 
(Table 4.1). IFNγ concentrations were then determined at nine separate time points from digested 






A non-compartmental pharmacokinetic analysis was performed to elucidate age-dependent 
differences for key pharmacokinetic parameters (Table 4.2). Adult mice demonstrated a rapid 
increase in IFNγ concentrations in the lung, peaking one hour after intranasal delivery (Figure 
4.1A; Table 4.2). The majority of IFNγ was cleared from the lungs by 12 hours post-
administration, which is further reflected by a mean residence time (MRT) of only 20 hours. 
Terminal elimination from adult lungs was calculated from 12 to 48 hours post-dose and was used 
to generate the elimination half-life (t½) of 14 hours, suggesting that IFNγ would be cleared from 
the lungs within 56-70 hours after delivery (4-5 half-lives) (Figure 4.1C, solid line). The terminal 
elimination half-life was 16 hours in infant mice as demonstrated by the reduced slope (Figure 
4.1C, dashed line). Consistent with lung, terminal elimination of IFNγ from the blood was also 
more rapid in adult compared to infant mice (Figure 4.1D).  Moreover, the average IFNγ area 
under the concentration time curve (AUC) in the blood of adult animals was markedly reduced 
compared to the lung (Figure 4.1A), suggesting that the majority of IFNγ is metabolized directly 
in the lung and/or not absorbed systemically. A closer look at the first 4 hours after intranasal 
delivery revealed a 2-hour delay in peak blood concentrations from that achieved in the lung 
(Figure 4.1A, inset), indicating that pulmonary absorption does not occur immediately. Many age-
Table 4.1. Age-based pulmonary IFNγ dosing 
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dependent differences in IFNγ kinetics were noted between infants and adults. Specifically, AUCs 
and peak concentrations achieved in infant lungs were dramatically lower than that achieved in 
adults (Figure 4.1B; Table 4.2), despite identical weight-based dosing. This discrepancy may 
reflect reduced efficiency in cytokine delivery to the narrow infant airways or higher lung to body 
weight ratios in infants compared to adults. Unlike adults, infants demonstrated bi-modal IFNγ 
peak concentrations (Cpk) in the lung 1 and 8-hrs after delivery (Figure 4.1B), possibly due to 
stimulation of endogenous IFNγ-secreting immune cells. Twelve and 48 hours were used to 
calculate the elimination t½ of 16 hours, indicating ~64-80 hours would be required to clear IFNγ 
from infant lungs. Consistent with their longer t½, infants compared to adults had a more gradual 
terminal elimination slope reflective of a reduced rate of IFNγ clearance from infant compared to 
adult lungs (Figure 4.1C; Table 4.2) Interestingly, IFNγ Cpk in the blood of infants was delayed 
by 6 hours compared to the 2-hour delay in adults, indicating that pulmonary absorption occurs 
more slowly in infants. Unlike cytokine clearance in the lung, only 31% of total IFNγ measured in 
the blood was cleared by 4 hours in infant mice, which is further reflected in the extended MRT 
of 102 hours compared to a MRT of 3.73 hours in adults. Together, these data describe important 
age-dependent differences in IFNγ kinetics following intranasal delivery, including reduced AUC, 







Table 4.2. Pharmacokinetic parameters following intranasal IFNγ 
Figure 4.1. The pharmacokinetic profile of i.n. IFNγ depends largely on age at the time of administration. 
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4.2.2 Intranasal IFNγ increases innate recruitment and activation in RSV-infected infant 
mice 
We previously demonstrated in Chapter 3 that infant mice had reduced recruitment of monocytes 
and DCs (Figure 3.2 A, B and C, D, respectively) in response to RSV infection when compared 
to adults. Additionally, the activation of infant AMs (Figure 3.3) was also reduced compared to 
adults following RSV infection. To determine if local IFNγ administration could increase 
inflammatory innate cell recruitment and activation of AMs, i.n. IFNγ was administered to infant 
mice on days 1, 3, and 5 post-RSV infection and immunophenotyping of cells isolated from the 
airway performed using flow cytometry. The frequency of monocytes (monos; Sig F- CD11c+ 
CD11b+) in the BAL of IFNγ treated infants increased significantly by 3 DPI and remained 
elevated through 10 DPI compared to naïve and RSV+ infants (Figure 4.2A). The proportion of 
DCs (Sig F- CD11c+ MHCII HI) in the BAL also rose significantly in IFNγ-treated infants when 
compared to naïve (Figure 4.2B).  
Figure 4.1 (continued) Adult and infant Balb/c mice were treated with a single i.n. dose of IFNγ 
(16ng/gm). IFNγ concentrations were subsequently measured in homogenized lung tissue and serum at 
the indicated times. (A) Adult and (B) infant IFNγ concentrations in the lung (y-axis) and blood (z-axis) 
were reported on discriminate scales to accommodate differential concentration ranges; insets provide 
more detailed depiction of the kinetic changes during the early time points (0-4 hours). Data was 
transformed on a log scale to identify the terminal elimination phase of IFNγ in adult and infant (C) 
lungs and (D) blood. Each time point represents the mean of n = 3 samples per group ± SD. Originally 
published in: Eichinger KM, Resetar E, Orend J, Anderson K, Empey KM. Age predicts cytokine 
kinetics and innate immune cell activation following intranasal delivery of IFNgamma and GM-CSF in 




Unsurprisingly, IFNγ, a known macrophage-activating cytokine, led to increased 
expression of surface markers indicating activation on AMs in the BAL of IFNγ-treated infants. 
The proportion of AMs in the BAL of IFNγ-treated infants was significantly reduced at 7 and 10 
DPI (Figure 4.3A) compared to naïve and RSV+ infants. This likely occurred due to increased 
infiltration of innate inflammatory cells into the BAL, such as previously mentioned monocytes 
and DCs. Expression of the activation markers CD11b+ and CD80+ were significantly increased in 
IFNγ-treated infants as early as 3 DPI and remained elevated through 10 DPI (Figure 4.3B, C). 
Upregulation of MHCII+ was slightly delayed compared to CD11b+ and CD80+ with increased 
expression as a result of IFNγ treatment occurring at 7 and 10 DPI before dropping to near baseline 
Figure 4.2. IFNγ treatment increases innate recruitment in RSV-infected infants. 
Infant (PND 4-5) Balb/c mice were infected with i.n. RSV L19. Intranasal IFNγ (16ng/g) or vehicle was 
administered on 1, 3, and 5DPI. BAL was collected at 3, 7, 10, and 15 DPI and processed for flow 
cytometry. Frequencies of monocytes (monos) and DCs were calculated. The percentage of monos (A) 
and DCs (C) comprising the BAL were compared between naïve, RSV+, and RSV/IFNγ+ mice using 
2-way ANOVA with Bonferroni post-test. Data points represent the mean of n ≥ 3-4 samples (2-3 infant 
BALs pooled per sample) per group ± SD; * and # ρ-value < 0.05. * signifies a statistical difference 
between naïve and RSV/IFNγ+ and # between RSV and RSV/IFNγ+. 
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levels by 15 DPI (Figure 4.3D). IFNγ augmented the expression of SR-A when compared to RSV+ 
but followed a similar expression pattern as RSV+ infants with increases seen early and late in 








Although repeated treatment with intranasal IFNγ at a dose of 16ng/g resulted in increased 
recruitment of innate cells and activation of AMs in infant mice, we know from our 
pharmacokinetic analysis that IFNγ exposure was lower in infants than adults after a single, i.n. 
IFNγ dose. In fact, average, adult AUCs were 3.6 times greater than AUCs in infant mice (Table 
4.2). This was associated with significant increases in the expression of MHCII on adult compared 
to infant CD11c+ CD11b- cells through 48 hours (Figure 4.4). 
 
  
Figure 4.3 (continued) Infant (PND 4-5) Balb/c mice were infected with RSV L19. Intranasal IFNγ 
(16ng/g) or vehicle was administered on 1, 3, and 5 DPI. BAL was collected at 3, 7, 10, and 15 DPI and 
processed for flow cytometry. Frequencies of AMs and their expression of surface activation markers 
were calculated and compared between naïve, RSV+, and RSV/IFNγ+ mice using 2-way ANOVA with 
Bonferroni post-test. Data points represent the mean of n ≥ 3-4 samples (2-3 infant BALs pooled per 
sample) per group ± SD; * , ^ and # ρ-value < 0.05. * signifies a statistical difference between naïve and 
RSV/IFNγ+, # between RSV and RSV/IFNγ+, and ^ between naïve and RSV+. 




To optimize infant IFN AUCs and subsequent innate cell activation, a non-compartmental 
pharmacokinetic approach, as described in our methods, estimated a new 60ng/g dose of i.n. IFN 
would be required to achieve adult-level AUCs (280ng*hr/ml) in the infant mice. Thus, we 
predicted that 60ng/g of i.n. IFN would generate faster and greater expression of MHCII on 
CD11c+ CD11b- cells with enhancement of RSV clearance.  
To test the effect of IFNγ dose response on myeloid cell activation and viral clearance, 
RSV-infected infant mice receiving PBS (vehicle) only were compared to those treated with 16 or 
60ng/g of IFNγ. Significant differences in IFNγ BAL concentrations occurred as soon as 4 DPI 
and dissipated over time reflecting the end of IFNγ dosing at 5 DPI (Figure 4.5A). Despite its 
potential for toxicity, neither the 16ng/g nor the 60ng/g IFNγ groups demonstrated significant 
impairment in weight gain compared to PBS-treated controls over the course of the study (Figure 
4.5B), suggesting minimal pulmonary absorption. These findings are consistent with published 
data generated in our lab showing negligible IFNγ levels in the serum of infant (PND 4) Balb/c 
mice following a single i.n. dose of IFNγ (182). 
Figure 4.4 (continued) A single, i.n. IFNγ dose (16ng/g) was administered to naive infant (PND 4-5) 
and adult (8-10wks) Balb/c mice. Whole right lung was harvested at the indicated times post-dose and 
processed for flow cytometry. MHCII+ expression on myeloid cells (CD11c+ CD11b-) was compared 
between infants and adults using 2-way ANOVA with Bonferroni post-test. Data points represent the 
mean of n = 3 samples per group ± SD; * ρ-value < 0.05. Originally published in: Eichinger KM, Egaña 
L, Orend JG, Resetar E, Anderson KB, Patel R, Empey KM. Alveolar macrophages support interferon 
gamma-mediated viral clearance in RSV-infected neonatal mice. Respiratory research 2015;16:122. 
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To determine the effect of IFNγ dose on myeloid cell (CD11c+ CD11b-) activation in RSV-
infected infant lungs, the expression of MHCII was examined. At each time point tested, the 60ng/g 
dose increased myeloid cell activation significantly more than infants treated with 16ng/g or PBS 
alone (Figure 4.5C). CD11c+ CD11b- cells from mice receiving 16ng/g also significantly 
increased MHCII expression on 7 and 10 DPI compared to PBS-treated mice (Figure 4.5C) but 
not at 4 DPI, suggesting a stronger activation signal may be required for initial activation of infant 
CD11c+ CD11b- cells.  
To determine the functional effect of optimizing i.n. IFNγ dosing, RSV clearance was 
quantified by viral plaque assay. By 4 DPI, RSV clearance was greatest in the 60ng/g group 
followed by the 16ng/g of IFNγ compared to PBS; however, only the group receiving 60ng/g 
demonstrated enhanced RSV clearance at 7 DPI (Figure 4.5D).  By 10 DPI, 80% (4/5) of animals 
in both IFNγ groups had undetectable viral loads while only 50% (2/4) of infants in the PBS group 





Figure 4.5. Infants demonstrate dose dependent myeloid activation and viral clearance. 
Infant (PND 5-7) Balb/c mice were infected with RSV L19 and treated with i.n. IFNγ (16 or 60ng/g) or 
Veh. (PBS) on 1, 3, and 5 dpi. Luminex was used to quantify IFNγ in BAL (A) and % of original weight 
was calculated from baseline litter weights (B). Lungs were collected for flow cytometry to analyze the 
% of CD11c+ CD11b- cells expressing MHCII+ (C) and viral titers using H&E plaque assay (D). # and 
* represent significant differences between infants treated with 16 and 60ng/g compared to PBS treated 
infants, respectively. ^ indicates significant differences between infants treated with 16 vs. 60ng/g of 
IFNγ using a 2-way ANOVA with Bonferroni post-test; p<0.05. Data points represent the mean of n ≥ 
2-5 samples per group ± SD. Originally published in: Eichinger KM, Egaña L, Orend JG, Resetar E, 
Anderson KB, Patel R, Empey KM. Alveolar macrophages support interferon gamma-mediated viral 
clearance in RSV-infected neonatal mice. Respiratory research 2015;16:122. 
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4.2.3 Intranasal IFNγ treatment reduces pulmonary mucus and detection of apoptotic 
cells in the lungs of RSV-infected infant mice 
To determine the pathological consequences of achieving higher, adult-like IFN AUCs in the 
infant airway during RSV infection, mucus production was determined in RSV-infected mice 
treated with 16 or 60ng/g of IFN or PBS alone; IFNR1KO (Balb/c background) mice were 
included as an additional control group to assess mucus production in the absence of IFNγ 
signaling (Figure 4.6A-E). Airway mucin scores were determined as previously described (1). 
Mucus production was evident (bright pink staining; arrows) in representative RSV-infected infant 
lung sections (Figure 4.6A & B). Conversely, mucus production was absent in uninfected infant 
mice (Figure 4.6C), those treated with 16ng/g of IFN (Figure 4.6D) and mucus was markedly 






To determine the effect of i.n. IFN on RSV-mediated apoptosis in the infant lung, TUNEL 
staining was performed at 8 DPI on lung sections from infant mice that were A) mock-infected; 
Figure 4.6. Local IFNγ reduces airway mucus production. 
WT and IFNγ receptor knock out (IFNγRKO) infants (PND 5-7) were infected with RSV L19 or cell 
lysate, then treated with i.n. IFNγ (16 ng/g or 60 ng/g) or PBS on 1, 3, and 5 DPI. The lungs (n = 5 
samples per group) were harvested at 8 DPI and sections compared by extent of PAS staining, indicated 
by bright pink staining (arrows). Airways were scored 0 to 4 for PAS positivity according to previously 
published methods (1). Representative examples of airway mucin production from RSV/IFNRKO (A), 
RSV (B), Cell lysate (C), RSV/16ng/g IFN (D), and RSV/60ng/g IFN (E). Pie charts are provided to 
numerically represent a percentage of the total airways ranked according to mucin scores. Originally 
published in: Eichinger KM, Egaña L, Orend JG, Resetar E, Anderson KB, Patel R, Empey KM. 
Alveolar macrophages support interferon gamma-mediated viral clearance in RSV-infected neonatal 
mice. Respiratory research 2015;16:122. 
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B) RSV-infected; C) RSV-infected and treated with 16ng/g of i.n. IFN; or D) RSV-infected and 
treated with 60ng/g of i.n. IFN (Figure 4.7).  Figure 4.7 shows representative lung section from 
each mouse per group. RSV-infected (Figure 4.7B) lungs had significant increases in TUNEL 
staining compared to uninfected lungs (Figure 4.7A). Interestingly, both 16ng/g (Figure 4.7C) 
and 60ng/g (Figure 4.7D) IFN-treated groups had reduced TUNEL staining compared to RSV-




Figure 4.7. Intranasal IFNγ reduces apoptosis in infant lungs at 8DPI. 
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4.2.4 The loss of AMs impairs RSV clearance in infant mice 
AMs are the predominate phagocytic cell in the airway, responsible for clearing debris, pathogens, 
and apoptotic cells from the air space, thereby working to return the airway to homeostasis yet, 
they are ideally poised to initiate a strong inflammatory response if required  (110). Through the 
use of locally delivered CLip, we sought to understand the role of AMs in infant RSV infection by 
eliminating them from the airspace. Based on previously performed pilot studies in our lab, daily 
dosing of i.n. CLip was shown to effectively reduce the CD11c+ CD11b- population, commonly 
referred to as AMs in the literature, in RSV-infected neonatal mice. CLip treatment began -1 DPI 
in PND 2; dosing continued daily with either CLip or PBS; pups then received i.n. IFN (16ng/g) 
or PBS on days 1, 3, and 5 DPI. Regardless of i.n. IFN treatment, numbers of CD11c+ CD11b- 
cells in both the BAL and lung digest were significantly reduced with CLip at 4 and 8 DPI (Figure 
4.8). The CD11c+ CD11b- cell population was reduced by 84% and 91% at 4 and 8 DPI, 
respectively (Figure 4.8A & B). Moreover, total CD11c+ CD11b- cells harvested from the lung 
Figure 4.7 (continued) Infant Balb/c mice (PND 5-7) were infected with RSV L19 and treated with i.n. 
IFNγ (16 or 60ng/g) or PBS on 1, 3, and 5 dpi.  At 8 dpi right lungs were harvested, fixed with formalin 
and TUNEL stained. Represents a single lung section from each animal in RSV-/IFN- (A1-A5), 
RSV+/IFN- (B1-B5), RSV+ IFN 16ng/g (C1-C5), and RSV+ IFN 60ng/g (D1-D5). Images were 
captured at 40X magnification and the average number of apoptotic cells per lung section were 
quantified and graphed (E); n = 5 samples per group.  * indicates a significant difference compared to 
RSV+ using ANOVA with a Tukey post-test; p<0.05. Originally published in: Eichinger KM, Egaña 
L, Orend JG, Resetar E, Anderson KB, Patel R, Empey KM. Alveolar macrophages support interferon 
gamma-mediated viral clearance in RSV-infected neonatal mice. Respiratory research 2015;16:122. 
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digest (LD) were significantly reduced by 57% and 55% at 4 and 8 DPI, respectively, following 
CLip treatment (Figure 4.8C & D). 
 
 
Figure 4.8. Depletion of pulmonary infant CD11c+ CD11b- cells using CLip. 
Infant Balb/c mice (PND 2) were treated with i.n. CLip and/or IFNγ. BAL (A and B) and digested right 
lung lobes (C and D) were harvested at 4 (A and C) and 8 (B and D) DPI. Total CD11c+ CD11b- cells 
were determined via flow cytometry. * Indicates a significant difference between groups using ANOVA. 
p < 0.05. Data points represent the mean of n ≥ 2-5 samples per group ± SD. Originally published in: 
Eichinger KM, Egaña L, Orend JG, Resetar E, Anderson KB, Patel R, Empey KM. Alveolar 
macrophages support interferon gamma-mediated viral clearance in RSV-infected neonatal mice. 
Respiratory research 2015;16:122. 
 97 
The functional effects of AM depletion and i.n. IFNγ treatment were tested following RSV 
infection via viral plaque assay. At 4 DPI, CLip (-)/ IFNγ (+) animals had the lowest viral titers, 
which were significantly lower than CLip (-)/ IFNγ (-) and CLip (+)/ IFNγ (-) treated animals 
(Figure 4.9A). The CLip (-)/ IFNγ (+) group had lower viral titers than the CLip (+)/ IFNγ (+) 
group but the difference was not significant. The CLip (+)/ IFN (+) group had significantly lower 
viral titers than CLip (+)/ IFNγ (-) treated animals. These results suggest that IFNγ treatment 
played a larger role in reducing viral burdens than AM depletion. To evaluate the contribution of 
each treatment independently, we analyzed viral titers by 2-way ANOVA.  This analysis confirmed 
our hypothesis that IFNγ treatment was primarily responsible for the differences in viral titers. In 
fact, IFNγ treatment accounted for 45% of the variability; however macrophage depletion also 
significantly contributed to differences in viral titers, accounting for 10% of the variability. 
Bonferroni post-hoc analysis revealed that the significant effect of macrophage depletion (CLip 
treatment) was primarily a result of the differences in viral titers of CLip (+) vs. CLip (-) animals 
that were not treated with IFNγ. 
 At 8 DPI, CLip (+)/IFNγ (-) animals had the highest viral burden which was significantly 
higher than both CLip (-)/ IFNγ (-) and CLip (-)/IFNγ (+) animals (Figure 4.9B). However, viral 
titers of CLip (+)/IFNγ (-) animals were not significantly higher than CLip (+)/IFNγ (+) animals 
demonstrating that the effects of IFNγ on reducing RSV in the lungs was lost by 8 DPI in the 
absence of AMs. In fact, treatment with IFNγ accounted for only 5% of the variability observed. 
The presence or absence of AMs played a critical role in RSV clearance, accounting for 43% of 
the variability. Regardless of IFNγ treatment, infants whose AM populations were eliminated with 
CLip had RSV viral titers that were nearly a log fold higher than CLip (-) neonates at 8 DPI.   
 98 
The potential for biological toxicity resulting from either CLip or IFNγ treatment was 
analyzed by calculating the neonates’ ability to gain weight over time. CLip treatment but not IFNγ 
significantly impaired the ability of neonates to gain weight (Figure 4.9C). Irrespective of IFNγ 
treatment, the daily percent gain in weight began to slow in CLip (+) neonates when compared to 
CLip (-) neonates beginning at 4 DPI and continued until the final time point. At 7 DPI, both CLip 
(+) groups demonstrated significantly impaired weight gain when compared to CLip (-)/IFNγ (-) 
neonates. These data suggest that AM depletion, either directly and/or indirectly, plays an 
important role in viral clearance late in RSV infection while the presence of IFNγ in the airway is 





Figure 4.9. AM depletion reduces RSV clearance and impairs weight gain. 
Infant Balb/c mice (PND 2) were treated with i.n. CLip and/or IFN. Left lungs were collected on 4 (A) 
and 8 (B) DPI for RSV quantification using plaque assay. Litters were weighed daily and the percent 
change in weight (C) was calculated from their baseline weight prior to i.n. treatments. Data points 
represent the means of n ≥ 4-8 samples per group ± SD. (A and B); * indicates ρ < 0.05 using ANOVA 
with a Tukey post-test. (C); *indicates a statistical difference between control (CLip-/IFN-) and CLip 
treatment groups (CLip+/IFN+ and CLip+/IFN-) using repeated measures ANOVA with a Bonferroni 
post-test (ρ < 0.05). Originally published in: Eichinger KM, Egaña L, Orend JG, Resetar E, Anderson 
KB, Patel R, Empey KM. Alveolar macrophages support interferon gamma-mediated viral clearance in 
RSV-infected neonatal mice. Respiratory research 2015;16:122. 
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4.2.5 IFNγ treatment of human airway epithelial cells decreases RSV replication 
To determine IFNγ’s ability to reduce the RSV burden directly in AECs, we used an in-vitro assay 
using the A549 human alveolar basal epithelial cell line, in which A549 cells were pre-treated for 
1 hour with IFNγ and infected with RSV for 24-48 hours. RSV was quantified from lysed A549 
cells (intracellular) as well as the extracellular media surrounding the cells in order to quantify 
budded RSV (extracellular). RSV quantified from within A549 cells (intracellular) continued to 
replicate in untreated A549 cells, increasing by a log-fold in 24 hours (Figure 4.10A). RSV within 
cells pre-treated with IFNγ did not effectively replicate between 24 and 48 hours as evidenced by 
the unchanged RSV burden quantified from within A549 cells (Figure 4.10A). Similar to the 
intracellular data, significantly more budded (extracellular) RSV was quantified from untreated 
A549 cells between 24 and 48 hours (Figure 4.10B). Pre-treatment of A549 cells with IFNγ 
resulted in significantly less extracellular RSV than untreated cells at 48 hours and remained 
relatively unchanged from the viral burden quantified from IFNγ treated cells at the 24 hour time 
point (Figure 4.10B). This data suggests that IFNγ can effectively inhibit viral replication in 
airway epithelial cells. 
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Figure 4.10. IFNγ pre-treatment of A549 cells prevents RSV replication. 
A549 cells pre-treated for 1 hour with IFNγ (100ng/mL) then infected with RSV L19 (Multiplicity of 
infection = 2). At 24 and 48 hours, intracellular (A) and budded (B, extracellular) virus was harvested 
and used to infect HEp2 cells. After 5 days, a standard H&E plaque assay was performed to quantify 
virus. * Indicates a significant difference between groups/ time points using 2-way ANOVA; Data points 
represent the mean of n ≥ 2 samples per group ± SD; p < 0.05.  
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4.2.6 Human monocyte differentiation 
By eliminating AMs through the use of CLip, our data has demonstrated the importance of infant 
murine macrophages in the clearance of RSV. We have also shown the stimulatory potential of 
IFNγ on AMs, including the increased expression of SR-A, which is known to participate in the 
clearance of apoptotic debris (183). We sought to investigate the clinical relevance of our findings 
in the infant murine RSV model to human samples. An Exempt IRB was written and approved 
(PRO14120128) for the acquisition of human infant monocytes from cord blood samples. Our 
objective was to differentiate infant monocytes into macrophages and test the ability of IFNγ 
treatment to increase efferocytosis of apoptotic debris.  
Before obtaining infant cord blood samples, we began to optimize the differentiation of 
human monocytes into macrophages using human blood samples obtained from healthy adult 
volunteers. We first attempted to isolate human monocytes by taking advantage of their adherent 
nature. Following isolation of mononuclear cells from heparinized whole blood samples using 
centrifugation with Lymphoprep™, mononuclear cells (MNCs) were plated into 6-well plates at a 
density of 3 x 106 cells /well and incubated for 90 minutes. Our first check on the purity of our 
samples involved harvesting and visualizing the non-adherent cells in the supernatant as well as, 
the plated cells adhered to the culture dish. Microscopic evaluation showed contaminating 
lymphocytes in the plated cells (Figure 4.11A) and that a significant proportion of non-adherent 
cells in the supernatant were monocytes (Figure 4.11B).  
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Figure 4.11. Inefficient monocyte isolation following plating method. 
 
 
Monocyte isolation following plating was also analyzed by phenotypic characterization via 
flow cytometry (Figure 4.12A & B). All adherent cells recovered after a 90 minute incubation are 
displayed according to their forward (FSC) and side scatter (SSC) characteristics (Figure 4.12A). 
Cell populations were identified using a panel of surface and intracellular markers and overlaid 
onto the FSC vs. SSC plots. Cells were identified as follows: monocytes (SSCHI CD14+ CD16-), 
probable NK cells (SSClo CD14- CD16+ HLA-DR- CD36- CD68- CD11b+), and probable 
lymphocytes (SSClo CD14- CD16+ HLA-DR+/- CD36- CD68- CD11b-). The proportions of these 
cell types in the population of cells recovered from the surface of the plate are listed (Figure 
4.12B). Monocytes and lymphocytes were recovered from the plate in similar percentages (~40%), 
MNCs were isolated from heparinized whole blood by using Lymphoprep in SepMate50 tubes. 
Following MNC isolation, 3 x106 cells were added to a 6-well plate and allowed to adhere for 90 
minutes. After incubation, supernatant containing non-adherent cells was collected and spun onto glass 
slides. Plated cells were harvested using TrypLE and spun onto glass slides. Microscopic analysis 
occurred following differential cell staining at 40X. 
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while NK cells represented a smaller percentage (6.5%). In the supernatant, NK cells and 
lymphocytes constituted the majority of cells recovered (75%) but a significant monocyte 
population (13%) was detected. The results demonstrated non-specific and inefficient monocyte 
isolation using the plating method in 6 well plates. 
In order to increase monocyte recovery using the plating method, we hypothesized that 
increasing the surface area would allow more monocytes to adhere to the plate surface while 
contaminating cells like lymphocytes would remain in the supernatant. Increasing surface area 
only slightly improved monocyte recovery with 49% of adherent cells identified as monocytes 
(CD14+ CD16-, Figure 4.12C). The process remained highly inefficient as the majority of adherent 
cells were not monocytes and 17% of cells identified in the supernatant were monocytes (Figure 
4.12C). To maximize monocyte recovery, our next step was to test an immunomagnetic negative 
selection cell isolation kit. This kit utilizes a combination of magnetic bead linked antibodies 
targeting surface receptors of T cells, B cells, NK cells, neutrophils, etc. The sample is then run 
through a powerful magnet which binds magnetically labeled cells and allows unlabeled, enriched 
monocytes to be poured from the magnet for subsequent studies. Our use of the monocyte 
enrichment kit, following MNC isolation with Lymphoprep, resulted in a very pure (94%) CD14+ 
CD16- cell population (Figure 4.12C). The enriched CD14+ cells were seeded in a 24-well plate 
at a density 3.5 times higher than the recommended density for HeLa cells to create a “monocyte 
lawn”, which increases adherence and is in contrast to our previous hypothesis that more space 
would enhance monocyte adherence. The media was supplemented with GM-CSF (25ng/mL) to 
induce macrophage differentiation and after 7 days of culturing with GM-CSF, 89% of monocytes 
had differentiated to macrophages (CD14+ CD16+, Figure 4.12C). Under the microscope, 
differentiated macrophages appeared flattened with pseudopods extending outward, which differs 
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from monocyte’s rounded appearance (personal observation). These results demonstrate the 
superiority of immunomagnetic cell isolation compared to plating for the enrichment and isolation 
of human monocytes and the successful differentiation of the enriched monocytes to macrophages 
using GM-CSF. Effective monocyte enrichment and differentiation will be crucial as our lab 
moves forward in working with infant cord blood samples to discern the effect of IFNγ treatment 
on infant macrophages. 
 
   
  
Figure 4.12. Optimization of human monocyte enrichment and differentiation. 
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4.2.7 The effect of IFNγ treatment on T cell immunity in RSV-infected infant mice 
Data presented in this report have demonstrated the importance of IFNγ and AMs in the resolution 
of primary, infant RSV infection, but the importance of T lymphocytes in clearing RSV has been 
well established (61, 94-97).  Activation of APCs, like macrophages and dendritic cells, largely 
determines the T-helper cell phenotype priming of naïve T cells (133, 144, 170, 184). However, 
the ability of local pulmonary delivery of IFNγ to alter the T cell phenotype of RSV-infected infant 
mice has not been previously investigated. 
Figure 4.12 (continued) MNCs were using Lymphoprep in SepMate50 tubes. Following MNC isolation, 
3 x106 cells were added to a 6-well plate (A & B) or 17 x 106 cells were added to a 150mm petri-dish 
(C, top panels) and allowed to adhere for 90 minutes. After incubation, supernatant containing non-
adherent cells was collected while plated cells were harvested using TrypLE. Alternatively, MNCs 
underwent immunomagnetic cell isolation according to manufacturer instructions to obtain enriched 
monocytes (C, bottom left panel, CD14+ purified). Enriched monocytes were cultured with GM-CSF 
(25ng/mL) x 7 days to obtain differentiated macrophages (C, bottom right panel). Samples from each 
scenario were collected and processed for flow cytometry.  
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4.2.7.1 IFNγ reduces CD4+ CD44HI Tbet+:GATA3+ T-cell ratios compared to RSV infection 
alone 
To determine how T cell phenotype changes in infants following the local delivery of a Th1-type 
cytokine, i.n. IFNγ was administered to RSV-infected infant mice.  Intracellular Tbet+ and 
GATA3+ expression in CD4+ CD44HI T-cells in the URL and BAL was subsequently analyzed. 
Although frequencies of CD4+ and CD4+ CD44HI T cells were unaltered following i.n. IFNγ 
(Figure 4.13), Tbet+:GATA3+ CD44HI CD4+ T cell ratios were significantly reduced in the URL 
and BAL compared to untreated controls (Figure 4.14A). Importantly, reduced CD4+ CD44HI 
Tbet+:GATA3+ T cell ratios in the BAL were driven by reductions in CD4+ CD44HI Tbet+ T cell 
frequency rather than increases in CD4+ CD44HI GATA3+ T cells (Figure 4.14B). These data 
suggest that local IFNγ delivery to the infant airway during early RSV infection reduced the 
frequency of CD4+ Tbet+ T-cells without altering CD4+ GATA3+ frequencies at 10 DPI. 
 
Figure 4.13. Following i.n. IFNγ, T cell frequencies remain similar to RSV infected infants while both groups have 




Figure 4.13 (continued) Adult (6-8 weeks) and infant (PND 4-5) Balb/c mice were infected with RSV 
L19. Infants received i.n. IFNγ (16ng/g) or vehicle on days 1, 3, and 5 DPI. BAL and URL were 
collected at 10 DPI and processed for flow cytometry. The lymphocytes were gated according to typical 
FSC vs. SSC characteristics. % CD44HI and MFI was determined from TCRβ+ CD4+ or CD8+ T cells in 
the lymphocyte gate. The CD4+ T cell frequencies and MFI of CD44HI CD4+ (A, B, and C, respectively) 
and CD8+ T cell frequencies and MFI of CD44HI CD8+ T cells (D, E, and F, respectively) were 
compared between the BAL and URL using 2-way ANOVA with a Bonferroni post-test. Additionally, 
the CD4+ T cell frequencies and MFI of CD44HI CD4+ (A, B, and C, respectively) and CD8+ T cell 
frequencies and MFI of CD44HI CD8+ T cells (D, E, and F, respectively) were compared between age 
and treatment groups for BAL using ANOVA with a Bonferroni post-test. Points represent individual 
mice (adults) or individual samples from ≥ 2 pooled infants, lines represent the mean of n ≥ 4 samples 
per group ± SD; * ρ-value < 0.05, ** ρ-value < 0.01. Data in A - F are representative of 2 independent 
experiments. All CD44HI cells were also CD62L-. Originally published in: Eichinger KM, Kosanovich 
JL, Empey KM. Localization of the T-cell response to RSV infection is altered in infant mice. Pediatric 
pulmonology 2018;53(2):145-153. 
Figure 4.14. Intranasal IFNγ reduces Tbet+:GATA3+ CD4+ T-cell ratios at 10 DPI compared to RSV infection alone. 
 109 
 
4.2.7.2 Local IFNγ increases RSV F-protein specific CD8+ T-cells in infant murine BAL 
We next sought to determine if IFNγ altered the CD8+ T cell response in the RSV-infected infant 
airway. Following i.n. delivery of IFNγ, total CD8+ T cells were reduced in the infant airway 
compared to untreated controls (Figure 4.15A). The overall reduction in the CD8+ T cells was 
accompanied by significant reductions in CD8+ CD44HI T cells (data not shown) and reductions in 
CD8+ CD44HI T cells expressing the transcription factor Tbet (Figure 4.15B). These data were 
surprising given our previous findings, which showed that i.n. IFNγ expedited viral clearance 
compared to age-matched controls (1). To resolve these seemingly incongruous results, we utilized 
an RSV F85-93-protein specific pentamer to determine the effect of i.n. IFNγ on CD8
+ T cell 
specificity.  Intriguingly, local IFNγ administration significantly increased the frequency of RSV 
F85-93 protein-specific CD8
+ T cells in the BAL of RSV-infected infant mice compared to untreated 
Figure 4.14 (continued) Infant (PND 4-5) Balb/c mice were infected with RSV L19 and administered 
i.n. IFNγ (16ng/g) or vehicle on 1, 3, and 5 DPI. BAL and URL were collected at 10 DPI and processed 
for flow cytometry. Lymphocytes were gated according to typical FSC vs. SSC characteristics. Ratios 
of TCRβ+ CD4+ CD44HI Tbet+ cells to TCRβ+ CD4+ CD44HI GATA3+ cells were calculated from total 
cell counts of the URL and BAL (A).  The frequency of CD4+ CD44HI GATA3+ and Tbet+ T-cells were 
compared in BAL for RSV and RSV + IFNγ infants (B). A 2-way ANOVA was used to compare the 
Tbet+:GATA3+ CD4+ T-cell ratios between URL, BAL, and treatment groups with a Bonferroni post-
test (A). The frequencies of CD4+ CD44HI GATA3+ and Tbet+ T cells in the BAL were compared 
between RSV and RSV + IFNγ infants using 2-way ANOVA with a Bonferroni post-test (B). Points 
represent individual samples of ≥ 2 pooled infants, lines represent the mean of n = 4 samples per group 
± SD; * ρ < 0.05, ** ρ < 0.01. Data is representative of a single experiment. All CD44HI cells were also 
CD62L-. Originally published in: Eichinger KM, Kosanovich JL, Empey KM. Localization of the T-
cell response to RSV infection is altered in infant mice. Pediatric pulmonology 2018;53(2):145-153. 
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controls (Figure 4.15C). Together, these results suggest that IFNγ contracts the CD8+ T cell 




Figure 4.15. IFN-γ priming of RSV-infected infant mice improves RSV F85-93 -protein specific CD8+ T cell 
accumulation within the BAL compared to RSV alone, despite overall reductions in CD8+ T-cells. 
 
 
Infant (PND 4-5) Balb/c mice were infected with RSV L19 and administered i.n. IFNγ (16ng/g) or 
vehicle on 1, 3 and 5 DPI. BAL was collected at 10 DPI and processed for flow cytometry. The 
lymphocytes were gated according to typical FSC vs. SSC characteristics. Total CD8+ T-cells (A), total 
CD8+ CD44HI Tbet+ T-cells (B), and the percentage of CD19- RSV F85-93 protein-specific CD8+ T-cells 
(C) were compared between groups using an unpaired, 2-tailed t test.  For the quantification of RSV F85-
93 protein-specific CD8+ T-cells, we first subtracted the percentage of background obtained from an LPS 
negative control BAL sample stained with RSV F85-93 protein-specific pentamer. Points represent 
individual samples of ≥ 2 pooled infants, lines represent the mean of n ≥ 9 samples per group ± SD; ** 
ρ-value < 0.01. Data in A - C are representative of 2 independent experiments. All CD44HI cells were 
also CD62L-. Originally published in: Eichinger KM, Kosanovich JL, Empey KM. Localization of the 
T-cell response to RSV infection is altered in infant mice. Pediatric pulmonology 2018;53(2):145-153. 
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4.3 DISCUSSION  
In this study, the cytokine kinetics and immune stimulating effects of IFNγ were examined in adult 
and infant Balb/c mice following i.n. administration. Long-term protection against RSV by 
vaccination is a global health priority, yet concerns over vaccine-enhanced RSV disease and 
limited infant host immunity continue to pose a significant challenge. Moreover, repeated 
infections with RSV throughout life suggests that induction of sterilizing immunity may not be 
feasible and vaccinations that induce sufficient immunity to protect against serious RSV infection 
may be a more realistic goal. Stimulating the innate immune response to prevent or treat pulmonary 
infections is of growing interest in the areas of antimicrobial resistance, impaired host immunity, 
and for viral infections lacking an effective vaccine (185-187). Many of these strategies target 
pattern recognition receptors to activate transcription factors such as NF-kB and interferon 
regulatory transcription factor (IRF3), resulting in the expression of inflammatory cytokines and 
other facets of cellular activation (188). Vaccine strategies combine non-infectious antigen with 
immune potentiating adjuvants in an effort to condition the adaptive immune response in 
preparation for subsequent exposure to infectious organisms. However, infants often do not reap 
the same protective benefits from vaccination as older children and adults due to inefficient or 
suppressive innate and adaptive host immunity (189, 190). A growing number of studies have 
reported safe and effective antiviral activity with vaccine-mediated enhancement of pro-
inflammatory cytokines (191-194), yet less is known about direct immune stimulation. 
In the present investigation, analysis of cytokine delivery was focused on pulmonary innate 
immune cell exposure and activation following intranasal delivery of IFNγ in infant versus adult 
murine lungs. Following identical weight-based dosing, infant compared to adult mice had 
markedly reduced AUCs and Cpks, indicating reduced cytokine concentrations were achieved in 
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infant compared to adult murine lungs. It is reasonable to consider that the narrow infant airways 
compared to adults’ limited delivery of this 50kDa protein in an age-dependent manner. However, 
examination of lung and body weights over time indicated that the rate of postnatal infant lung 
growth exceeded that of body weight through 10 days of age, suggesting that pulmonary doses of 
weight-based drugs were underestimated when scaling from adult doses. These findings are 
consistent with previous studies demonstrating that pulmonary deposition of aerosolized drugs 
depend primarily on differences in ventilation per gram of body weight and may account, in part, 
for lower AUCs and Cpks in infant compared to adult mice treated with IFNγ or GM-CSF (195). 
Moreover, reduced cytokine clearance (apparent) rates, which are calculated based on dose and 
AUC, were also lower in infant compared to adult murine lungs and blood, suggesting that 
bioavailability rather than increased proteolytic activity was responsible for the reduced infant 
concentrations. Together, these data showed reduced AUCs and clearance rates in infant compared 
to adult mice treated with a single intranasal dose of IFNγ. 
Discrete weight-based doses of IFNγ were used based on previous studies in infant and 
adult mice designed to optimize immune activation (1, 119, 148). Indeed, IFNγ treatment on days 
1, 3, and 5 DPI resulted in increased recruitment of monocytes and DCs to the BAL during infant 
RSV infection. This recruitment is likely the result of activation and the release of chemokines by 
airway epithelial cells and AMs. Activation of AMs followed IFNγ treatment of RSV-infected 
infants as demonstrated by increased expression of CD11b, CD80, MHCII, and SR-A. However, 
following a single, weight-based dose of IFNγ, adult animals had an IFNγ AUC that was 3.6 times 
larger than that of infants, which resulted in expedited and enhanced MHCII expression on CD11c+ 
CD11b- cells in adults compared to infants. The large age-based differences in IFN exposure was 
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not a result of differential IFN metabolism but was most likely an artifact of the neonate’s larger 
lung to body size ratio or the potential loss of some of the dose due to ingestion. 
Taking this into consideration, a non-compartmental model analysis was used to determine 
a new neonatal dose of IFN that would achieve more adult-level AUCs. We predicted the new 
neonatal IFNγ dose of 60ng/g would not only expedite viral clearance, but would also modulate 
associated risk factors linked to skewed Th2 pathology, such as mucus production. The data 
presented here showed the capacity of IFNγ to induced AM activation and RSV clearance in a 
clear, dose-dependent manner without provoking weight loss. To determine the extent to which 
AMs contributed to RSV clearance, we then depleted neonatal AMs using CLip, which further 
demonstrated that AMs significantly contribute to viral clearance in the neonatal lung.  
Low levels of IFN in the BAL are consistently associated with greater disease severity in 
neonates (196), yet it is unclear what IFN’s protective role is. Consistent with this finding is data 
published by Cohn et al. demonstrating that mucus production is inhibited by IFNγ in an adult 
mouse model (197) and our previously published data showing greater mucus production in RSV-
infected neonatal mice in which there is minimal IFN production compared to RSV-infected adult 
mice (1). Consistent with previous findings, these data show reductions in goblet cell hyperplasia 
(as indicated by PAS staining) in RSV+ neonatal lungs treated with inhaled IFNγ (16ng/g and 
60ng/g) when compared to untreated RSV+ pups. Mounting evidence continues to support the role 
of IFN as a regulator of mucus production (198-201).  
RSV non-structural proteins, NS1 and NS2, have been shown to impair early cellular 
apoptosis. It is speculated that this is advantageous to the virus; allowing RSV to spread from one 
cell to another throughout the airway (14). Other data support the idea that RSV sensitizes cells to 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis by 
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upregulating the expression of death-receptors 4 and 5 (202). The sensitization is tempered 
however by early increases in Mcl-2, a member of the anti-apoptotic Bcl-2 family, which acts to 
delay the effects of TRAIL-mediated signaling and delays apoptosis in infected epithelial cells 
(202). We reasoned, then, that IFN, a well-established and appreciated inducer of cellular 
apoptosis (203) may be associated with less severe RSV disease clinically due to its facilitation of 
apoptosis thereby limiting the spread of the virus. To test the hypothesis that IFNγ interferes with 
RSV-mediated impairment of apoptosis, we examined the effect of i.n. IFN on apoptosis in RSV 
infected neonatal mice. Surprisingly, RT-PCR data showed that i.n. IFNγ elicited no change in 
caspase 3 or 8 expression by 4 or 7 DPI in RSV infected neonates treated with 60ng/g of IFN 
compared to PBS-treated controls (data not shown), despite enhanced viral clearance. However, 
significant reductions in TUNEL-positive cells in groups receiving i.n. IFN suggest possible 
enhanced clearance of apoptotic cells rather than IFN-mediated apoptosis. 
We postulated that IFNγ may be augmenting mechanisms of viral resistance in airway 
epithelial cells that dramatically reduce the viral burden at the onset of infection. IFNγ treatment 
was independently associated with significantly lower viral titers at our earliest time point, 4 DPI, 
suggesting that IFNγ treatment reduced the initial viral burden. High levels of IFNγ exposure prior 
to RSV infection have been shown to dramatically inhibit RSV replication in adult Balb/c mice 
(204). Additionally, exposure of a human airway epithelial cell line (A549) to IFN for 48 hours 
prior to RSV infection reduced 2-day post-infection viral titers when compared to IL-4 treated or 
control cells. This reduction was associated with the upregulation of antiviral proteins, such as 
IFIT1 and Mx1 (205). Similarly, we demonstrated that A549 pretreatment with IFNγ (100ng/mL) 
for one hour prior to RSV infection significantly inhibited RSV replication within the cell 
(intracellular) and reduced budded virus (extracellular). 
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This is the first study to our knowledge, using a neonatal animal model, to examine the role 
of AMs in the clearance of RSV through the i.n. administration of CLip. We demonstrated that 
AMs play a significant role in RSV clearance and that delayed viral clearance is associated with 
reduced weight gain in a neonatal murine model of RSV. Although AM-mediated regulation of 
weight gain requires further investigation, impaired weight gain in CLip versus PBS-treated pups 
highlights the importance of AMs during neonatal RSV infection. Mice do not develop clinical 
symptoms of RSV but a failure to appropriately gain weight suggests that the animals experienced 
detrimental effects from a lack of effective viral clearance. Clinical data from human neonates < 
2 years of age found that faster RSV viral clearance was associated with shorter hospitalizations 
(206). In a model of influenza, ablation of AMs resulted in significant increases in pulmonary viral 
load, severe airway inflammation, weight loss, and death in an otherwise sublethal influenza 
infection (207). Collectively, this suggests that AMs play a critical role in the clearance of 
respiratory infections like RSV and are essential in returning the host to homeostasis.   
Data presented previously (Chapter 3) demonstrated the striking differences in CD4+ and 
CD8+ T cell frequencies in the BAL between RSV-infected adults and infants, in line with results 
published by Lines et al., in a neonatal murine model of influenza (102). In the infant influenza 
model, delayed viral clearance was associated with poor T-cell accumulation in the BAL despite 
a vigorous T-cell response in the interstitium (102). The small proportions of T-cells found in the 
BAL of RSV-infected infants may indicate a lack of effective recruitment. However, delivery (i.n.) 
of either IFNγ, CXCL9, or CCL2 did not increase T cells in the BAL in an infant model of 
influenza (102). Although these agents were administered late in infection (7, 8, and 9 DPI), our 
studies also showed that i.n. IFNγ early in RSV infection (1, 3, and 5 DPI) did not increase the 
frequencies of T cells recovered from the alveolar space at 10 DPI. Local delivery of IFNγ to the 
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infant airway unexpectedly lowered the frequency of CD4+ Tbet+ T cells compared to untreated 
controls, while the frequencies of CD4+ GATA3+ T cells remained stable. Surprisingly, CD8+ T 
cell populations were also reduced in IFNγ-treated infants yet, the RSV F protein-specific CD8+ T 
cell response increased compared to untreated controls. 
Initially, we suspected the decrease in CD4+ Tbet+ T cells may be reflective of a rebound 
effect given the strong inflammatory pressure of IFNγ, but analysis of an earlier seven-day time 
point showed similar reductions in Tbet+ CD4+ T -cells with no differences in overall CD4+ T cell 
numbers or GATA3+ expression (data not shown).  Given that CD4+ Tbet+ frequencies decreased 
but GATA3+ CD4+ frequencies remained unchanged, further studies will be required to understand 
what phenotype these CD4+ T cells became, including investigating frequencies of Th17 CD4+ T 
cells. 
Finally, IFNγ-treated infants demonstrated a reduction in the BAL effector memory CD8+ 
T cell pool compared to untreated controls but increased RSV F-protein-specific CD8+ T cells, 
suggesting that IFNγ may regulate CD8+ T cell contraction while enriching the pool of RSV-
specific effector memory CD8+ T cells by 10 DPI. The current findings are consistent with 
previously published reports showing that IFNγ is associated with CD8+ effector/memory 
contraction and enhanced specificity (208-210). Moreover, Sercan and colleagues demonstrated 
the importance of IFNγ receptor signaling in CD11b+ macrophage-like cells in the control of CD8+ 
effector proliferation (208, 209). This is consistent with our previous reports and data presented 
here, showing the upregulation of CD11b+ on AMs in the BAL of infant mice primed with i.n. 
IFNγ (1) and provides indirect evidence that IFNγ may contribute to the observed decrease in 
CD8+ effector/memory cells. Furthermore, IFNγ signaling blocked the formation of memory 
precursor CD8+ T cells that respond to weak TCR agonists and instead promoted the accrual of 
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high-affinity memory CD8+ T cells (210). Although the F protein is highly antigenic, it does not 
contain the primary, immunodominant epitope, thus future studies will determine the effect of i.n. 
IFNγ on effector/memory CD8+ T cell development targeting the immunodominant M2 protein. 
Clinical studies correlate higher IFNγ responses during infant RSV infection with 
improved clinical symptoms but the mechanisms underlying this response remain poorly 
understood. In this report, we demonstrate that local administration of IFNγ to RSV-infected infant 
mice stimulates innate immune cell activation, reduces viral titers, and increases RSV F85-93 CD8
+ 
T cell specificity. Our data suggests that careful consideration be given to IFNγ dosing in infants 
due to altered IFNγ pharmacokinetics and reduced exposure, but that with adequate dosing 
increased AM activation can be achieved. A complete pharmacokinetic profile of an inhaled IFNγ 
dose response study in infants has not been conducted, so it is difficult to predict the upper-end of 
the therapeutic threshold of inhaled IFNγ. However, the study presented in this chapter as well as 
clinical data (167) demonstrated low systemic absorption with an intranasal/inhaled dose. This 
suggests that the dose of locally administered IFNγ could be increased significantly to achieve 
appropriate levels of activation within the lung and remain below the therapeutic levels of IFNγ in 
the blood following administration for systemic conditions such as chronic granulomatous disease 
(164). Additionally, IFNγ had profound ameliorating effects on primary RSV-related pathology 
resulting in reduced mucus production and apoptotic cellular debris, which may be a result of 
increased AM activation. Results from these studies have implications for the therapeutic potential 
of acute, immunomodulation administered directly to the lungs of RSV-infected infants.  
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5.0  SECONDARY RSV IMMUNE RESPONSES 
5.1 INTRODUCTION 
RSV infections show distinct seasonality in temperate regions with onset beginning in fall, peaking 
between mid-December and early February, and dropping off dramatically in late spring. In 
tropical regions, outbreak patterns are less predictable, having multiple peaks throughout the year 
or remaining fairly constant (34). In the United States, primary attack rates in infants during RSV 
outbreaks ranged from 64-98% (33, 211, 212). Virtually all children less than 24 months of age 
have experienced at least one RSV infection (211) and 50-75% have been infected twice (211, 
212). While an amelioration of symptoms following secondary RSV infection has been 
demonstrated (211), another study showed no symptom improvement during secondary infection 
and a third infection was necessary to appreciably reduce illness severity (212). Recovering from 
the acute effects of primary RSV infection is not the only hurdle for infants. Inefficient immunity 
developed in response to primary infant exposure has profound effects on disease patterns later in 
life (66, 213, 214) and leaves individuals vulnerable to re-infection throughout life.  
Analysis of cytokine signatures measured from the nasal lavages of RSV-infected infants 
with symptoms of an upper respiratory tract infection (mild RSV) compared to acute bronchiolitis 
(a severe form of RSV) demonstrated that infants afflicted with acute bronchiolitis had higher IL-
4/IFNγ ratios (178). This clinical finding prompted researchers to investigate modes of cytokine 
delivery during primary RSV infection to understand how various cytokines alter primary, as well 
as secondary RSV immune responses. Recombinant RSV virus expressing IL-4 did not affect viral 
titers in primary infant RSV infection and significantly enhanced Th2 immune responses upon 
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wild-type RSV re-challenge (174). IFNγ delivered via pulmonary instillation or through 
recombinant RSV technology attenuated RSV during primary infant RSV infection (174) and 
protected animals from histopathology and airway hyperresponsiveness upon secondary challenge 
(174, 215). However, in adult mice, IFNγ-expressing RSV virus resulted in enhanced disease 
following secondary wild-type RSV challenge (216), highlighting the importance of an age 
appropriate RSV animal model. 
Given the importance of the adaptive immune response in preventing or attenuating 
secondary RSV infections, it is of no surprise that most research has focused on fine-tuning RSV 
adaptive immunity. However, the innate immune response not only plays an important role in 
initiating primary RSV responses but also in orchestrating secondary RSV immunity. Mice 
exposed to RSV as neonates and then re-challenged as adults showed increased levels of innate 
inflammatory cytokines and AM depletion attenuated weight loss and reduced recruitment of NK 
and T cells (217). These results hint at a recently recognized phenomenon known as “trained 
immunity”. Immunological dogma states that only members of adaptive immunity can mount 
pathogen-specific memory following antigen receptor gene rearrangements, but studies have 
shown that a number of innate immune cells can develop increased responsiveness to secondary 
stimuli. Trained immunity or innate immune memory occurs following germline-encoded 
recognition and/or effector molecule exposure (pathogen-associated molecular patterns (PAMPs), 
danger-associated molecular patterns (DAMPs), cytokines, etc.) resulting in epigenetic rewiring 
and sustained alterations in translational programs (218).  
In this study, our aim was to characterize changes in innate and adaptive immunity in 
secondary RSV immune responses as a result of IFNγ treatment during primary infant RSV 
infection to determine the long-term beneficial effects of this treatment. We demonstrate 
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incomplete protection from RSV re-challenge and similar T cell phenotype signatures between 
animals treated with IFNγ or vehicle during primary RSV. IFNγ treatment sustained improvements 
in CD8+ RSV F85-93 specificity and reduced central airway resistance. Using an adoptive transfer 
model, we also show signals of AM trained immunity as a result of IFNγ treatment during primary, 
infant RSV. These findings demonstrate the broad, far-reaching effects of local IFNγ 
administration during primary infant RSV and have important implications for future 
vaccine/therapeutic development. 
5.2 RESULTS 
5.2.1 Infant mice infected with RSV are partially protected from secondary RSV 
Our data demonstrates that primary RSV infection in adult Balb/c mice elicits complete, sterilizing 
immunity for up to 11 weeks against secondary RSV challenge (Figure 5.1A). Chapter 4 outlined 
how local administration of IFNγ during infant, primary RSV infection effected changes in innate 
and adaptive RSV immune responses. To determine how IFNγ during primary, infant RSV 
infection affects protection against secondary RSV exposure, infants were infected with RSV and 
i.n. IFNγ or vehicle was administered. Then, the animals were allowed to recover for 6 weeks and 
were re-challenged with RSV. Secondary RSV groups were compared to age-matched naïve and 
primary RSV controls. Unlike the complete sterilizing immunity seen in adults receiving 
secondary RSV exposure (Figure 5.1A), infant mice infected with RSV and then re-challenged as 
adults developed only partially protective RSV immunity (Figure 5.1B). Both secondary exposure 
groups demonstrated a log-fold reduction in detectable virus at 2 DPI and effectively inhibited 
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viral replication between 2 and 4 DPI compared to primary RSV controls (Figure 5.1B). Infants 
who received IFNγ during primary RSV infection (RSV+IFNγ/RSV) had a small but non-
significant reduction in detectable virus in the lungs at 4 DPI compared to infants who received 
only PBS during primary infection (RSV/RSV) (Figure 5.1B).  
  
 
Adult (4 week old) Balb/c mice (A) were infected with RSV L19 or vehicle and the animals were then 
rested for 11 weeks.  Then, they were challenged (1⁰ RSV) or re-challenged (2⁰ RSV) with RSV and 
left lung collected for viral titers at 4 days post-RSV challenge. Infant mice (B; PND 4-5) were infected 
with RSV or vehicle and treated with IFNγ (16ng/g) or vehicle on 1, 3, and 5 DPI. After 6 weeks, the 
mice were re-challenged with RSV and left lungs collected for viral titers at 2 and 4 days post-RSV 
challenge. * represent significant differences between experimental groups using Mann-Whitney (A) or 
2-way ANOVA with Bonferroni post-test (B); **ρ = 0.0028, ***ρ < 0.001. Data points represent 
individual mice, the line represents the mean of n ≥ 4-11 samples per group ± SD.  
Figure 5.1 RSV infection during infancy is partially protective in secondary RSV exposure. 
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5.2.2 IFNγ treatment during primary, infant RSV increases AM and DC activation upon 
secondary RSV exposure 
Macrophages represent a larger proportion of SSCHI cells in the BAL of 1⁰ RSV mice (Figure 
5.2A) but macrophages (Sig F+ CD11cHI +/- CD11b) from RSV-experienced animals had higher 
expression of the co-stimulatory and antigen presentation receptors, CD86+ and MHCII+, 
respectively, with RSV+IFNγ/RSV mice having the highest expression (Figure 5.2B & C). 
RSV+IFNγ/RSV animals also had increased frequencies of Siglec F- macrophages (Sig F- CD11cHI 
+/- CD11b) (Figure 5.2D), which are associated with an inflammatory phenotype (219), with 
enhanced CD86+ and MHCII+ expression (Figure 5.2E & F).  
 
Figure 5.2 IFNγ treatment during primary, infant RSV increases AM activation upon secondary exposure. 
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Given the signals of enhanced antigen presentation and activation on macrophages, we 
hypothesized that RSV+IFNγ/RSV DCs would similarly display an activated phenotype in the 
MSLN. The frequency of DCs (CD11c+ MHCIIHI) was highest in 1⁰ RSV animals, which may be 
due to higher RSV lung titers and a lack of RSV immune memory (Figure 5.3A). Studies of 
pulmonary DC subtypes have demonstrated the superiority of CD103+ over CD11b+ DCs in 
eliciting effective cytotoxic CD8+ T cell responses generated from apoptotic cell-associated 
antigen (220), similar to RSV-infected apoptotic cells that are extruded into the airway. Therefore, 
we analyzed DC phenotype in the MSLN to determine how the DC phenotype may influence T 
cell responses upon secondary exposure. There were no significant differences in the frequencies 
of CD11b+ DCs between groups (Figure 5.3B). CD103+ DCs made up a larger proportion of DCs 
in the lymph node across groups and 1⁰ RSV mice had the highest frequency of CD103+ DCs 
(Figure 5.3C). Interestingly, RSV+IFNγ/RSV mice had higher CD86+ expression on CD11b+ and 
CD103+ DCs compared to RSV/RSV (Figure 5.3D). Lower co-stimulatory expression on CD103+ 
DCs in RSV/RSV mice was accompanied by increased expression of CD73+ (Figure 5.3E). This 
ecto-5’-nucleotidase converts extracellular adenosine monophosphate to adenosine, which may 
reduce the inflammatory signaling (106) of CD103+ DCs in RSV/RSV animals. Collectively, these 
Figure 5.2 (continued) Infant mice (PND 4-5) were infected with RSV or vehicle and treated with IFNγ 
(16ng/g) or vehicle on 1, 3, and 5 dpi. After 6 weeks, the mice were re-challenged with RSV and BAL 
collected and processed for flow cytometry at 2 days post-RSV challenge.  The percentage of cells 
identified as macrophages (A; Sig F+ CD11cHI +/- CD11b) were analyzed for expression of CD86+ (B) 
and MHCII+ (C). Percentages of Sig F- macrophages (D; Sig F+ CD11cHI +/- CD11b) expressing CD86+ 
(E) and MHCII+ (F) were also analyzed. * represent significant differences between experimental groups 
using ANOVA with Tukey’s post-test; *ρ < 0.05, ** ρ < 0.01, or ***ρ < 0.001. Data points represent 
individual mice, the line represents the mean of n ≥ 3-7 samples per group ± SD. 
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data suggest that IFNγ treatment during primary, infant RSV elicits a memory response that 
enhances AM and DC activation upon secondary challenge. 
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Figure 5.3 IFNγ treatment during primary, infant RSV enhances activation of DCs in MSLN. 
Infant mice (PND 4-5) were infected with RSV or vehicle and treated with IFNγ (16ng/g) or vehicle on 
1, 3, and 5 dpi. After 6 weeks, the mice were re-challenged with RSV and MSLN collected and 
processed for flow cytometry at 2 days post-RSV challenge.  The percentage of cells identified as DCs 
(A; CD11c+ MHCIIHI) were analyzed for expression of CD11b+ (B) and CD103+ (C). CD86+ (D) and 
CD73+ (E) expression were than analyzed on CD11b+ and CD103+ DCs and graphed side by side but 
were not compared across CD11b+ and CD103+ DC groups. * represent significant differences between 
experimental groups using ANOVA with Tukey’s post-test; *ρ < 0.05, ** ρ < 0.01, or ***ρ < 0.001. 
Data points represent individual mice, the line represents the mean of n ≥ 2-8 samples per group ± SD. 
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5.2.3 Infants treated with IFNγ during primary RSV infection have greater RSV 
specificity upon re-challenge 
DCs in the lymph nodes of RSV+IFNγ/RSV mice demonstrated increased CD86+ and decreased 
CD73+, suggesting enhanced activation that may result in improved T cell responses. To determine 
the effects of differential DC activation on T cell memory, BAL was collected and memory T cell 
phenotypes analyzed via flow cytometry. As expected, re-exposure groups had more CD4+ and 
CD8+ effector memory (Figure 5.4 A and C, respectively; TCRβ
+ CD4/8+ KLRGlo CD127HI 
CD44HI CD62L-) as well as, short-lived effector memory CD4+ and CD8+ T cells (Figure 5.4 B 
and D, respectively; TCRβ
+ CD4/8+ KLRGHI CD127lo CD44HI) compared to 1⁰ RSV and naïve 
mice. However, there were no differences between RSV/RSV and RSV+IFNγ/RSV in the number 






 Although both re-exposure groups had similar numbers of memory T cells in the BAL, we 
hypothesized that IFNγ treatment during primary, infant RSV infection would lead to improved 
RSV F85-93-protein specificity in CD8
+ T cells during secondary RSV exposure, as was seen in 
RSV+IFNγ infants during primary RSV infection (Chapter 4). A similar number of CD8+ T cells 
Figure 5.4 Primary, infant RSV infection elicits memory T cells found in the BAL during secondary exposure. 
Infant mice (PND 4-5) were infected with RSV or vehicle and treated with IFNγ (16ng/g) or vehicle on 
1, 3, and 5 dpi. After 6 weeks, the mice were re-challenged with RSV and BAL collected and processed 
for flow cytometry at 4 days post-RSV challenge.  The numbers of CD4+ (A) and CD8+ (C) effector 
memory cells (TCRβ
+ CD4/8+ KLRGlo CD127HI CD44HI CD62L-), as well as, CD4+ (B) and 
CD8+ (D) short-lived effector memory cells (TCRβ
+ CD4/8+ KLRGHI CD127lo CD44HI) were 
compared across experimental groups. * represent significant differences between experimental groups 
using ANOVA with Tukey’s post-test; *ρ < 0.05, ** ρ < 0.01, or ***ρ < 0.001. Data points represent 
individual mice, the line represents the mean of n ≥ 3-4 samples per group ± SD. 
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(TCRβ
+ CD8+) were recovered from the BALs of secondary exposure groups at 4 days post-RSV 
challenge but both groups had more CD8+ T cells than 1⁰ RSV or naïve animals (Figure 5.5A). 
RSV/RSV and RSV+IFNγ/RSV animals had more activated (CD44HI) CD8+ T cells expressing 
Tbet, the transcription factor required for IFNγ production, than control groups (Figure 5.5B). 
Importantly, the higher numbers of RSV F85-93 CD8
+ T cells (CD19- TCRβ
+ CD8+ F85-93
+) 
demonstrated in IFNγ-treated infants during primary infection were similarly elevated in RSV+ 











We next sought to determine what type of T-helper memory response was elicited by 
secondary RSV challenge by quantifying Th1 (IL-2 and IFNγ) and Th2 (IL-4, IL-5, and IL-13) 
cytokines from the BAL. IL-2 concentrations increased more quickly in the BAL of RSV/RSV 
and RSV+IFNγ/RSV mice compared to control groups but 1⁰ RSV had comparable levels by 4 
days post-RSV challenge (Figure 5.6A). The primary Th1 cytokine, IFNγ, was elevated in both 
re-exposure groups at both time points analyzed (Figure 5.6B). RSV/RSV and RSV+IFNγ/RSV 
groups had elevated concentrations of IL-4 (Figure 5.6C) and IL-13 (Figure 5.6E) by 4 days post-
Figure 5.5 Increased RSV F85-93-specific CD8+ T cells from the BAL of RSV+IFNγ/RSV mice. 
Infant mice (PND 4-5) were infected with RSV or vehicle and treated with IFNγ (16ng/g) or vehicle on 
1, 3, and 5 dpi. After 6 weeks, the mice were re-challenged with RSV and BAL collected and processed 
for flow cytometry at 4 days post-RSV challenge.  The numbers of CD8+ (A; TCRβ+ CD8+), activated 
Tbet+ CD8+ cells (B; TCRβ+ CD8+ CD44HI Tbet+), and RSV F-specific CD8+ T cells (C; CD19- TCRβ+ 
CD8+ RSV F85-93+) were compared across experimental groups. * represent significant differences 
between experimental groups using ANOVA with Tukey’s post-test; *ρ < 0.05 or ** ρ < 0.01. Data 
points represent individual mice, the line represents the mean of n ≥ 4-5 samples per group ± SD. 
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challenge compared to 1⁰ RSV controls but IL-5 (Figure 5.6D) was elevated in re-exposure groups 
at both time points. Together these results suggest that although primary, infant RSV stimulates 
memory T cell development, it is only partially protective against secondary challenge. 
Administration of IFNγ during primary, infant RSV increased CD8+ RSV F85-93 specificity 
following secondary RSV exposure but did not alter the T helper cytokine signature in the BAL.  
 
 
Figure 5.6 IFNγ treatment during primary, infant RSV does not alter T helper cytokine profile. 
 131 
 
5.2.4 Following secondary RSV exposure, network complexity and airway resistance 
decreased with IFNγ treatment during primary, infant RSV infection  
Given that the T helper cytokine response was similar between re-exposure groups at both 2 and 
4 days post-RSV exposure, we employed a dynamic network analysis to help elucidate what 
relationships existed between cytokines and how those relationships may influence RSV immune 
responses. The schematics of dynamic network analyses show all cytokines (circles) for which 
concentration data from first-wash was provided. If the cytokine participated in the network 
analysis, it appears red; white if the cytokine was not involved. The black arrows show positive 
feed-forward responses between cytokines and the red arrows show an inhibitory relationship 
between cytokines. Overall, we observed that network complexity increased with secondary RSV 
exposure and that more cytokine networks were engaged between days 2 and 4 post-secondary 
exposure in these groups (Figure 5.7). Interestingly, IFNγ treatment during primary, infant RSV 
infection reduced the complexity of cytokine networks upon secondary exposure and eliminated 
the inhibitory feedback (red arrows) demonstrated by the RSV/RSV group at 2 days post-RSV 
challenge (Figure 5.7). 
Figure 5.6 (continued) Infant mice (PND 4-5) were infected with RSV or vehicle and treated with IFNγ (16ng/g) or 
vehicle on 1, 3, and 5 dpi. After 6 weeks, the mice were re-challenged with RSV and BAL collected for cytokine 
analysis using Luminex at 2 and 4 days post-RSV challenge. Concentrations of IL-2 (A), IFNγ (B), IL-4 (C), IL-5 
(D), and IL-13 (E) were compared across experimental groups at each time point. * represent significant differences 
between RSV-exposure groups using ANOVA with Tukey’s post-test; *ρ < 0.05 vs. 1⁰ RSV. Data points represent 
individual mice, the line represents the mean of n ≥ 4-14 samples per group ± SD. Dotted line represents the limit 




Our observation of a loss of inhibitory cytokine feedback at 2 days post-RSV exposure in 
RSV+IFNγ/RSV compared to RSV/RSV animals led us to hypothesize that innate inflammatory 
cell recruitment would be increased in the RSV+IFNγ/RSV group. To determine if innate 
Figure 5.7 IFNγ treatment during primary, infant RSV reduces cytokine network complexity following secondary exposure. 
Infant mice (PND 4-5) were infected with RSV or vehicle and treated with IFNγ (16ng/g) or vehicle on 1, 3, and 5 
dpi. After 6 weeks, the mice were re-challenged with RSV and BAL collected for cytokine analysis using Luminex 
at 2 and 4 days post-RSV challenge. Collaborators, Drs. Yoram Vodovotz and Ruben Zamora, used cytokine 
concentrations to develop dynamic network analyses using a stringency limit of 0.7. Red circles indicate cytokines 
actively involved in the immune response while white circle represent cytokines that are not playing a role in the 
network. Black lines demonstrate a stimulatory relationship and red lines indicate an inhibitory relationship between 
cytokines. Neither black nor red arrows suggest directionality. Based off of cytokine values from n ≥ 4-11 samples 
per group ± SD. 
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inflammatory cell recruitment was increased in RSV+IFNγ/RSV animals, BAL was collected and 
cell identification and quantification was performed via flow cytometry and chemokine 
quantification by Luminex. Monocytes (Figure 5.8A; Sig F- F4/80+ CD206- CD11c+ CD11b+) and 
neutrophils (Figure 5.8C; Sig F- Ly6G+ CD11bHI CD11c-) were elevated in both re-exposure 
groups compared to the controls. DCs (Figure 5.8B; Sig F- CD11c+ MHCIIHI) were also elevated 
in RSV/RSV and RSV+IFNγ/RSV groups compared to naïve controls. Although the total number 
of eosinophils was small, RSV+IFNγ/RSV animals had more of this inflammatory cell type 
(Figure 5.8D; Sig F+ F4/80+ CD206- CD200R- CD11c- CD11b+) than controls. Neutrophil (KC; 
keratinocyte chemokine) and eosinophil (eotaxin) chemokine concentrations correlated with the 
cellular composition of the BAL. KC was elevated at 2 and 4 days post-RSV challenge for both 
re-exposure groups (Figure 5.8E). It should be noted that KC was elevated in the 1⁰ RSV group 
at 2 days post-RSV challenge but neutrophils were not identified in BAL samples via flow 
cytometry (Figure 5.8C). This is likely a kinetic effect observed in 1⁰ RSV, in which neutrophil 
recruitment to the BAL peaks around 2 days post-infection (data not shown) when KC 
concentrations are high. This is supported by the fact that KC values returned to baseline by 4 days 
post-RSV challenge in 1⁰ RSV animals. A difference in kinetics may also explain increased 
eosinophils in the BAL of RSV+IFNγ/RSV animals at 4 days post-RSV challenge. Eotaxin began 
to rise in RSV+IFNγ/RSV animals at 2 days post-RSV challenge but both secondary exposure 
groups had similar concentrations by 4 days post-RSV challenge (Figure 5.8F), which suggests 





Figure 5.8 IFNγ treatment during primary, infant RSV does not alter secondary innate inflammatory cell recruitment. 
Infant mice (PND 4-5) were infected with RSV or vehicle and treated with IFNγ (16ng/g) or vehicle on 1, 3, and 5 
dpi. After 6 weeks, the mice were re-challenged with RSV and BAL collected and processed for flow cytometry 
and chemokine analysis. The total number of monocytes (A; Sig F- F4/80+ MR- CD11c+ CD11b+), dendritic cells 
(B; Sig F- CD11c+ MHCII+), neutrophils (C; Sig F- Ly6G+ CD11bHI CD11c-), and eosinophils (D; Sig F+ F4/80+ 
CD206- CD200R- CD11c- CD11b+) were compared across experimental groups at 4 days post-RSV challenge using 
ANOVA with Tukey’s post-test; *ρ < 0.05, ** ρ < 0.01, or ***ρ < 0.001. KC (E) and eotaxin (F) concentrations 
were compared between groups at 2 and 4 day time points.  * represent significant differences between RSV-
exposure groups using ANOVA with Tukey’s post-test; *ρ < 0.05 vs. 1⁰ RSV. Dotted line represents the limit of 
detection. Data points represent individual mice, the line represents the mean of n ≥ 3-14 samples per group ± SD. 
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Due to the differences in cytokine network complexity between RSV/RSV and 
RSV+IFNγ/RSV groups observed previously, we sought to determine the physiological effects of 
IFNγ treatment during primary infant RSV infection on secondary RSV responses. To understand 
how IFNγ treatment may have altered airway hyperresponsiveness, we collected measures of 
airway mechanics at baseline and during methacholine-induced bronchoconstriction. Static 
compliance, a measure of the lung’s ability to stretch and expand, was reduced across all RSV-
infected groups (Figure 5.9A). Hysteresis, which can be thought of as collective atelectasis, was 
reduced in the RSV+IFNγ/RSV group compared to 1⁰ RSV controls (Figure 5.9B). Importantly, 
IFNγ treatment of infants infected with RSV decreased central resistance to the level of control 
groups, while resistance in RSV/RSV animals remained elevated at the highest dose of 
methacholine tested (Figure 5.9C). Furthermore, the cytokines IL-3 and IL-9 were elevated in the 
BALs of RSV/RSV animals (Figure 5.9 D & E, respectively) and have been associated with the 




Figure 5.9 IFNγ treatment during primary, infant RSV reduces AHR upon secondary challenge. 
Infant mice (PND 4-5) were infected with RSV or vehicle and treated with IFNγ (16ng/g) or vehicle on 1, 3, and 5 
dpi. After 6 weeks, the mice were re-challenged with RSV and BAL collected for cytokine analysis at 2 and 4 days 
post-RSV challenge. At 6 days post-challenge, animals from each group were tested for AHR using FlexiVent. 
Baseline compliance (A) and hysteresis (B) were compared across groups using ANOVA with Tukey’s (A) or 
Bonferroni (B) post-test; uncapped line (A) indicates difference between naïve and all RSV-exposed groups, *ρ < 
0.05 or ** ρ < 0.01. Airway resistance (C, Rn) measures were compared using 2-way ANOVA with Bonferroni 
post-test; *ρ < 0.05 for RSV/RSV vs. 1⁰ RSV. IL-3 (D) and IL-9 (E) concentrations were compared between groups; 
* represent significant differences between RSV-exposure groups using ANOVA with Tukey’s post-test; *ρ < 0.05 
vs. 1⁰ RSV, ϕ ρ < 0.05 vs. RSV+IFNγ/RSV. Dotted line represents the limit of detection. Data points represent 
individual mice, the line represents the mean of n ≥ 3-14 samples per group ± SD. 
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Under more stringent analytical conditions, the dynamic network analysis supported the 
finding that IL-3 and IL-9 may be contributing to elevated airway resistance in RSV/RSV animals 
(Figure 5.10). This positive feedforward interaction between IL-3 and IL-9 in the RSV/RSV group 
will require further studies investigating what cells are the primary producers of these cytokines 
and how IFNγ treatment during primary, infant RSV infection alters this response. Together these 
results suggest that IFNγ treatment of RSV-infected infants alters their RSV immune response by 
reducing both the complexity and inhibitory feedback of the cytokine network and protects against 
the development of AHR following secondary exposure.  
 
Figure 5.10 Elevated IL-3 and IL-9 associated with increased AHR in RSV/RSV animals. 
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5.2.5 AMs stimulated with IFNγ during primary, infant RSV display signals of innate 
immune memory  
Our results from 2 days post-RSV challenge (Figures 5.2) suggested AMs, which are long-lived 
airway resident cells (110), may have been directly impacted by IFNγ treatment during primary, 
infant RSV. To determine if the activation threshold of infant AMs may have been lowered by 
IFNγ treatment during primary RSV infection, innate inflammatory cytokines/chemokines 
typically produced by AMs were measured from the BAL at early time points following RSV re-
exposure. The inflammatory cytokines IL-6 (Figure 5.11A) and IL-12p70 (Figure 5.11C) were 
elevated in RSV+IFNγ/RSV mice 2 days after RSV re-exposure. Similarly, concentrations of 
RANTES/CCL5 (chemokine ligand-5; Figure 5.11B) and MCP-1/CCL2 (chemokine ligand-2; 
Figure 5.11D), which recruit various leukocytes to sites of inflammation, were increased in 
RSV+IFNγ/RSV animals earlier than other groups.  
Figure 5.10 (continued) Infant mice (PND 4-5) were infected with RSV or vehicle and treated with IFNγ (16ng/g) 
or vehicle on 1, 3, and 5 dpi. After 6 weeks, the mice were re-challenged with RSV and BAL collected for cytokine 
analysis using Luminex at 2 and 4 days post-RSV challenge. Using a higher stringency level of 0.95, collaborators, 
Drs. Yoram Vodovotz and Ruben Zamora, used cytokine concentrations to develop dynamic network analyses. 
Purple rectangle highlights the stimulatory relationship between IL-3 and IL-9 in RSV/RSV animals. Based off of 




Next, AMs were identified from the BAL using the gating strategy outline in Chapter 3 
(Figure 3.1). All RSV-infected groups had a reduction in AMs (Figure 5.12A; Sig F+ F4/80+ 
CD206+ CD200R+ CD11cHI) compared to naïve controls. CD11b expression was not significantly 
Figure 5.11 Inflammatory cytokine/chemokine production hastened in RSV+IFNγ/RSV mice. 
Infant mice (PND 4-5) were infected with RSV or vehicle and treated with IFNγ (16ng/g) or vehicle on 1, 3, and 5 
dpi. After 6 weeks, the mice were re-challenged with RSV and BAL collected for cytokine/chemokine analysis 
using Luminex at 2 and 4 days post-RSV challenge. Concentrations of IL-6 (A), RANTES/CCL5 (B), IL-12p70 
(C), and MCP-1/CCL2 (D) were compared across experimental groups at each time point. * represent significant 
differences between RSV-exposed groups (naïve graphed for reference) using ANOVA with Tukey’s post-test; *ρ 
< 0.05 vs. 1⁰ RSV, ϕ ρ < 0.05 vs. RSV+IFNγ/RSV. Data points represent individual mice, the line represents the 
mean of n ≥ 4-14 samples per group ± SD. Dotted line represents the limit of detection. 
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increased in secondary exposure groups but was increased in 1 RSV controls (Figure 5.12B), as 
was seen previously in Chapter 3. Fewer AMs expressed CD73+ in secondary exposure groups 
compared to controls (Figure 5.12C) suggesting less inhibition of inflammatory signaling. While 
the expression of CD86+ on AMs did not differ significantly between groups (Figure 5.12D), 
secondary exposure groups had greater numbers of MHCII+ AMs (Figure 5.12E). 
 
 




It was noted at 2 days post-RSV challenge that a higher proportion of cells in the BALs of 
secondary exposure groups were Siglec F- AMs, especially in RSV+IFNγ/RSV animals (Figure 
5.2D). We hypothesized that conventional AMs, which are defined by Siglec F expression, 
downregulate Siglec F in response to RSV detection, becoming more inflammatory and that this 
response is exaggerated in a memory RSV immune response. Indeed, a larger population of Sig F- 
AMs (Sig F- F4/80+ CD206+ CD200R+ CD11cHI) were identified in the BALs of secondary 
exposure animals (Figure 5.13A). These Sig F- AMs demonstrated an activated phenotype 
including increased expression of CD11b+ (Figure 5.13B) and CD73+ (Figure 5.13C), whose 
production of adenosine may be required to temper the inflammatory response. Additionally, Sig 
F- AMs in secondary exposure groups were found to have greater co-stimulatory/antigen-
presentation capabilities, characterized by enhanced expression of CD86+ (Figure 5.13D) and 
MHCII+ (Figure 5.13E).  
Figure 5.12 (continued) Infant mice (PND 4-5) were infected with RSV or vehicle and treated with IFNγ (16ng/g) 
or vehicle on 1, 3, and 5 dpi. After 6 weeks, the mice were re-challenged with RSV and BAL collected and processed 
for flow cytometry at 4 days post-RSV challenge.  The number of cells identified as AMs (A; Sig F+ F4/80+ CD206+ 
CD200R+ CD11cHI) were analyzed for expression of CD11b+ (B), CD73+ (C), CD86+ (D) and MHCII+ (E). * 
represent significant differences between experimental groups using ANOVA with Tukey’s post-test; *ρ < 0.05, ** 
ρ < 0.01, or ***ρ < 0.001. Data points represent individual mice, the line represents the mean of n ≥ 3-5 samples 





Figure 5.13 Secondary RSV exposure increases Siglec F- AM population. 
Infant mice (PND 4-5) were infected with RSV or vehicle and treated with IFNγ (16ng/g) or vehicle on 1, 3, and 5 
dpi. After 6 weeks, the mice were re-challenged with RSV and BAL collected and processed for flow cytometry at 
4 days post-RSV challenge.  The number of cells identified as Sig F- macrophages (A; Sig F- F4/80+ CD206+ 
CD200R+ CD11cHI) were analyzed for expression of CD11b+ (B), CD73+ (C), CD86+ (D) and MHCII+ (E). * 
represent significant differences between experimental groups using ANOVA with Tukey’s post-test; *ρ < 0.05, ** 
ρ < 0.01, or ***ρ < 0.001. Data points represent individual mice, the line represents the mean of n ≥ 3-5 samples 
per group ± SD. 
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In the secondary RSV challenge model, we could not discount the possibility that enhanced 
AM activation may have occurred as a result of an adaptive, memory immune response, including 
RSV-specific antibodies, memory B cells, and lung-resident, memory T cells, becoming activated 
and producing cytokines, etc. with the re-introduction of RSV. To determine whether AMs can 
develop innate memory in response to RSV and eliminate the influence of an adaptive, memory 
immune response, we performed an adoptive transfer of AMs from mice exposed to RSV during 
infancy (+/- IFNγ treatment) into naïve adults who were then challenged with RSV. Briefly, infant 
Balb/c mice were infected with RSV or vehicle and treated with i.n. IFNγ or vehicle on days 1, 3 
and 5 post-infection. The mice were allowed to recover for 6 weeks then were sacrificed and their 
AMs were harvested. Each experimental group’s AMs were pooled and stained with CFSE so that 
they could be tracked in recipient animals. Then, CFSE-stained AMs were transferred into RSV-
naïve recipient mice. One day after the CFSE+ AM transfer, recipient mice were challenged with 
RSV and samples were collected at 4 DPI. 
AMs were identified in BAL samples harvested from recipient mice using the gating 
strategy outlined in Figure 5.14. Cells were first divided according to CFSE staining then, AMs 







The overwhelming majority of BAL cells in recipient mice were CFSE- but approximately 
6% of BAL cells were CFSE+ and this percentage was similar across groups (Figure 5.15A). 
Nearly 100% of CFSE+ cells were identified as AMs (Figure 5.15B) however, a small percentage 
of CFSE+ cells were Sig F- AMs (Figure 5.15C). Interestingly, a higher percentage of AMs 
downregulated Sig F- , in response to RSV infection if they were exposed IFNγ during infancy. 
When MHCII+ expression was examined as a marker of activation, we found that a higher 
percentage of CFSE+ AMs and Sig F- AMs expressed MHCII compared to their CFSE- 
counterparts (Figure 5.15D & E). Furthermore, MHCII+ MFI on CFSE+ AMs and Sig F- AMs in 
RSV+IFNγ/RSV animals was significantly higher than the same CFSE- populations (Figure 5.15F 
Figure 5.14 Gating of CFSE+ AMs. 
Infant mice (PND 4-5) were infected with RSV or vehicle and treated with IFNγ (16ng/g) or vehicle on 1, 3, and 5 
dpi. After 6 weeks, the mice were culled, BAL collected, and AMs isolated and stained with CFSE. CFSE+ 
macrophages were adoptively transferred (i.n. 5 x 105 cells/100mcl) into naïve recipients. One day after transfer, 
recipient mice were challenged with RSV or vehicle. BAL was collected at 4 days post-RSV challenge and analyzed 
via flow cytometry. Cells were first separated according to their CFSE status then identified as AMs (Sig F+ F4/80+ 
CD206+ CD11c+) or Sig F- AMs (Sig F- F4/80+ CD206+ CD11c+). 
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& G). Of note, the average MHCII+ MFI on RSV+IFNγ/RSV CFSE+ Sig F- AMs was 




Figure 5.15 CFSE+ RSV+IFNγ/RSV macrophages express more MHCII+ than CFSE- macrophages. 
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Next, the total number of CFSE+ events in the BAL were analyzed to verify that animals 
within each group had a similar number of surviving, transferred CFSE+ cells.  Although the 
number of surviving, transferred macrophages varied within and between groups, with the IFNγ 
control group (Naïve+IFNγ/RSV) having the smallest number, no significant differences were 
detected (Figure 5.16A). Most CFSE+ cells were identified as AMs (Figure 5.16B) and there was 
a small but non-significant trend toward a higher number of CFSE+ AMs expressing MHCII+ in 
the groups re-exposed to RSV (Figure 5.16D). Importantly, the number of CFSE+ Sig F- AMs was 
significantly higher in the RSV+IFNγ/RSV group (Figure 5.16C) and this group had the highest 
number of CFSE+ Sig F- AM expressing MHCII+ (Figure 5.16E). These data suggest that in the 
absence of adaptive memory, AMs exposed to IFNγ during primary, infant RSV display “trained 
memory”, lowering their threshold of activation upon RSV re-exposure.  
Figure 5.15 (continued) Infant mice (PND 4-5) were infected with RSV or vehicle and treated with IFNγ (16ng/g) 
or vehicle on 1, 3, and 5 dpi. After 6 weeks, the mice were culled, BAL collected, and AMs isolated and stained 
with CFSE. CFSE+ macrophages were adoptively transferred into naïve recipients. One day after transfer, recipient 
mice were challenged with RSV or vehicle. BAL was collected at 4 days post-RSV challenge and analyzed via flow 
cytometry. The proportion of BAL cells that were CFSE+ (A), AMs (B), Sig F- AMs (C) were compared to their 
CFSE- counterparts. Expression of MHCII+ was analyzed on AMs (D) and Sig F- AMs (E), as well as, the MFI of 
MHCII+ AMs (F) and Sig F- AMs (G) were compared between CFSE+ and CFSE- cells. * represent significant 
differences between experimental groups using 2-way ANOVA with Bonferroni post-test; *ρ < 0.05, ** ρ < 0.01, 





Figure 5.16 RSV+IFNγ/RSV Sig F- AMs differentially activated upon RSV re-exposure. 
Infant mice (PND 4-5) were infected with RSV or vehicle and treated with IFNγ (16ng/g) or vehicle on 1, 3, and 5 
dpi. After 6 weeks, the mice were culled, BAL collected, and AMs isolated and stained with CFSE. CFSE+ AMs 
were adoptively transferred (i.n. 5 x 105 cells/100mcl) into naïve recipients. One day after transfer, recipient mice 
were challenged with RSV or vehicle. BAL was collected at 4 days post-RSV challenge and analyzed via flow 
cytometry. The number of CFSE+ BAL cells (A), CFSE+ AMs (B), CFSE+ Sig F- AMs (C) were compared between 
experimental groups. Expression of MHCII+ was analyzed on CFSE+ AMs (D) and CFSE+ Sig F- AMs (E). * 
represent significant differences between experimental groups using 2-way ANOVA with Bonferroni post-test; 




To determine if the phenotypic signals of “memory” in RSV+IFNγ/RSV AMs resulted in 
improved functional outcomes, viral titers were analyzed at 4 days post-RSV challenge (Figure 
5.17A & B). No significant differences in lung viral titers were detected although, 
RSV+IFNγ/RSV animals had slightly lower average titers when compared to other RSV+ groups 
when viewed on log-scale (Figure 5.17A) and linear scale (Figure 5.17B) where the variability 
can be seen more easily.  
 
 
Figure 5.17 Viral titers unaltered by adoptive transfer of AMs. 
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5.2.6 IFNγ signaling necessary to control eosinophil recruitment and AM activation 
Our data has shown that intrapulmonary IFNγ treatment during primary infant RSV infection 
activates AMs, increasing their co-stimulatory and antigen presentation capabilities through the 
increased expression of CD80+/CD86+ and MHCII+ during both primary and secondary RSV 
exposures. However, to confirm that IFNγ signaling is necessary to elicit these effects, we 
reproduced our RSV model in IFNγR1KO mice. However, the IFNγR1KO mice were bred on a 
C57BL/6 background and our infant RSV model was developed using Balb/c mice. Therefore, 
before we began testing in IFNγR1KO mice, we validated the effects of local, IFNγ treatment in a 
C57BL/6 infant RSV model.  
Briefly, C57BL/6 infants were infected with RSV at PND 4-5 and then treated with IFNγ 
(16ng/gm) on 1, 3, and 5 days post-infection. At 3 DPI, BAL was collected and analyzed for AM 
activation and left lungs were collected for viral quantification. The frequency of AMs (Sig F+ 
F4/80+ CD206+ CD200R+ CD11cHI) in the BAL was similar across all groups (Figure 5.18A). 
Like in Balb/c infants, AMs in C57BL/6 infants were very responsive to IFNγ demonstrated by 
Figure 5.17 (continued) Infant mice (PND 4-5) were infected with RSV or vehicle and treated with IFNγ (16ng/g) 
or vehicle on 1, 3, and 5 dpi. After 6 weeks, the mice were culled, BAL collected, and AMs isolated and stained 
with CFSE. CFSE+ AMs were adoptively transferred into naïve recipients. One day after transfer, recipient mice 
were challenged with RSV or vehicle. Left lungs were collected at 4 days post-RSV challenge and viral titers 
quantified using H&E plaque assay. Calculated viral titers viewed on a log-scale (A) or linear scale (B) and 
compared using ANOVA with Tukey’s post-test. Data points represent individual mice, the line represents the mean 
of n ≥ 3-5 samples per group ± SD. 
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significant increases in CD86+ (Figure 5.18B) and MCHII+ (Figure 5.18C). Additionally, we 
confirmed that IFNγ treatment in C57BL/6 infants reduced RSV titers in the lung (Figure 5.18D). 
 
 
Figure 5.18 Infant RSV model validated in C57BL/6 infant mice. 
Infant (PND 4-5) C57BL6 mice were infected with i.n. RSV L19 (5x105 pfu/g). Intranasal IFNγ (16ng/g) or vehicle 
was administered on 1 DPI. BAL was collected at 3 DPI and processed for flow cytometry and left lungs collected 
for RSV quantification using H&E plaque assays. Frequencies of AMs (A; Sig F+ F4/80+ CD206+ CD200R+ 
CD11cHI) and their expression of CD86+ (B) and MHCII+ (C) were compared between groups using ANOVA with 
Tukey’s post-test. Viral titers (D) of RSV and RSV+IFNγ were compared using an unpaired t-test. ). * represent 
significant differences between experimental groups; * ρ < 0.05 or ***ρ < 0.001. Data points represent individual 
mice, the line represents the mean of n ≥ 3-5 samples per group ± SD. 
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To determine how IFNγ signaling during primary RSV infection influences secondary 
immune responses, WT and IFNγR1KO mice were infected with RSV and i.n. IFNγ or vehicle 
was administered, then the animals were allowed to recover for 6 weeks and were re-challenged 
with RSV. At 4 days post-RSV challenge, BAL was collected and analyzed via flow cytometry. A 
number of reports have shown a correlation between elevated levels of IFNγ in the lungs during 
primary infection and a reduction in the recruitment of eosinophils during secondary exposure 
(174, 215, 216). Eosinophils in the BAL of IFNγR1KO animals receiving secondary RSV 
exposure were significantly elevated (Figure 5.19A), whereas the populations in WT secondary 
exposure animals were not different compared to naïve. AM populations (Sig F+ F4/80+ CD206+) 
were similar across both IFNγR1KO and WT animals (Figure 5.19B). As expected, expression of 
CD86+ (Figure 5.19C) and MHCII+ (Figure 5.19D) increased on AMs in WT secondary exposure 
groups but a similar increase was not observed in these IFNγR1KO groups. These data demonstrate 
the importance of IFNγ signaling in controlling eosinophil recruitment to the BAL following RSV 





Figure 5.19 IFNγ signaling critical in controlling eosinophil recruitment and AM activation. 
Adult (6-8 week old) KO and wild-type (WT) C57BL6 mice were infected with RSV or vehicle and treated with 
IFNγ (16ng/g) or vehicle on 1, 3, and 5 dpi. After 6 weeks, the mice were re-challenged with RSV and BAL collected 
and processed for flow cytometry at 4 days post-RSV challenge.  The number of eosinophils (A; Sig F+ F4/80+ 
CD206- CD11c- CD11b+) and macrophages (B; Sig F+ F4/80+ CD206+) were compared between groups. 
Macrophages expressing CD86+ (C) and MHCII+ (D) were graphed for each group. * represent significant 
differences between experimental groups using ANOVA with Bonferroni’s post-test; *ρ < 0.05, ** ρ < 0.01, *** ρ 
< 0.001, or ****ρ < 0.0001. Data points represent individual mice, the line represents the mean of n ≥ 3-4 samples 
per group ± SD. 
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5.3 DISCUSSION 
Severe RSV disease predominately affects infants (28, 34) but the virus continues to infect 
individuals throughout their lives (33, 225) and the immune response mounted during primary 
exposure has a profound influence on responses to subsequent infections (66, 149, 213, 214). 
Manipulation of the infant RSV immune response using archetypal Th2 (IL-4) or Th1 (IFNγ) 
cytokines have demonstrated the ability to alter secondary immune responses but only IFNγ has 
shown improvements in reducing eosinophilia and airway hyperresponsiveness (174, 215). Given 
IFNγ’s successes in animal models and its association with less severe RSV disease clinically 
(178), we used our infant mouse model to investigate the effect of IFNγ during primary RSV 
infection on secondary challenge.  
 Our results demonstrated that RSV immunity elicited following infant RSV infection 
provided incomplete protection from secondary challenge. IFNγ treatment during infant, primary 
RSV infection sustained improved CD8+ RSV F85-93 specificity but did not appear to dramatically 
alter the T helper cytokine profile in the airway. Interestingly, IFNγ treatment reduced inhibitory 
feedback within the dynamic cytokine network and simplified the cumulative cytokine response, 
while also significantly reducing airway resistance. Moreover, this study demonstrated the 
importance of IFNγ signaling in the activation of AMs and that IFNγ treatment during infant 
primary RSV infection produces long-term changes in AMs, increasing their activation upon 
secondary exposure even in the absence of adaptive immunity. Our study provides insight into the 
long-term immunomodulatory effects of IFNγ stimulation during primary infant RSV infection 
and demonstrates preliminary evidence for a role in the induction of trained immunity. These 
results will be important in informing future age-specific vaccine and therapeutic approaches.  
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The importance of adaptive immunity in protection from RSV infection is well 
documented, with neutralizing antibody (4) and T cells (61, 94, 226) representing central correlates 
of protection. Although neutralizing antibody titers were not measured in our study, increased 
concentrations of IFNγ during primary, infant RSV infection have been shown to attenuate 
antibody responses (174, 227). However, viral titers were similar in both secondary exposure 
groups with RSV+IFNγ/RSV animals having slightly lower viral titers by 4 days post-challenge, 
which makes a significant decrease in neutralizing antibody development as a result of IFNγ 
treatment unlikely. The improvement in RSV F85-93 CD8
+ T cell specificity observed following 
IFNγ treatment during primary infection (Chapter 4) was maintained in secondary RSV challenge. 
We previously demonstrated negligible IFNγ production by infants in response to primary RSV 
(1). IFNγ signaling has been shown to be important in regulating CD8+ T cell memory 
development (208, 209) and restricts the formation of memory CD8+ T cells responding to weak 
T cell receptor signaling, which promotes the accumulation of high-affinity T cells (210). The 
absence of IFNγ in primary infant RSV suggests that infants may develop low-affinity CD8+ 
memory T cells that compromises their ability to clear secondary RSV infections. Surprisingly, 
IFNγ treatment during primary infant RSV did not appear to alter T helper phenotypes based on 
cytokine signals measured from BAL. These results are supported by data from Harker et al. that 
showed no alterations in Th phenotypes resulting from primary neonatal infection with a 
recombinant RSV virus expressing IFNγ (174).  The same recombinant RSV virus used in an adult 
secondary RSV infection model demonstrated reduced viral titers but enhanced disease upon 
secondary RSV exposure, highlighting the importance of utilizing age-appropriate animal models 
in the evaluation of potential therapies or investigating mechanisms of RSV immunity. 
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IFNγ treatment during primary infant RSV infection reduced the production of IL-3 and 
IL-9 during secondary RSV challenge. Both cytokines have been associated with enhanced AHR 
(222-224) and may have been factors in the elevated resistance seen in the airways of RSV/RSV 
mice. Previous work in our lab has shown that IFNγ treatment of macrophages induces 
transcription of inducible nitric oxide synthase (iNOS) (1), which is responsible for the creation of 
nitric oxide. The presence of nitric oxide or via direct induction by IFNγ, stimulates the expression 
of cyclooxygenase-2 (COX-2) (228), leading to increased conversion of arachidonic acid to 
prostaglandins. Prostaglandins work to control the development of Th9 T cells (223, 229), which 
may be responsible for the reduction in IL-9 levels in RSV+IFNγ/RSV animals. Preliminary 
evidence from our lab has demonstrated that RSV-infected infants treated with IFNγ had higher 
concentrations of the prostaglandin, PGD2, in the BAL compared to RSV-infected infants treated 
with vehicle (data not shown). This finding lends support to the role of IFNγ-induced expression 
of COX-2 and subsequent production of prostaglandins that may suppress Th9 development. 
However, more studies are required to identify the source of IL-9 in RSV/RSV animals and 
understand the mechanism behind IFNγ’s ability to limit its production and improve airway 
mechanics. 
Previous studies of secondary RSV infections have primarily focused on manipulating 
factors during primary RSV infection with a goal of improving one or more aspects of adaptive 
immunity to prevent secondary infection. One area that has been largely overlooked is how 
immunomodulation during primary infection alters innate immunity in the absence of adaptive 
responses. This effect has been termed “trained immunity or innate immune memory” (218) and 
has been demonstrated in organisms lacking adaptive immunity (230), as well as, in mammalian 
studies demonstrating cross-protection when challenged with different pathogens (231). One study 
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by Yamaguchi and colleagues showed that when the TLR9 agonist, CpG, was administered to 
mice four weeks after primary infant RSV infection the animals had higher concentrations of IFNγ, 
lower IL-5, and reduced eosinophil accumulation in the BAL when they were re-challenged with 
RSV four weeks after CpG treatment (232). This suggests that, in the absence of antigen, 
stimulation of TLR9 on innate immune cells alters secondary RSV responses.  
In our study, AMs previously exposed to RSV (a TLR3/4/7/8 agonist) and IFNγ during 
infancy underwent enhanced activation following adoptive transfer into naïve animals that were 
subsequently challenged with RSV. These results are suggestive of AM trained immunity and may 
indicate an epigenetic reprogramming resulting in a pro-inflammatory phenotype elicited by re-
stimulation. The induction of an inflammatory AM phenotype relies on a metabolic switch from 
oxidative phosphorylation under homeostatic conditions, to glycolysis following activation via 
PAMPs, such as TLRs (120). The metabolic intermediates of glycolysis (ex. acetyl-coenzyme A) 
have been shown to be essential for epigenetic changes, such as histone acetylation, resulting in 
trained immunity (218, 233). One mechanism by which IFNγ sustains AM pro-inflammatory 
responses induced by TLR stimulation is through the prevention of adenosine receptor 
upregulation (A2bR), thereby reducing adenosine’s negative-feedback signaling (234), prolonging 
glycolytic metabolism, and promoting the accumulation of metabolic intermediates required for 
trained immunity (218, 233).  
In summary, immunomodulation of a primary, infant RSV infection via local IFNγ 
treatment can have a broad range of effects on secondary RSV immune responses; improving 
memory CD8+ T cell responses, reducing AHR, and eliciting innate immune memory. These 
studies provide important information regarding potential benefits of immunomodulation during 
severe RSV or possibly as a prophylactic measure. Nearly 50% of children hospitalized with severe 
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RSV disease go on to develop asthma later in childhood (40, 42). Based on results showing an 
amelioration of AHR through IFNγ treatment demonstrated by us and others (215), IFNγ treatment 
may be a beneficial therapeutic approach during severe RSV. Moreover, the demonstration of 
trained immunity in IFNγ treated AMs from RSV-infected infants poses interesting questions 
regarding its potential utility in modulating vaccine immunogenicity.  
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6.0  RSV PRE-FUSION F PROTEIN PAIRED WITH A DELTA INULIN-DERIVED 
ADJUVANT PROTECTS VACCINATED DAMS AND THEIR OFFSPRING AGAINST 
RSV INFECTION AND ALTERS PRIMARY INFANT IMMUNE RESPONSE TO 
VIRAL CHALLENGE 
6.1 INTRODUCTION 
The only commercially available option for prevention of RSV infection is prophylaxis 
with the monoclonal antibody palivizumab (Synagis®) (235). Palavizumab is costly, requires 
multiple doses throughout the RSV season, and is only indicated for use in high-risk infants (236). 
Yet, the majority of infants hospitalized with severe RSV are otherwise healthy (30), emphasizing 
the critical need for a better means of RSV protection. The development of an effective RSV 
vaccine has been hampered by neonatal immune immaturity (75), the risk of vaccine-enhanced 
disease (VED) in infants (73, 76), and the short time frame between birth and first RSV exposure. 
While maternally-derived antibodies may protect infants from infection as their own immune 
systems develop, infants often develop severe RSV disease in the first months of life, suggesting 
that maternal-to-infant anti-RSV antibody transfer is often inadequate and likely varies from one 
individual to another based on their RSV exposure history. Thus, immunizing mothers during 
pregnancy is a promising approach to ensure the passive transfer of sufficiently high levels of RSV 
neutralizing antibodies from mothers to their offspring.  
The RSV fusion (RSV F) glycoprotein, which mediates viral entry into host cells, is the 
primary target of neutralizing antibodies in human sera (237).  RSV F rapidly rearranges from a 
pre-fusion to a post-fusion conformation, with the former inducing more potent neutralizing 
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antibodies. VED was observed with a formalin-inactivated alum-adjuvanted RSV (FI-RSV) 
immunization in vaccine trials of the 1960’s that resulted in the death of two young children. 
Analyses of lung sections from these children along with additional preclinical studies suggest that 
the FI-RSV-associated VED was due to a combination of poorly neutralizing antibodies and excess 
Th2 priming of the infants’ immune systems to RSV (22, 238-240). Stabilized forms of pre-fusion 
RSV F protein such as, DS-Cav1, are believed to be more representative of live RSV (22) and 
induce high neutralizing antibody titers, particularly when combined with an appropriate adjuvant 
(27). As such, stabilized pre-fusion RSV F protein vaccine candidates have advanced to clinical 
trials to determine their safety and efficacy in adults and RSV-seropositive toddlers (241). 
Subunit vaccines are generally poor immunogens, requiring adjuvants for adequate 
immunogenicity. Aluminum salts are the most widely used vaccine adjuvants because their Th2 
immune bias makes them highly effective at increasing antibody titers (242-244). However, 
investigations into the causes of VED in FI-RSV-vaccinated children have consistently 
demonstrated the contribution of Th2-mediated pathology (63, 175, 245, 246). Thus, an ideal RSV 
vaccine adjuvant would be one that elicits a strong antibody response without imparting Th2-bias. 
Advax adjuvant is derived from delta inulin, a plant-based polysaccharide, which in its 
microcrystalline form, enhances vaccine immunogenicity and protection against a wide range of 
pathogens, including Japanese encephalitis virus (247, 248), hepatitis B virus (249), HIV (250), 
SARS coronavirus (251, 252), West Nile virus (253), Listeria monocytogenes (254), Bacillus 
anthracis (255), and influenza (256). Advax adjuvant has been further shown to overcome immune 
insufficiencies associated with young age (257) and pregnancy (258). The addition of a TLR9 
agonist (CpG oligonucleotide) to Advax (Advax–SM) enhanced vaccine protection and 
ameliorated eosinophilic lung pathology in a murine model of SARS coronavirus infection (251). 
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We therefore hypothesized that Advax-SM may be an ideal adjuvant for a pre-fusion RSV F 
protein vaccine, to enhance the humoral and cellular response while mitigating potential Th2-
associated lung pathology (250, 251, 253-256, 259-261). Additionally, this study sought to 
determine the safety and efficacy of anti-RSV maternal antibodies as a form of immunomodulation 
on the primary RSV immune response of offspring. T cell and neutralizing antibody responses, 
viral lung titers, and histopathology were assessed in immunized and challenged dams and their 
offspring at pre- and post-wean time-points. 
6.2 RESULTS 
6.2.1 Protective immunity in the lungs of DS-Cav1 + Advax-SM immunized dams 
following RSV challenge 
To determine the efficacy of immunization with DS-Cav1 formulated with or without Advax-SM, 
7-8-week-old female Balb/c mice were i.m. vaccinated with DS-Cav1 + Advax-SM (DS-Cav1 + 
Advax-SM dams), unadjuvanted DS-Cav1 (DS-Cav1 dams), or PBS vehicle control (PBS dams). 
Immunized females were then bred and boosted with their respective vaccine formulation, as 
boosting during pregnancy has been shown to provide superior protection to infants in clinical 
studies of pertussis (262-264). After weaning of their pups, immunized dams were challenged with 
RSV according to the experimental timeline (Figure 6.1A). Pre-challenge plaque reducing 
neutralizing titers (1/PRNT50) indicated that the addition of Advax-SM to DS-Cav1 enhanced the 
RSV neutralizing antibody response by an average of 4-fold over unadjuvanted vaccine (Figure 
6.1B). DS-Cav1, but not DS-Cav1 + Advax-SM or PBS dams, lost weight transiently at 2 DPI 
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(Figure 6.1C). At 4 DPI, the time of peak RSV replication, DS-Cav1 + Advax-SM and DS-Cav1 
dams had significantly reduced viral titers compared to PBS dams (Figure 6.1D). When 
challenged 57 days after initial vaccination, only DS-Cav1 + Advax-SM completely protected 
dams with 100% (n=12/12) of animals in this group showing no detectable virus in their lungs. 
Within each vaccination group, viral titers (right y-axis) were negatively correlated with 
neutralizing antibody titers (left y-axis); 1/PRNT50 values ≥ 40 were associated with complete 
protection from RSV (Figure 6.1E). PBS dams had no detectable neutralizing antibody and had 
high viral titers, whereas all DS-Cav1 + Advax-SM dams had 1/PRNT50 values ≥ 40 and sterilizing 
immunity. Unadjuvanted DS-Cav1 dams with 1/PRNT50 values ≥ 40 similarly had sterile lungs, 
whereas those with undetectable neutralizing antibody had detectable virus in their lungs (Figure 
6.1D-E). These results demonstrate that immunization of dams with DS-Cav1 + Advax-SM 




Figure 6.1 Protective immunity in the lungs of DS-Cav1 + Advax-SM immunized dams following RSV challenge. 
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6.2.2 DS-Cav1 + Advax-SM immunization of dams reduces lung inflammation and mucus 
production 
To evaluate the risk of VED in immunized dams, histologic analysis was performed on lungs of 
immunized dams 4 days after RSV challenge to assess inflammation (Figure 6.2A-C) and mucus 
production (Figure 6.2D-F). H&E-stained lung sections showed enhanced peri-bronchial and peri-
vascular inflammation in DS-Cav1 compared to PBS- or DS-Cav1 + Advax-SM dams (Figure 
6.2A-C). Additionally, DS-Cav1 dams had increased mucin production as evidenced by increases 
in PAS staining of cells lining the airway (Figure 6.2E). Limited mucin production was detected 
in lung sections of PBS- and DS-Cav1 + Advax-SM-immunized dams (Figure 6.2D or 2F, 
Figure 6.1 (continued) Female, Balb/c mice (7-8 week old) were immunized at the time of co-housing 
(Day 0; D0) and again 2 weeks after breeding, in the second week of gestation (D21) as outlined (A). 
Vaccine formulations were as follows: PBS – vehicle control, DS-Cav1 alone, DS-Cav1 + Advax-SM. 
Dams gave birth (D28) and nursed their offspring for 21 days until weaning (D49). Four days after their 
pups were weaned, dams were subjected to an intranasal (i.n.) challenge with RSV L19 (D53). Pre-
challenge serum was collected immediately prior to RSV challenge for 1/PRNT50 levels (B). Weights 
were recorded daily and comparisons between immunization groups were made using repeated 
measures ANOVA with a Bonferroni post-test where * indicates ρ < 0.05 between DS-Cav1 and DS-
Cav1 + Advax-SM (C). At 4 DPI, dams were culled and tissues collected for analysis (D57). Left lungs 
were harvested and processed for viral quantification using H&E plaque assays (D). Viral titers were 
performed in triplicate and individual symbols within each group represent the mean titer for each 
animal, lines represent the mean of n ≥ 11 animals per group ± SD. Viral titers were compared between 
groups using ANOVA with a Tukey post-test; *** ρ < 0.001. Lungs with no detectable virus were 
considered sterile and percentages of sterile lungs were calculated for each vaccine formulation; 
percentages are shown in panel D. In panel E, 1/PRNT50 titers at 4 DPI are shown on the y-axis and are 
represented by open symbols and compared to viral lung titers (z-axis) represented by closed symbols. 
Results are representative of 2 independent experiments. 
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respectively). Quantification of mucin production (1, 119) confirmed that DS-Cav1 dams 




Figure 6.2 DS-Cav1 + Advax-SM immunization of dams reduces lung inflammation and mucus production. 
Female, Balb/c mice (7-8 week old) were immunized, bred, and challenged with RSV L19 in accordance with 
Figure 6.1. At 4 DPI, right lungs (n = 3/group) were harvested and stained with H&E (A-C) and PAS (D-F) 
and imaged at 10X magnification; bar indicates 100um. Lung sections stained with PAS were scored 0 to 4 
for PAS positivity for PBS (G), DS-Cav1 (H), and DS-Cav1 + Advax-SM (I), with 0 having no PAS and 4 
being 76-100% PAS+, according to the methods. 
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6.2.3 Formulation of DS-Cav1 with Advax-SM ameliorates increased Th2-type cytokine 
production exhibited by DS-Cav1 dams following RSV challenge 
Following RSV challenge of immunized mice, Th2 biased immune responses have consistently 
been implicated in airway hyperresponsiveness (AHR) and VED immunopathology, characterized 
by inflammation, mucus production, and pulmonary eosinophilia (175, 245, 246). Consistent with 
histology demonstrating peri-vascular and -bronchial inflammation and enhanced mucus 
production in DS-Cav1 dams, these animals had significantly elevated concentrations of the Th2 
cytokines, IL-4 and IL-13, quantified from first-wash BAL samples (Figure 6.3A and B). 
Concentrations of the Th1 cytokine, IFNγ, were significantly higher in DS-Cav1 + Advax-SM 
dams while PBS and DS-Cav1 dams had similarly low levels (Figure 6.3C). IL-4 and IL-13 
concentrations were reduced in DS-Cav1 + Advax-SM dams and these animals had minimal 
inflammation on H&E staining with only a small increase in PAS-staining over PBS dams (Figure 
6.2D-F). 
In models of allergic asthma, signaling through the common β subunit by the Th2 cytokines 
IL-3, IL-5, and GM-CSF was found to be critical for the expansion and accumulation of 
eosinophils in the lungs of sensitized mice (222). At 4 DPI, PBS and DS-Cav1 + Advax-SM dams 
had low levels of these Th2 cytokines whereas concentrations were significantly elevated in DS-
Cav1 dams (Figure 6.3D-F). 
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Figure 6.3 Formulation of DS-Cav1 with Advax-SM ameliorates increased Th2-type cytokine 
production exhibited by DS-Cav1 dams following RSV challenge. 
 
 
At 4 DPI, first wash samples were collected from immunized dams and analyzed for cytokines using 
Luminex, dotted lines indicate the assay’s limit of detection for individual cytokines. Cytokine concentrations 
were compared between groups using ANOVA with a Tukey post-test. Symbols represent individual mice in 
their respective immunization groups and lines represent the mean of n ≥ 7 animals per group ± SD; *ρ < 
0.05, **ρ < 0.01, ***ρ < 0.001. 
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6.2.4 Contrasting innate immune responses in the airways of immunized dams following 
RSV challenge 
Pulmonary eosinophilia is an important indicator of VED as it has been a feature in FI-RSV 
immunized hosts following RSV exposure (73, 265, 266). As expected, elevated concentrations of 
IL-3, IL-5, and GM-CSF in the first wash of DS-Cav1 dams (Figure 6.3D-F) were associated with 
alveolar (Figure 6.4A) and interstitial eosinophilia (Figure 6.4E; Siglec F+ F4/80+ CD206- 
CD11clo/- CD11b+), which were absent in PBS and DS-Cav1 + Advax-SM dams. In the lung tissue 
of DS-Cav1 dams, eosinophils were producing IL-5 (Figure 6.4F) and TNFα (Figure 6.4G), 
which may be propagating further eosinophil recruitment and enhancing inflammation, 
respectively. 
FI-RSV-immunized children who developed VED following natural RSV exposure also 
had high numbers of infiltrating neutrophils and mononuclear cells in their airways (76, 267, 268). 
Monocyte (Siglec F- F4/80+ CD206- CD11c+ CD11b+) numbers in the BAL were greater in DS-
Cav1 + Advax-SM compared to PBS dams, though a similar increase in DS-Cav1 dams was noted 
(Figure 6.4B). Similarly, significant increases in neutrophils (Siglec F- CD11bHI Ly6G+ CD11clo) 
were seen in the BALs of DS-Cav1 and DS-Cav1 + Advax-SM dams (Figure 6.4C). 
Siglec F- (Sig F-) macrophages (Siglec F- F4/80+ CD206+ CD11c+ CD11b+), which are 
associated with an inflammatory lung environment (219), were significantly increased in the BAL 
and lungs of DS-Cav1 dams (Figure 6.4D & H). Sig F- macrophages in the lungs of DS-Cav1 
dams were producing IL-5 (Figure 6.4I) and TNFα (Figure 6.4J), both of which were absent in 





Figure 6.4 Disparate innate immune responses in the airways of immunized dams following RSV challenge. 
Total cells quantified in the BAL at 4 DPI (A-D) or digested lung tissue (E-J) are shown for eosinophils (A, 
E) making IL-5 (F) or TNFα (G), monocytes (B), neutrophils (C), Siglec F- macrophages (D), and Siglec F- 
macrophages (H) making IL-5 (I) or TNFα (J). Populations of cells within the BAL and digested lung tissue, 
surface marker expression, and intracellular cytokines were compared between immunization groups using 
ANOVA with a Tukey post-test. Symbols represent individual mice in their respective immunization groups 
and lines represent the mean of n = 3-8 animals per group ± SD; *ρ < 0.05, **ρ < 0.01, ***ρ < 0.001. 
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6.2.5 Immunization with DS-Cav1 + Advax-SM increases Th1 responses to RSV infection 
Previously published reports have highlighted the importance of T cells in RSV clearance, as well 
as their role in promoting or preventing VED (61, 65, 175). Cytokine and innate cellular data 
reported above suggested that Advax-SM adjuvant ameliorates the Th2 bias observed in dams 
immunized with DS-Cav1 alone. To further investigate the T-helper bias elicited by maternal DS-
Cav1 immunization in the presence or absence of Advax-SM, RSV-specific IgG subtypes were 
assessed. 
Anti-RSV IgG1 titers were increased in both DS-Cav1 + Advax-SM- and DS-Cav1 dams 
(Figure 6.5A). However, IgG2a titers were significantly elevated only in DS-Cav1 + Advax-SM 
dams (Figure 6.5B). The mean IgG1/IgG2a ratio, which if > 1 is reflective of a greater Th2 bias 
and if < 1 a greater Th1 bias, was 7.6 in DS-Cav1 dams, whereas the ratio was 0.53 in DS-Cav1 + 
Advax-SM dams (Figure 6.5C). 
To further assess the T helper response, T cells from the BAL were phenotyped, quantified, 
and intracellular cytokines measured. At 4 DPI, the number of activated (CD44+ CD25+) CD4+ T 
cells producing IL-4 was elevated in the BAL of DS-Cav1 dams (Figure 6.5D), while the number 
of IFNγ-producing, activated CD4+ T cells was not different between immunization groups 
(Figure 6.5E). There was a non-significant trend toward reduced numbers of activated CD8+ T 
cells producing IFNγ in the BAL of DS-Cav1 dams (Figure 6.5F). In order to measure Th1 (IFNγ) 
vs. Th2 (IL-4) cytokine production from the general T cell population, we compared the numbers 
of TCRβ
+ cells producing IFNγ to those producing IL-4. The IFNγ+/IL-4+ ratio was significantly 
higher in TCRβ
+ cells from DS-Cav1 + Advax-SM dams compared to DS-Cav1 dams (Figure 
6.5G), signifying a collective reduction in IL-4 and a greater IFNγ response from T cells in DS-
Cav1 + Advax-SM dams. 
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Using an MHC I pentamer specific for RSV F85-93, we next asked whether RSV F-specific 
CD8+ T cell responses were increased in dams immunized with DS-Cav1 + Advax-SM compared 
to the other immunization groups.  Strikingly, F85-93 specific Ki-67
+ Tbet+ CD44HI CD8+ T cells 
were significantly higher in DS-Cav1 + Advax-SM dams compared to PBS or DS-Cav1 dams 
(Figure 6.5H). DS-Cav1 + Advax-SM dams also had increased numbers of non-F85-93 specific 
CD8+ T cells expressing markers of proliferation (Ki-67+), activation (CD44HI), and Tbet+, the 
transcription factor that drives IFNγ production, compared to PBS- and DS-Cav1 dams (Figure 
6.5I). Together, these results indicate that DS-Cav1 + Advax-SM induced a Th1-biased response 
with a low IgG1/IgG2a RSV-specific antibody response, increased RSV F85-93-specific CD8
+ T 
cells, and an elevated T cell IFNγ to IL-4 ratio compared to dams immunized with DS-Cav1 alone.  
 
 
Figure 6.5 Immunization with DS-Cav1 + Advax-SM increases Th1 responses to RSV infection. 
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6.2.6 Infants and weanlings of DS-Cav1 + Advax-SM dams are protected from RSV 
The primary objective of maternal vaccination is to protect offspring through the passive transfer 
of neutralizing antibody. In humans, transplacental transfer of maternal antibody to the fetus occurs 
during pregnancy and through breast milk postnatally. In mice the predominant source of maternal 
antibody is breast milk.  To assess the capacity of maternal immunization to prevent RSV infection 
in their offspring, nursing infant mice (PND 5-6) born to immunized mothers were challenged with 
RSV. At 4 DPI, infants born to DS-Cav1 + Advax-SM dams (DS-Cav1 + Advax-SM infants) 
exhibited significantly greater RSV protection (sterilizing immunity in 11/15; 73%) compared to 
infants born to DS-Cav1 dams (DS-Cav1 infants) (sterilizing immunity in 1/9; 11.1%) (Figure 
6.6A). Correlating with RSV protection, 58% (n = 7/12) of DS-Cav1 + Advax-SM infants had 
1/PRNT50  40 compared to only 38% (n = 3/8) of DS-Cav1 infants (Figure 6.6C). 
Figure 6.5 (continued) RSV-specific IgG isotype titers were measured from the serum of immunized dams at 
4 DPI, according to the methods. IgG1 (A), IgG2a (B), and the IgG1 to IgG2a ratio (C) were compared 
between immunization groups using ANOVA with Tukey post-test. At 4 DPI, activated (CD44+ CD25+) 
CD4+ T cells producing IL-4+ (D) and IFNγ+ (E), as well as, activated CD8+ producing IFNγ+ (F) were 
analyzed from the BAL. A ratio of IFNγ vs. IL-4 producing TCRβ+ cells was created from BAL cells. 
Additionally, an MHC I pentamer specific for RSV F85-93 was used to identify RSV F85-93 specific, activated 
(CD44HI), proliferating (Ki-67+) Tbet+ CD8+ T cells (H) and non-RSV F85-93 specific, activated, proliferating 
Tbet+ CD8+ T cells (I) from the BAL at 4 dpi. Lymphocyte populations were compared using ANOVA with 
Tukey post-test. Symbols represent individual mice in their respective immunization groups and lines 
represent the mean of n ≥ 4 animals per group ± SD; *ρ < 0.05, **ρ < 0.01, ***ρ < 0.001. Data represents 2 
independent experiments. 
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To determine if RSV protection was maintained in offspring after nursing ceased, offspring 
(PND 35) that were weaned at 21 days of age were challenged with RSV. Weanlings born to dams 
immunized with DS-Cav1 + Advax-SM (DS-Cav1 + Advax-SM weanlings) had higher levels of 
sterilizing immunity (57%, n = 8/14) at 4 DPI compared to weanlings of DS-Cav1 dams (DS-Cav1 
weanlings) (0%, n = 0/7) (Figure 6.6B). Similarly, a higher proportion of DS-Cav1 + Advax-SM 
weanlings had 1/PRNT50  40 (38%, n = 3/8) compared to DS-Cav1 weanlings (0%, n = 0/7) 
(Figure 6.6D). In offspring born to both DS-Cav1 immunized groups, nursing infants had higher 
neutralizing antibody titers compared to weanlings born to mothers in the same immunization 
groups, reflecting the expected decay of neutralizing antibody levels post-wean (Figure 6.6C-D). 
As expected, offspring of PBS dams (PBS infants/ PBS weanlings) had high viral lung titers and 
no measurable neutralizing antibody at 4 DPI. Taken together these results demonstrate that 
maternal DS-Cav1 + Advax-SM immunization provides RSV protection immediately after birth 





Figure 6.6 Infants and weanlings of DS-Cav1 + Advax-SM dams are protected from RSV. 
Infants (PND 5-6) and weanlings (PND 35) born to immunized dams (PBS infants/weanlings, DS-Cav1 
infants/weanlings, DS-Cav1 + Advax-SM infants/weanlings) were challenged with RSV and left lungs 
harvested and processed for viral quantification using H&E plaque assays (A and B). Lungs with no detectable 
virus were considered sterile and percentages of sterile lungs were calculated for each offspring group; 
percentages are shown in panels A and B. Serum was collected from offspring at 4 DPI and 1/PRNT50 titers 
measured. Viral titers and RSV neutralization assays were performed in triplicate and individual symbols 
within each group represent the mean titers for each animal, lines represent the mean of n ≥ 7 animals per 
group ± SD. Viral titers and neutralizing antibody levels were compared between groups using ANOVA with 
a Tukey post-test; *** ρ < 0.001. 
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6.2.7 Innate cellular responses of offspring are influenced by maternal immunization 
During viral infections, protection of RSV-naïve infants is largely dependent on the presence of 
maternal antibodies and innate immunity (269). To determine if maternal immunization influenced 
innate cellular responses in their offspring, flow cytometry was used to characterize innate 
immunity in the BAL of infants and weanlings of immunized dams. At 4 DPI, no differences in 
the frequency of NK cells within the SSClo gate were detected between groups of infants (Figure 
6.7A) or weanlings (Figure 6.7G). CD11b+ CD27- expression on NK cells, denoting increased 
cytolytic activity (270), was similar across infant and weanling groups, although overall expression 
was higher in weanlings suggesting an age-dependent maturation of the immune response (Figure 
6.7C and I). FcγRIII (CD16+) expression on cytolytic NK cells decreased in DS-Cav1 + Advax-
SM infants and weanlings (Figure 6.7E, K, respectively), as well as DS-Cav1 weanlings, which 
may indicate shedding of the receptor post-antibody dependent cell-mediated cytotoxicity (ADCC) 
to limit inflammation (271-273). 
Alveolar macrophages (AMs) are the most abundant leukocyte in the airways, acting as 
sentinels, and expressing both activating and inhibitory Fcγ receptors (269, 274), which may be 
differentially affected by passively-acquired IgG subtypes. Following RSV exposure, maternal 
antibody IgG subtypes complexed with RSV may bind to Fcγ receptors on macrophages leading 
to differences in activation.  The frequency of AMs (Sig F+ F4/80+ CD206+ CD11cHI) within the 
SSCHI population was greater in DS-Cav1 infants as compared to PBS infants (Figure 6.7B); a 
non-significant trend toward a higher AM frequency was also observed in DS-Cav1 + Advax-SM 
infants. An increase in the frequency of activated AMs (MHCII+) was observed in DS-Cav1 + 
Advax-SM weanlings (Figure 6.7J) but not infants (Figure 6.7D). Lastly, DS-Cav1 + Advax-SM 
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infants showed a reduced frequency of AMs expressing SR-A (Figure 6.7F), which may suggest 
a reduced need for scavenging and phagocytosis of cellular debris. 
 
 
Figure 6.7 Innate cellular responses of offspring are influenced by maternal immunization. 
Infants (PND 5-6) and weanlings (PND 35) born to immunized dams were challenged with RSV and BAL cells 
harvested. The percentages of NK cells (CD3- or TCRβ-/DX5+) of SSClo cells and AMs (Sig F+ F4/80+ CD206+ 
CD11cHI) of SSCHI cells were compared between infant (A and B, respectively) and weanling (G and H, respectively) 
groups. The percentages of NK cells expressing CD11b+ CD27- and the percentages of activated (MHCII+) AMs 
were compared between infant (C and D, respectively) and weanling (I and J, respectively) groups. Lastly, CD16+ 
expression on cytolytic NK cells and expression of SR-A+ on AMs were compared between infant (E and F, 
respectively) and weanling (K and L, respectively) groups. Individual symbols within each group represent 
individual samples (2-3 pooled infant BALs) or individual animals (weanlings), lines represent the mean of ≥ 4 
samples per group ± SD. Comparisons between passive-immunization groups were made using ANOVA with a 
Tukey post-test; *ρ < 0.05, **ρ < 0.01, ***ρ < 0.001. 
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Despite a small reduction in the number of monocytes and neutrophils in the BAL of DS-
Cav1 + Advax-SM infants compared to DS-Cav1 or PBS infants, no significant differences were 
observed between groups (Figure 6.8A and B). Similarly, no differences in monocytes were 
observed in the BAL of weanlings born to dams from any of the immunization groups (Figure 
6.8D). A slight increase in neutrophils was detected in the BAL of DS-Cav1 + Advax-SM 
weanlings compared to PBS weanlings (Figure 6.8E). A small population of eosinophils was 
identified in the BAL of infants, but no significant differences were observed between groups 
(Figure 6.8C). No eosinophils were detected in the BALs of weanling groups (Figure 6.8F). 
 
 




6.2.8 DCs and T cells of weanlings are influenced by maternal vaccination 
DCs express Fcγ receptors which can acquire and initiate cross-presentation of antigen from 
immune complexes resulting in the induction of antigen-specific CD4+ and CD8+ T cell responses 
(275, 276). Here, we examined the pre-challenge RSV-specific IgG subtype ratios in weanlings of 
immunized dams to determine if maternal antibodies may influence DC activation and T cell 
responses following RSV challenge. RSV-specific antibody subtype levels measured in weanling 
sera prior to challenge were largely reflective of subtype levels in dams from their respective 
immunization groups (Figure 6.5A-C). DS-Cav1 weanlings had significantly higher anti-RSV 
IgG1 titers than DS-Cav1 + Advax-SM weanlings (Figure 6.9A) but low titers of IgG2a (Figure 
6.9B), resulting in a mean IgG1/IgG2a ratio > 14 (Figure 6.9C). Conversely, DS-Cav1 + Advax-
SM weanlings had extremely low IgG1 titers and high IgG2a levels producing a mean IgG1/IgG2a 
ratio approaching zero (Figure 6.9C). 
Given that IgG2a antibodies generally have higher binding affinities than IgG1 to 
activating Fcγ receptors (274), we hypothesized that DCs from DS-Cav1 + Advax-SM weanlings 
Figure 6.8 (continued) Infants (PND 5-6) and weanlings (PND 35) born to immunized dams were challenged 
with RSV and BAL cells harvested. Monocytes (Sig F- F4/80+ CD206- CD11c+ CD11b+) in infant (A) and 
weanling (D) groups, as well as, neutrophils (Sig F- CD11bHI Ly6G+ CD11c-/lo) in infant (B) and weanling (E) 
groups were analyzed. Eosinophils (Sig F+ F4/80+ CD206- CD11c- CD11b+) from infant and weanling BALs were 
also identified (C and F, respectively). Individual symbols within each group represent individual samples (2-3 
pooled infant BALs) or individual animals (weanlings), lines represent the mean of ≥ 4 samples per group ± SD. 
Comparisons between passive-immunization groups were made using ANOVA with a Tukey post-test; *ρ < 0.05. 
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would exhibit greater activation following RSV challenge leading to an enhanced T cell response. 
The total number of DCs in the BAL of weanlings at 4 DPI did not differ significantly between 
groups (Figure 6.9D). Expression of the co-stimulatory marker, CD86, on DCs was highest in DS-
Cav1 + Advax-SM weanlings, although both passively-immunized groups had greater expression 
than PBS weanlings who had no maternally-acquired anti-RSV IgG (Figure 6.9E). A similar 
pattern of enhanced expression was observed when the mean fluorescence intensity (MFI) of CD86 
was analyzed, demonstrating the highest CD86 MFI on the DCs of DS-Cav1 + Advax-SM 
weanlings (Figure 6.9F). At 8 DPI, PBS weanlings had a non-significant trend toward more total 
CD8+ lymphocytes in the BAL than either DS-Cav1 groups (Figure 6.9G). Total activated (CD44+ 
CD25+) CD8+ T cells producing IFNγ was not significantly different between groups, but this cell 
population was slightly increased in DS-Cav1 and DS-Cav1 + Advax-SM weanling groups 
(Figure 6.9H). Notably, the IFNγ MFI was highest for CD8+ T cells from the DS-Cav1 + Advax-
SM weanlings and was significantly higher in DS-Cav1 and DS-Cav1 + Advax-SM weanling 
groups compared to PBS (Figure 6.9I). Together, these data indicate that anti-RSV antibodies in 
weanlings (predominately IgG2a) resulting from maternal vaccination with DS-Cav1 + Advax-
SM provided greater RSV neutralization following RSV challenge, more rapid DC maturation in 





Figure 6.9 DCs and T cells of weanlings are influenced by maternal vaccination. 
Pre-challenge serum was collected from weanlings (PND 37) born to immunized dams then the animals were 
challenged with RSV. IgG1 (A), IgG2a (B), and the IgG1 to IgG2a ratios (C) were measured from weanling pre-
challenge serum and compared between passive-immunization groups using ANOVA with Tukey post-test. DCs 
(Sig F- CD11c+ MHCIIHI) (D), the percentages of DCs expressing CD86+ (E), and the MFIs of CD86 on DCs (F) 
were compared between groups. BAL samples were collected from weanling groups and analyzed for activated 
(CD44+ CD25+) CD8+ T cells (G), IFNγ+ activated Tbet+ CD8+ T cells (H), and the IFNγ MFI of activated Tbet+ 
CD8+ T cells (I). Individual symbols within each group represent individual mice, lines represent the mean of ≥ 
3 samples per group ± SD. Comparisons between groups were made using ANOVA with a Tukey post-test; *ρ < 
0.05, ***ρ < 0.001. Data represents 2 independent experiments. 
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6.2.9 Lung pathology in weanling mice is influenced by maternal vaccination 
Based on the lymphocyte changes observed in weanlings born to immunized dams, we next asked 
if there were differences in lung pathology in these offspring following viral challenge. At 8 DPI, 
lung sections from each weanling group showed mild perivascular and peribronchial lymphocytic 
inflammation with no major differences in inflammation observed between groups (Figure 6.10A-
C). However, quantification of PAS staining demonstrated a greater amount of mucus within the 
airways of DS-Cav1 and DS-Cav1 + Advax-SM weanlings, as compared to PBS weanlings 
(Figure 6.10D-I). Mucus was reduced in all groups by 12 DPI, though the differences between 
groups remained consistent (S2). These results suggest that the presence of RSV-specific maternal 






Figure 6.10 Lung pathology in weanling mice is influenced by maternal vaccination. 
Weanlings (PND 37) born to immunized dams were challenged with RSV and right lung harvested for histology 
at 8 DPI. Lungs were stained with H&E (A-C) and PAS (D-F) and imaged at 10X magnification; bar indicates 
100um. Lung sections stained with PAS were scored 0 to 4 for PAS positivity for PBS (G), DS-Cav1 (H), and 




Neutralizing anti-RSV antibodies have long been known to protect against RSV infection, yet 
natural infection fails to elicit long-lasting, protective neutralizing antibody (277-280), which is 
cited as the cause of RSV reinfection throughout life (281). The isolation of antigenic sites on pre-
fusion RSV F protein, capable of eliciting robust and potent RSV neutralization, has renewed hope 
for RSV vaccines for disease prevention, including through maternal immunization (27, 282-284). 
However, it remains critically important to understand the immune factors that may protect or pose 
a risk to mothers and their children when assessing newly proposed RSV vaccines. The goal of 
this work was to elucidate the safety, efficacy, and infant immune response to maternal 
immunization with a pre-fusion RSV F candidate in combination with a non-Th2-polarizing 
adjuvant. 
The results showed that dams immunized with DS-Cav1 + Advax-SM had high pre-
challenge neutralizing antibody, comprised of both IgG1 and IgG2a, which translated into 
sterilizing immunity in 100% of dam lungs at 4 DPI. By contrast, dams immunized with DS-Cav1-
alone showed lower levels of neutralizing antibody that was of the IgG1 subclass and only partial 
viral protection with more than half of the dams having detectable virus at 4 DPI. This is consistent 
with previously published data showing that DS-Cav1 alone provided only partial protection in 
adult cotton rats and mice (243, 285), but that when combined with an adjuvant, was capable of 
eliciting sterilizing immunity against RSV challenge (243).  
In a previous RSV vaccination study, mice that were immunized intramuscularly with live 
RSV + Advax-2 adjuvant, a formulation similar to Advax-SM comprising delta inulin plus CpG, 
or alum adjuvant, showed increases in neutralizing antibody levels and viral protection compared 
to unadjuvanted live RSV immunization (286). In contrast to our findings, the authors saw 
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moderate bronchial and minor alveolar or interstitial inflammation after RSV challenge in 
protected, immunized mice with and without an adjuvant, although there was a trend toward lower 
lung inflammation scores in mice immunized with live RSV formulated with Advax-1 (delta 
inulin). Unfortunately, the presence of lung eosinophilia or evidence of Th2 bias was not reported 
in that study. Unpublished data generated in our lab suggests that use of a live RSV virus as antigen 
likely caused Th2 priming and the subsequent airway inflammation observed in the above studies. 
By contrast, our data shows that the Th2-biased immunity and VED induced by RSV in animals 
immunized with DS-Cav1 alone can be ameliorated by a non-Th2 polarizing adjuvant such as 
Advax-SM. Our results with Advax-SM adjuvant in RSV are consistent with that from SARS 
coronavirus vaccines, where Advax-SM adjuvant similarly prevented lung eosinophilic 
immunopathology otherwise seen in mice immunized with inactivated virus or recombinant spike 
protein alone or with alum adjuvant (251). This further highlights the importance of understanding 
the discrete immune responses elicited by different adjuvants, antigens, and the combinations 
thereof (243, 285).  
Notably, despite having lower lung RSV titers than PBS control animals, DS-Cav1 dams 
exhibited features suggestive of VED with increased airway inflammation and mucus production. 
This pulmonary pathology was associated with markedly increased Th2 cytokines in the BAL and 
inflammatory eosinophils and macrophages expressing IL-5 and TNFα in the lung. DS-Cav1 dams 
also had an increased number of IL-4+ CD4 T cells, a trend toward lower IFNγ+ CD8 T cells, and 
IgG1 RSV-specific antibodies, consistent with a strong Th2 bias following RSV challenge. 
Importantly, these features of Th2 polarization and associated VED were not seen in dams 
immunized with DS-Cav1 formulated with Advax-SM. 
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Eosinophils have remained a focus of investigation into the cause of VED since they were 
noted in autopsy samples from the FI-RSV vaccinated children who died as a result of VED after 
RSV infection (73). The exact contribution of eosinophils to the excess inflammation and general 
pathology of VED remains uncertain since neutrophils and monocytes comprised a larger 
proportion of the cellular infiltrate in these post-mortem specimens (73, 76, 268). In our study, 
both DS-Cav1 and DS-Cav1 + Advax-SM dams had higher frequencies of neutrophils and 
monocytes in the BAL compared to PBS controls, whereas only dams immunized with DS-Cav1 
alone demonstrated increased lung pathology post-RSV challenge. These data suggest that the 
frequency of eosinophils and Sig F- inflammatory macrophages producing IL-5 and TNFα in the 
lung and BAL, rather than the presence of neutrophils or monocytes, correlated most closely with 
VED. 
Siglec F- macrophages are a less well characterized cell type that can be identified in the 
alveolar space and promote inflammation during infections (219). Interestingly, much like 
eosinophils, these cells were significantly elevated in the BAL of DS-Cav1 dams (Fig. 4D) and 
both eosinophils and Sig F- macrophages producing IL-5 and TNFα were significantly elevated in 
the lung tissue of DS-Cav1 dams (Fig. F, G and I, J, respectively). These inflammatory 
macrophages and eosinophils are likely promoting pulmonary pathology in DS-Cav1 dams and 
may have contributed to the elevated IL-5 concentrations detected in the BAL (Fig. 3E). 
IL-5 is an important factor in the recruitment and activation of eosinophils during acute 
inflammation and is associated with airway remodeling processes, such as fibrotic changes and 
enhanced collagen deposition in the lungs of asthmatics (287-290). In clinical trials, neutralization 
of IL-5 or blockade of the IL-5 receptor-α with the use of the monoclonal antibodies, mepolizumab 
and benralizumab, respectively, have proven effective in reducing blood and airway eosinophilia 
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but this reduction has not always improved functional measures of lung physiology in asthmatics 
(290, 291). It has been posited that the closely related cytokines, IL-3 and GM-CSF may be able 
to overcome IL-5 neutralization by mepolizumab, possibly limiting its ability to improve asthma 
symptoms (291).  
In addition to IL-5, IL-3 and GM-CSF, Th2 cytokines that share a common β chain (βc) 
with IL-5 drive eosinophil differentiation in the bone marrow and are central to eosinophil survival, 
migration, and activation (288, 292, 293). In the βc-/- model of acute asthma, knockdown of the 
common beta receptor subunit for IL-3, IL-5, and GM-CSF significantly reduced airway 
eosinophilia, AHR, and recruitment of activated T cells to the lungs after allergen challenge, 
highlighting the close interplay between AHR, eosinophilia, and Th2 immunity (222). In our study, 
RSV-challenged DS-Cav1 dams had elevated levels of IL-3, IL-5, and GM-CSF in the BAL, in 
conjunction with airway and pulmonary eosinophilia. These factors, together with elevated 
concentrations of IL-13 and IL-4, increased IL-4+ CD4 T cells, and increased mucus in DS-Cav1 
dams following RSV challenge, are suggestive of an AHR-promoting phenotype and are consistent 
with a Th2-polarized immune response. 
Multiple models of RSV vaccination have investigated the importance of CD4+ T cells in 
the development of VED (175, 245, 246). Consistent with the results of our studies, a study by 
Knudson et al. demonstrated the critical role of Th2 CD4+ T cells in mediating VED, including 
weight loss, mucus hypersecretion, and AHR in FI-RSV-immunized mice (175). Similarly, CD4+ 
T cells and their production of IL-4 and IL-13 were shown to be important drivers of VED in a 
model of immunization with vaccinia virus expressing RSV G glycoprotein.  In fact, IL-13, a 
potent Th2 cytokine, was shown to be sufficient to induce mucus hypersecretion and AHR in naïve 
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mice (294), while also promoting the recruitment of eosinophils to the lung parenchyma and 
airway in VED (63).  
CD8+ T cells are important in the clearance of RSV during primary infection (61) and have 
also been shown to play a role in preventing VED in models of RSV vaccination (64, 65, 179). A 
study by Stevens et al. suggested that memory CD8+ T cells reduce pulmonary eosinophilia 
without modulating the CD4+ T cell response (295), while others have suggested that CD8+ T cells 
are important modulators of CD4+ T cells and eosinophil recruitment (64, 179). Ultimately, the 
number of RSV-specific CD8+ T cells (64) producing IFNγ (179) is important in controlling Th2-
driven pathology. Our results showed that DS-Cav1 + Advax-SM immunization increased the 
number of CD8+ T cell in the BAL with a higher ratio of IFNγ+/IL-4+ TCRβ
+ lymphocytes. Dams 
immunized with DS-Cav1 + Advax-SM also had increased RSV F85-93-specific CD8
+ T cells 
expressing Tbet, the transcription factor that drives IFNγ production in CD8+ T cells. Given that 
our antigen was RSV pre-F, increases at 4 DPI in non-RSV F85-93- CD8
+ T cells expressing Tbet 
were likely representative of F-specific CD8+ T cells targeting alternate F epitopes. 
Despite enhanced RSV viral clearance, memory CD8+ T cells directed toward single RSV 
epitopes have been shown to induce severe pathology upon RSV exposure. Morbidity and 
immunopathology in this model were attributed to rapid production of IFNγ by these memory 
CD8+ T cells, which were primed in the absence of RSV-specific CD4+ T cells and antibodies (62). 
While the potential for pathogenic memory CD8+ T cell responses should be considered when 
evaluating RSV vaccine candidates, our results suggest that enhanced RSV-specific CD8+ T cell 
responses do not cause excess pathology when accompanied by high titers of RSV-specific 
neutralizing antibody and increased proliferating CD4+ T cells (S3), both of which provide 
regulatory signals that likely temper memory CD8+ T cell responses. Therefore, we hypothesize 
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that maternal DS-Cav1 + Advax-SM immunization primes for enhanced CD8+ T cell RSV F-
specificity and IFNγ production that in combination with a reduced Th2 bias, will help control the 
virus and prevent mucus production and mitigate the recruitment of inflammatory eosinophils and 
macrophages following RSV challenge. 
The precise mechanism of VED remains unknown, however, FI-RSV studies suggest that 
poorly neutralizing antibody contributes to immune complex deposition in the small airways 
leading to exacerbated inflammation with RSV infection (240). To date, there have been no reports 
of VED in RSV seropositive individuals, suggesting that previous RSV exposure may mitigate the 
risk (296). In a maternal immunization model, the transfer of maternally-derived antibody 
establishes a seropositive-like environment in offspring. However, there is no guarantee that 
enhanced responses to RSV will be fully prevented in passively immunized infants or that a heavily 
Th2-biased response in the mother will not adversely affect the infant response upon RSV 
exposure. In fact, it remains unknown why some, otherwise healthy, infants develop a more severe 
form of RSV disease at an age when maternally-derived antibody should provide protection (90, 
297, 298).  
Our findings indicate that a majority of offspring from DS-Cav1 + Advax-SM dams were 
completely protected from RSV, both immediately after birth, as well as 2 weeks after offspring 
were weaned and the transfer of maternal antibodies via breast milk had ceased. However, the 
frequency of DS-Cav1 + Advax-SM infants and weanlings with neutralizing antibody levels ≥ 40 
was lower than the frequency of infants and weanlings with undetectable virus in their lungs. This 
discrepancy may indicate a lack of sensitivity in our neutralizing antibody assay or may suggest a 
role for non-neutralizing antibodies in controlling infection through processes such as ADCC. In 
support of this theory, the expression of FcγRIII (CD16+) on cytolytic NK cells was significantly 
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reduced in DS-Cav1 + Advax-SM infants and weanlings and DS-Cav1 weanlings. Loss of FcγRIII 
on NK cells has been shown to occur following ADCC as a result of membrane-type 6 matrix 
metalloproteinase (MMP6) (272) and/or metalloproteinase-17 (ADAM-17) (271, 273) activity, 
inducing receptor shedding to minimize inflammation. Only DS-Cav1 dams had reduced FcγRIII 
expression on cytolytic NK cells (Fig. S4), which may suggest an increased need for ADCC due 
to ineffective RSV neutralization and a reduced CD8+ T cell response. Greater concentrations of 
IgG2a produced by DS-Cav1 + Advax-SM dams and transferred to their offspring may bind more 
efficiently to FcγRIII on NK cells in infants eliciting ADCC. Reduced FcγRIII expression on NK 
cells in DS-Cav1 and DS-Cav1 + Advax-SM weanling groups may reflect the more robust innate 
immune responses mounted by older compared to infant mice (50, 299). These hypotheses 
regarding changes in NK cell phenotype due to the influence of maternal antibody require further 
investigation. 
This study raises interesting questions regarding the role of IgG subtypes in the protection 
mediated by maternal immunization. The pre-challenge serum of DS-Cav1 + Advax-SM 
weanlings was dominated by IgG2a antibodies and this correlated with higher neutralization titers, 
sterilizing immunity, and enhanced DC maturation. Studies investigating the link between 
pathogen-pattern recognition receptors, like Toll-like receptors (TLRs), and pathogen clearance 
through IgG immune complex (IgGIC) formation, along with engagement of Fc receptors have 
shown the critical role TLR4 plays in the activation of phagocytic cells via its interaction with 
IgGIC bound to FcγRIII (300). RSV F protein is a known TLR4 agonist (3) therefore, the improved 
RSV neutralization by IgG2a following RSV challenge of DS-Cav1 + Advax-SM weanlings may 
lead to immune complex formation that is detected by FcγRIII and TLR4 on dendritic cells 
resulting in their activation. It is possible that more effective innate antiviral responses in DS-Cav1 
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+ Advax weanlings resulted in an overall decrease in the number of CD8+ T cells in the BAL but 
an increase in their functionality, as evidenced by a higher IFN MFI. 
Increased PAS staining at 8 DPI in the airways of both DS-Cav1 weanling groups may 
reflect enhanced T cell activity compared to PBS but requires further investigation, including AHR 
testing and memory T cell studies. Moving forward, it will be important to investigate passively-
acquired IgG subtype ratios in the promotion or amelioration of lung pathology in response to RSV 
infection, considering both the activating and anti-inflammatory roles of IgG subtypes (19, 269, 
301).  
A limitation of this study is that human mothers would have been previously infected with 
RSV prior to maternal immunization, whereas in this study dams were RSV-naïve prior to 
immunization. Therefore, the VED we observed in DS-Cav1 dams challenged with RSV may not 
occur in sero-positive human mothers. Nevertheless, this study provides important insights into 
the mechanisms of VED associated with DS-Cav1 immunization. In particular, the data provide 
supporting evidence for the use of a non-Th2-polarizing adjuvant, such as Advax-SM, to improve 
the safety and efficacy of DS-Cav1 immunization, which is currently being tested alone or in 
combination with alum adjuvant in Phase I clinical trials (NCT03049488). 
Taken together, these results demonstrate that maternal immunization with DS-Cav1 + 
Advax-SM warrants further investigation, as it was found to protect dams and offspring from 
primary RSV infection. Just as importantly, our studies provide novel insights regarding the 
influence maternally-transferred anti-pre-F antibodies may have on offspring’s innate and adaptive 
immune responses to primary RSV exposure. Undoubtedly, the influence imparted during this 
initial infection will also affect the nature of subsequent RSV immune responses, constituting a 
form of immune imprinting. Functional studies will be important in the future to reveal the impact 
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of this on lung physiology and risk of long-term AHR. Future research in maternal immunization 
should aim to elucidate how the quantity, affinity/avidity, and IgG subtype ratios of maternally-
derived antibodies impact acute and memory immune responses in offspring, as these factors will 
have important consequences on the efficacy and safety of maternal vaccination. 
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7.0  CONCLUSIONS AND FUTURE DIRECTIONS 
7.1 CONCLUSIONS 
In this dissertation, we have provided evidence of age-based differences in RSV immune responses 
but that immunomodulation during primary, infant RSV infection can have acute and long-term 
effects on RSV immunity. From the moment newborns take their first breaths, the neonatal lung 
is bombarded by aeroallergens and microorganisms and the neonatal immune system must balance 
its responsibility to protect against infection and promote the continued development of the 
respiratory system. RSV has taken advantage of this internal balancing act and established itself 
as the most significant viral cause of serious respiratory tract infections in the very young.  
 While it is thought that infants’ Th2-biased immune responses may protect them from over-
exuberant Th1 immunopathology, we have demonstrated that the administration of the archetypal 
Th1 cytokine, IFNγ, during primary, infant RSV infection reduced viral titers, stimulated the innate 
immune system, reduced mucus production, reduced the detection of apoptotic cells, and improved 
RSV-specific CD8+ T cell responses. Moreover, we provided evidence of long-term benefits of 
IFNγ treatment through the reduction of airway resistance upon secondary RSV exposure and 
demonstrated preliminarily that IFNγ-treated AMs exhibit phenotypic signs of trained immunity. 
Also, detection of elevated levels of the immunoregulatory molecule, extracellular adenosine, in 
infant airways identified a previously unrecognized mechanism of immunosuppression specific to 
infants that may differentially affect cells of the immune system. RNA sequencing of infant and 
adult AMs showed four times less DEGs in infants in response to RSV infection, highlighting the 
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multi-level control of immune responses and the degree to which the infant immune response is 
blunted. 
 Finally, we demonstrated that effective RSV immunity can be passively-acquired in infants 
through maternal immunization. Maternal immunization with DS-Cav1 + Advax-SM elicited a 
balanced Th1/Th2 response in dams and IgG2a RSV-specific maternal antibodies were more 
effectively neutralizing in offspring. Importantly, the presence of maternal anti-RSV antibodies 
augmented innate and adaptive immune responses in offspring and increased mucus production 
upon RSV exposure. The last finding of enhanced active immunity upon RSV exposure is 
important given the Phase III status of Novavax’s maternal RSV vaccine candidate and requires 
further investigation. It serves as a reminder that upon natural RSV exposure, the role of protective 
maternal antibodies does not end with pathogen neutralization; antibody-bound pathogens also 
serve as immunomodulatory agents in the development of memory immune responses.  
7.2 FUTURE DIRECTIONS 
Studying RSV in the context of an infant model of the disease has deepened my desire to continue 
studying age-specific differences in immunity and has also left many avenues open for further 
exploration, namely metabolic and epigenetic alterations in infant AMs and the induction of active 
immunity by maternal antibody-pathogen immune complexes. In the lung, AMs play critical roles 
in immune surveillance and the maintenance of homeostasis. As the most abundant leukocyte in 
the airways, they represent a critical link between innate and adaptive immunity. Our RNA 
sequencing data demonstrated far fewer DEGs in infants in response to RSV compared to adults, 
suggesting multifactorial inhibition, likely from internal and external forces. One such external 
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force may be elevated levels of extracellular adenosine in the airways, which may be acting as an 
important metabolic signal that maintains AMs in a metabolic state favoring oxidative 
phosphorylation and a homeostatic phenotype. There is evidence that increased production of 
adenosine is promoted in the blood in an age-specific manner (159). It would be interesting to 
investigate the mechanism behind elevated adenosine levels in the infant airspace as well as 
examine age-specific differences in AM cellular metabolism using the Seahorse Live-cell 
metabolic assay platform (Agilent; North Billerica, Massachusetts). Highlighting age-related 
differences in innate immune cell metabolism may lead to new avenues of therapeutic exploration 
for the treatment of pediatric respiratory tract infections. 
The role of IFNγ treatment on the development of trained immunity in AMs is another 
intriguing area that requires further inquiry.  A recent and elegant paper by Yao and colleagues 
demonstrated the critical link between direct contact with effector CD8+ T cells and production of 
IFNγ in the priming of memory AMs in a model of adenovirus (302). Many of the findings and 
points of discussion suggested in this dissertation are corroborated by evidence presented by Yao, 
et al. including, high expression of MHCII on memory AMs, increased glycolytic metabolism, a 
defense ready gene signature, and heightened chemokine production (302). Future studies 
examining epigenetic, metabolic, and functional differences in AMs, trained during infant RSV 
infection in the presence of IFNγ, will give critical insight into how early-life viral infections affect 
cross protection against other respiratory viruses or bacterial infections. 
Lastly, more studies are required to fully evaluate the influence of anti-RSV maternal 
antibodies on the development of active immunity in offspring exposed to RSV. Data presented in 
this dissertation showed enhanced innate activation in the presence of maternal antibody and there 
was evidence to suggest that IgG subtype may differentially affect those responses. Additionally, 
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the presence of maternal anti-RSV antibody resulted in increased mucus production compared to 
PBS controls. The physiological significance of the increased mucus that was observed requires 
further evaluation but should provoke some degree of caution given the current Phase III status of 
Novavax’s maternal RSV vaccine. Some degree of mucus production is beneficial and helps trap 
and remove debris but the threshold beyond which mucus becomes pathogenic is not clearly 
defined. Therefore, studies are underway that will provide a more definitive link between changes 
in histology, including mucus production, and compromised airway mechanics measured by 
flexiVent technology. 
Typically, the assumption for maternal vaccination approaches is that higher maternal 
antibody production will result in better protection for their offspring. While that may be true 
acutely in terms of inhibiting RSV infection, our data suggests that following RSV exposure, anti-
RSV maternal antibodies that are likely bound to RSV elicit more robust RSV immunity in 
offspring. Future studies will investigate how the presence (quantity, quality, and dominant IgG 
subtype) of maternal anti-RSV antibodies affect RSV memory responses in offspring exposed to 
RSV. Interestingly, we have preliminary data that shows anti-RSV maternal antibodies have non-
specific, stimulatory effects on innate immune cells in offspring. In our pilot study, offspring born 
to dams immunized with DS-Cav1 + Advax-SM were compared to offspring born to dams 
immunized with vehicle alone. Both groups were then challenged with i.n. ova and at 4 days post-
challenge their innate immune responses were evaluated via flow cytometry. Type 2 innate 
lymphoid cells produced significantly more IL-9 in DS-Cav1 + Advax-SM offspring compared to 
PBS offspring, suggesting the presence of RSV-specific maternal antibody elicits a heightened 
response to a non-specific antigen. Together, this information suggests that thoughtful, detailed, 
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and perhaps, unconventional studies of maternal vaccination should be conducted to ensure the 
safety of this vaccination approach.  
Moving forward I intend on pursuing the hypothesis that age-dependent differences in 
cellular metabolism, especially of alveolar macrophages, contribute to many of the signals and 
consequences of reduced activation in RSV-infected infants demonstrated in this thesis. Central to 
this is understanding how extracellular levels of adenosine become elevated in the infant airway 
and how extracellular adenosine affects alveolar macrophage cellular metabolism. Seahorse Live-
cell analysis of infant alveolar macrophages will provide detailed information on these cells’ 
metabolic conditions that set the stage for understanding how alveolar macrophages develop 
trained immunity. Through my research investigating the immunomodulatory potential of IFNγ 
and maternal antibodies, I have been convinced that in the presence of RSV these stimuli activate 
macrophages to produce innate memory. Understanding trained immunity is especially important 
in the context of maternal immunization/maternal antibody given the announcement of topline 
results from the Phase III clinical trial of ResVax, a maternal RSV immunization for the protection 
of infants by Novavax. Although the results of the trial did not meet the company’s primary 
objective of prevention of medically significant RSV lower respiratory tract infection, the trial 
produced enough promising results that the company is moving forward in pursuing licensure. The 
caveat of this trial is that the primary and secondary endpoints were only measured through the 
infants’ first 90 days of life. Additionally, the safety evaluation only occurred through the first 180 
days of life, which is likely not long enough for a secondary RSV exposure to occur. My objective 
is to understand how the presence of maternal antibody at the time of initial RSV exposure 
influences secondary RSV immune responses as well as whether its presence elicits cross-
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